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Abstract
Chronic hepatitis B caused by infection with the hepatitis B virus (HBV) affects about
240 million people worldwide and is one of the major causes of severe liver cirrhosis and
liver cancer. Hepatitis B treatment options have improved dramatically in the last decade.
Effective direct-acting antiviral drugs, so-called nucleos(t)ide analogs, and one effective
immunomodulatory drug (pegylated interferon α-2a) are available presently. Current chal-
lenges for treating HBV involve the careful selection of patients who require therapy and
the thoughtful choice of the treatment option tailored to each patient individually. Person-
alized medicine aims to optimize treatment decisions based on the analysis of host factors
and virus characteristics.
The population of viruses within a host is called the viral quasispecies. This thesis
provides statistical methods to infer relevant information about the viral quasispecies of
HBV to support treatment decisions. We introduce a new genotyping methodology to
identify dual infections, which can help to quantify the risk of interferon therapy failure.
We present a method to infer short-range linkage information from Sanger sequencing
chromatograms, a method to support treatment adjustment after the development of re-
sistance to nucleos(t)ide analogs. Additionally, we provide the first full-genome analysis
of the G-to-A hypermutation patterns of the HBV genome. Hypermutated viral genomes
form a subpopulation of the quasispecies caused by proteins of the human innate immune
system editing the genome of exogenous viral agents. We show that hypermutation is as-
sociated with the natural progression of hepatitis B, but does not correlate with treatment
response to interferon.
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Kurzfassung
Die Hepatitis-B-Erkrankung wird durch eine Infektion mit dem Hepatitis-B-Virus (HBV)
verursacht. Weltweit sind schätzungsweise 240 Millionen Menschen chronisch infiziert.
Dabei stellt Hepatitis-B eine der häufigsten Ursachen für die Entwicklung von Leber-
zirrhose und Leberkrebs dar. Die Behandlungsmöglichkeiten wurden in den letzten zehn
Jahren signifikant verbessert. Mittlerweile stehen effektive direkt antivirale Medikamen-
te – sogenannte Nukleos(t)id-Analoga – und ein effektives immunmodulierendes Medika-
ment (pegyliertes Interferon α-2a) für die Behandlung zur Verfügung. Zentrale Fragen bei
der Behandlung von Hepatitis-B beinhalten die zielgerichtete Auswahl der Patienten, wel-
che therapiert werden müssen, sowie die passgenaue Auswahl der Behandlungsoption. Die
personalisierte Medizin verfolgt das Ziel, die Behandlung basierend auf der Analyse von
Patientencharakteristika und Eigenschaften des Virus zu optimieren.
Die Gesamtheit der Viren innerhalb eines Wirtes wird als virale Quasispezies bezeichnet.
Diese Arbeit stellt statistische Methoden zur Verfügung, um relevante Informationen über
die Quasispezies von HBV zur Unterstützung von Therapieentscheidungen zu ermitteln.
Wir entwickeln eine neue Methode zur Genotypisierung, welche Zweifachinfektionen mit
HBV identifiziert und somit hilfreich sein kann, das Risiko eines Therapieversagens einer
Interferonbehandlung korrekt einzuschätzen. Des Weiteren stellen wir eine Methode vor,
welche Linkage-Informationen der viralen Quasispezies, basierend auf den Chromatogram-
men der DNA-Sequenzierung nach Sanger, extrahieren kann. Diese Methode kann bei der
Umstellung einer Therapie mit Nukleos(t)id-Analoga nach Resistenzentwicklung verwendet
werden. Schließlich präsentieren wir die erste Vollgenomanalyse der G-zu-A Hypermutati-
onsmuster von HBV. Hypermutierte virale Genome stellen eine Teilmenge der Quasispezies
dar, welche durch von Proteinen der angeborenen Immunabwehr bewirkte Mutationen im
viralen Genom entsteht. Wir zeigen, dass diese Subpopulation mit dem natürlichen Verlauf
einer Hepatitis-B-Erkrankung, jedoch nicht mit dem Therapieansprechen auf Interferon,
statistisch signifikant assoziiert werden kann.
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1 Introduction
The theory of probabilities is nothing but good sense reduced to
calculation; it allows one to appreciate with exactness what accurate
minds feel by a sort of instinct, without often being able to explain it.
(Pierre Laplace, 1814)
1.1 Probabilistic Reasoning
The twenty-first century is the age of data. Vast amounts of data are created every day and
everywhere: in the internet, in industry, and in research. Technologies to acquire and store
these data were developed but the speed of growth in data volume is increasing and the
main question remains: how do we make sense of all these data and turn it into meaningful
knowledge? The challenges to be addressed are in essence of statistical and computational
nature and involve the development and application of statistical learning and reasoning
methods. These methods allow us to infer unobserved quantities of the world based on
model assumptions and observable evidence.
Probabilistic reasoning is a natural extension of Boolean logic, in which every statement
is either true or false, to situations that involve uncertainty (Jaynes, 2003). Uncertainty is
ubiquitous in almost all real-world applications either due to restrictions of various kinds
that limit our ability to observe and model the world or due to, according to quantum
mechanics, the inherently non-deterministic nature of the world. Probabilistic reasoning
does nothing more and nothing less than quantifying how the data at hand changes our
state of belief about the unobserved quantities of the world. The concept of uncertainty
is made precise by the use of probability theory, which, based on very few principles,
formalizes human rational reasoning. The inevitability of probability to characterize a
quantitative system that coherently describes uncertainties has been discussed by various
authors (Cox, 1946; de Finetti, 1974; Good, 1950; Lindley, 1982; Ramsey, 1931; Savage,
1961). Nevertheless, the real strength of probability theory lies in its successful application
to relevant problems of our age.
In a nutshell, given data D = {x1, . . . , xn} comprised of a set of observations xi ∈ Rp,
the goal is to infer which of several alternative models M1, . . . ,Mm matches the data best.
Probabilistic reasoning consists of three steps. First, in the modeling step, each model
Mi, i = 1, . . . ,m is specified as a hypothesis about how a vector of model parameters
θi ∈ Rl (the unobserved quantities of the world) have led to the data D. In addition,
prior distributions P (Mi) and P (θi|Mi) need to be defined that afford the integration
of prior knowledge. The formalized description of the data generation process facilitates
the computation of the data likelihood for each model given its parameters, P (D|Mi, θi).
Second, in the conditioning step, the probabilistic machinery is applied to derive the so-
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called posterior distribution of the model parameters,
P (θi|Mi,D) = P (θi|Mi)P (D|Mi, θi)
P (D|Mi) ,
and the probability of each model given the data,
P (Mi|D) = P (Mi)P (D|Mi)∑m
j=1 P (Mj)P (D|Mj)
,
with
P (D|Mi) =
∫
θi
P (θi|Mi)P (D|Mi, θi) dθi.
We are interested in models and parameter settings, which, given the data we have ob-
served, seem likely or at least more likely compared to other hypotheses. The “best” model
might still not reflect the real world, which usually is by far more complicated than what
we can include in our computations, but it might provide useful insights into the real world.
To test whether or not we have actually learned something is the essential part of the third
step, model evaluation.
1.2 Quasispecies of the Hepatitis B Virus
Chronic hepatitis B, defined as the persistent infection with the hepatitis B virus (HBV),
is a very complex disease with a highly variable natural progression. Patients may be in
one of four phases that are characterized by distinctive profiles in the activity of the host’s
immune system and the extent of viral replication. Many individuals infected with HBV
will develop only mild symptoms during their lifetime while others will die from severe
liver cirrhosis or liver cancer. Therefore, patient care has to be individualized starting
with the careful selection of patients who require therapy and the thoughtful choice of the
treatment option.
This thesis provides statistical methods to analyze the population of hepatitis B viruses
within a host, the so-called viral quasispecies, to address the challenges of personalized
HBV treatment. Determining the viral quasispecies of HBV is a challenging task as up to
1011 copies of the viral genome exist within each milliliter serum of an infected individual.
The viral population inside a patient may be highly diverse, and it can only be measured
indirectly using DNA sequencing1 technologies of the first or second generation.
First-generation DNA sequencing methods (Sanger sequencing) provide a very rough
aggregation of the viral population into a single DNA sequence (so-called population-based
sequencing). This aggregation suffers from two major limitations. First, genetic variants of
frequency less than 10% to 20% can not be detected. Second, linkage information between
genetic variants present at different positions in the genome is lost. Population-based
sequencing of the viral quasispecies provides position-wise mixtures of genetic variants,
which need to be decomposed using statistical inference to bring different viral variants to
light.
Second-generation sequencing technologies have mainly overcome these two limitations
and allow for deeper insights into the viral quasispecies. These technologies can amplify and
1DNA sequencing is the process of measuring the order of the four types of nucleotides within a DNA
molecule.
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read-out single viral variants and may provide hundreds of thousands of DNA sequences
for each patient sample. Each of these sequences corresponds to an individual member
of the viral population. Thus, linkage information is provided over the full read length,
which, as of 2014, is in the range of 500 bases. Depending of the number of sequences that
were generated, minor variants with relative frequencies as low as 10−4 can be detected.
Nevertheless, analyzing the viral quasispecies of HBV using second-generation sequencing
technologies in clinical applications has its own set of limitations and challenges, millions
of error-prone bases have to be analyzed and reduced to interpretable entities.
1.3 Outline
Chapter 2 provides the biological, medical, and statistical background of the thesis. We
start with a brief overview of the epidemiology of hepatitis B, followed by a description of
the natural course of the disease. Then, we focus on the causative agent of hepatitis B,
the hepatitis B virus, its proteins, its genome, and its replication cycle. We discuss the
genetic diversity of HBV and introduce genotypically homogeneous subgroups of HBV, the
HBV genotypes. We review current treatment options for HBV and state-of-the-art DNA
sequencing technologies. We conclude with an introduction to methods and models from
the fields of probabilistic reasoning and statistical learning.
In Chapter 3 we discuss the simultaneous infection with two heterologous HBV strains,
referred to as HBV dual infection. We introduce in vitro methods to identify and genotype
dual infections and discuss state-of-the-art in silico genotyping methods for HBV. We
derive the dual infection model, a probabilistic model to infer dual infections based on
population-based sequencing data. Results based on the analysis of synthetic test data
and real patient sera are presented and discussed.
In Chapter 4 we continue to discuss the problem of determining the viral quasispecies
of HBV based on population-based sequencing data. We show that short-range linkage
information can be extracted from sequencing chromatograms using a technical artifact of
the Sanger sequencing technology, the effect of sequence context-dependent incorporation
of dideoxynucleotides. The model is evaluated on in vitro and in silico test mixtures. The
potential and the limitations of our computational approach are discussed in detail.
In Chapter 5 we present a study that relates the phenomenon of G-to-A hypermutation
of the HBV genome to the clinical course of hepatitis B. This Chapter is based on second-
generation sequencing data that facilitates the analysis of the viral quasispecies in great
detail. We will show that the patterns of hypermutation can be linked to the natural
progression of hepatitis B and to the replication cycle of HBV.
In Chapter 6 we try to relate treatment response to interferon with G-to-A hypermu-
tation. We describe a prediction model that achieved high accuracy on our training data
but was not successfully validated in a follow-up study.
Chapter 7 concludes the thesis and provides an outlook for further advances in person-
alized HBV therapy.
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2 Background
As soon as we touch the complex processes that go on in a living
thing, be it plant or animal, we are at once forced to use the methods
of this science [chemistry]. No longer will the microscope, the
kymograph, the scalpel avail for the complete solution of the problem.
For the further analysis of these phenomena which are in flux and
flow, the investigator must associate himself with those who have
labored in fields where molecules and atoms, rather than multicellular
tissues or even unicellular organisms, are the units of study.
(John Jacob Abel, 1 915)
This Chapter outlines the biological, medical, and methodical background of the thesis.
In Section 2.1 a comprehensive overview of the hepatitis B disease and its epidemiology
is provided. Then, we focus on the causative agent, the hepatitis B virus, in Section 2.2
and on hepatitis B therapy in Section 2.3. Section 2.4 introduces state-of-the-art DNA
sequencing technologies. Last, Section 2.5 presents a brief introduction to probabilistic
reasoning and two special classes of statistical models, hidden Markov models and support
vector machines.
2.1 Hepatitis B
2.1.1 Disease and Epidemiology
Worldwide an approximate number of 240 million people are chronically infected with the
hepatitis B virus with mortality rates of about 600,000 per year (WHO, 2013). Chronic
hepatitis B infections are defined by the persistence of the hepatitis B surface antigen
(HBsAg) in sera for more than six months. Hepatitis B is most prevalent in China and
South East Asia where nearly 10% of the adult population is chronically infected and
the lifetime risk of being infected with hepatitis B is more than 60%. About 45% of the
world’s population lives in areas where hepatitis B is highly prevalent (more than 8% of
the population is HBsAg-positive), which aside from Asia includes the Amazone region,
sub-Saharan Africa, and Saudi Arabia (Figure 2.1). Hepatitis B is also highly prevalent in
the native populations of Alaska, Greenland, and Northern Canada. Moreover, 43% of the
world’s population lives in areas where the prevalence is intermediate (between 2% and
8% of the population is HBsAg-positive) and 12% lives in areas of low endemicity (less
than 2% of the population is HBsAg-positive). Despite the low prevalence of about 0.6%
of hepatitis B in Germany, it is regarded as a major health problem in Germany, too. In
2011, the Robert Koch Institute ranked 127 pathogens to establish strategic priorities for
the German national health surveillance and listed the hepatitis B virus in the top 5 list
of national health threats (Balabanova et al., 2011).
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Figure 2.1: Prevalence of hepatitis B as of 2005. Figure obtained from
Wikipedia (http://upload.wikimedia.org/wikipedia/commons/0/09/HBV_
prevalence_2005.png).
Disease progression. During lifetime 15% to 40% of HBsAg carriers develop severe
cirrhosis1 or hepatocellular carcinoma2 (HCC) (Hsieh et al., 1992; Lok and McMahon,
2009; Mahoney, 1999). Worldwide approximately 30% of cirrhosis and 53% of HCC can be
attributed to hepatitis B infections (Lavanchy, 2004). Liver damage is not caused by HBV
directly but develops as a consequence of the host’s immune response to the infection.
Cirrhosis is divided into two stages: compensated and decompensated. Compensated
cirrhosis indicates that the function of the liver is not significantly impaired. Patients with
compensated cirrhosis experience few or no symptoms. Decompensated cirrhosis, on the
other hand, implies that the scarring of the liver is in a progressed state such that essential
body functions are disrupted. Effective long-term suppression of the HBV replication
leads to substantial regression of cirrhosis (Marcellin et al., 2013). Otherwise, progression
to decompensated cirrhosis is accompanied with diarrhea, abdominal pain, fatigue, and
general weakness among other symptoms (Hoofnagle et al., 2007; Lok and McMahon,
2009). As the disease progresses more severe clinical complications are unpreventable,
especially ascites (fluid retention in the abdomen), jaundice, internal bleeding, and hepatic
encephalopathy. The later arises as the liver loses its main function and is no longer able
to remove toxins from the blood serum. Carriers with these complications require liver
transplantations to prevent death.
Vaccine. In 1965, Baruch S. Blumberg discovered the hepatitis B surface antigen in
the serum of an Australian aborigine while he studied sera of leukemia patients (Blumberg
et al., 1965). Blumberg named it the Australia antigen. Today the original name is still
reflected in the name of hepatitis B’s immunodominant antigenic determinant, the so-
called “a” determinant (detailed in Section 2.2.1). The work of Blumberg, for which he was
honored with the Nobel Prize in Physiology or Medicine, later led to the development of a
vaccine against hepatitis B that was available since 1982 (Lemon and Thomas, 1997; Lycke,
1976). This original vaccine contained purified HBsAg particles derived from plasma of
chronic hepatitis B carriers. These HBsAg particles were not infectious but could serve as
1Cirrhosis is defined as degeneration of liver tissue to scar tissue.
2Hepatocellular carcinoma is the most common type of primary liver cancer.
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a template to build antibodies against HBsAg (anti-HBs). Since 1989 the production of the
modern vaccine uses genetically modified yeast cells, into which the HBsAg gene has been
inserted (Lemon and Thomas, 1997; McAleer et al., 1984). Infections with the hepatitis
B virus can effectively be prevented by vaccination (Chen, 2009; Margolis, 1993; Viviani
et al., 1999; Szmuness et al., 1980). According to the World Health Organization, 179 of
their member states routinely vaccinate infants against hepatitis B (WHO, 2013). As of
today over one billion doses of the hepatitis B vaccine have been administered worldwide.
This has lead to significant reductions in the rates of chronic HBV infections to less than
1% among immunized children in many countries, where more than 8% of children used
to become chronically infected (WHO, 2013).
2.1.2 Acute Infections and Chronification
The hepatitis B virus can be transmitted either vertically (perinatally) or horizontally
(through contact with blood or other body fluids of an infected person). The first six
months of a hepatitis B infection are referred to as the acute phase of the infection. Approx-
imately two thirds of acute hepatitis B infections are clinically asymptomatic (Hoofnagle
et al., 2007). Symptoms of acute hepatitis B infections may include jaundice, dark urine,
abdominal pain, joint pain, nausea, emesis, and diarrhea. With an incidence of 0.5% to 1%
the infection leads to a quick decomposition of the liver referred to as fulminant hepatitis
(Lee, 1993).
Approximately 90% of infected adults achieve seroconversion from HBsAg to anti-HBs
within six months. This marks the endpoint of an acute infection. Chronic infections, on
the other hand, are characterized by the persistence of high levels of HBV DNA, HBsAg,
and the hepatitis B e antigen (HBeAg) in sera for more than six months. The chronification
rate for children lies between 30% and 90% depending on the age. The chronification rate
in immunocompromised populations is about 90% (Hoofnagle et al., 2007; WHO, 2013).
2.1.3 Natural Course of Chronic Infections
Chronic infections with the hepatitis B virus involve complex interactions of the virus,
the infected cells, and the host’s immune system. Their interplay, which may further be
influenced by various external factors, determines the progression of the disease and its
severity. The natural course of a chronic hepatitis B infection is described by a four phase
model (Hoofnagle et al., 2007; Lok and McMahon, 2009; McMahon, 2009; Yim and Lok,
2006). The immune-tolerant phase, the immune-active phase, the inactive carrier phase,
and the reactivation phase display different characteristics with respect to viral loads, liver
inflammation, alanine aminotransferase3 (ALT) levels, and very importantly the presence of
HBeAg. HBeAg is a non-structural HBV protein that acts as a tolerogen4. It downregulates
and manipulates innate and adaptive immune responses (Chang et al., 1987; Chen et al.,
2004). Not all infections undergo all four phases and multiple transitions between the
phases are possible (Figure 2.2). The immune-tolerant phase is usually absent in the
case of horizontal transmissions but may last for one to four decades if the infection was
3Alanine aminotransferase is an enzyme produced most notably in hepatocytes and its presence in serum
is a specific indicator of hepatocellular injury.
4A substance (often an antigen) that invokes a specific immune non-responsiveness/tolerance.
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Figure 2.2: Natural course of chronic hepatitis B. Dark arrows indicate typical phase
transitions, bright arrows indicate possible reversions of phase transitions. Vi-
sualization was adapted from McMahon (2009).
perinatal (Hui et al., 2007). The immune-tolerant phase is characterized by the presence
of HBeAg, normal or minimally elevated ALT levels, absent or minimal inflammation, and
high levels of HBV DNA (108 to 1011 copies per milliliter). The prognosis for patients
in the immune-tolerant phase is generally good due to the mild inflammation of the liver
(Chu et al., 2004). Nevertheless, progression to the immune-active phase occurs when the
host’s immune system recognizes HBV as an exogenous element. In the immune-active
phase liver damage on the cellular level results from the action of the immune system, in
particular from cytotoxic T lymphocytes producing antiviral cytokines (Iannacone et al.,
2007). The immune-active phase is further characterized by elevated ALT levels, high
viral loads (106 to 1010 copies per milliliter), and the presence of HBeAg. The immune-
active phase lasts as long as the host’s immune system does not develop antibodies to
HBeAg (anti-HBe), referred to as HBeAg seroconversion. HBeAg seroconversion arises
spontaneously or treatment induced and is usually followed by the inactive carrier phase,
in which ALT levels are normalized, inflammation is absent to minimal, and HBV DNA
levels are low or undetectable. Infected persons in the inactive carrier phase control the
infection with the presence of anti-HBe antibodies and, thus, again have good prognosis
unless the infection is reactivated, which may occur either spontaneously or by immune
suppression. In the reactivation phase HBeAg is not expressed (or expressed at low levels)
and HBV DNA levels are low to moderate (103 to 108 copies per milliliter). This phase
is further characterized by active liver inflammation indicated by elevated ALT levels.
The reactivation phase is also referred to as HBeAg-negative chronic hepatitis. HBV has
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Figure 2.3: The phylogenetic tree shows the genetic relationships between all members
of the Hepadnaviridae family. 315 complete genomes were used to compute
the unrooted neighbor joining tree. The cluster of Asian non-human primates
includes gibbons and orangutan hepatitis B virus sequences. The cluster of
African non-human primate sequences is composed of chimpanzees and gorilla
hepatitis B virus sequences. The stars indicate significant groupings (bootstrap
value greater than 85%). Permission to use this visualization was granted by
Elsevier (Locarnini et al., 2013).
escaped the anti-HBe immune pressure by specific mutations in the viral genome that
suppress or downregulate the expression of HBeAg. The most common of these genetic
variations is a single point mutation (G1896A) at nucleotide position 1896, which creates a
stop codon in the HBeAg coding region and abolishes the production of HBeAg (Okamoto
et al., 1994). Alternatively, a double point mutation (A1762T+G1764A) at positions 1762
and 1764 in the core promoter region downregulates expression of HBeAg (Buckwold et al.,
1996; Scaglioni et al., 1997). Often the inactive carrier phase is skipped and patients
enter the reactivation phase directly after HBeAg seroconversion. In all phases, HBsAg
is present. Seroconversion from HBsAg to anti-HBs, which happens spontaneously at
a yearly rate of 0.5% to 1.0%, marks the endpoint of a chronic infection and implies
life-long immunity, except for cases of immunosuppression due to chemotherapy or organ
transplantation (McMahon et al., 2001).
2.2 Hepatitis B Virus
The hepatitis B virus is a member of the family Hepadnaviridae, which is subdivided into
two genera, avihepadnavirus and orthohepadnavirus (Fields et al., 2007). We find avi-
hepadnaviruses in birds, e.g. duck hepatitis B virus (DHBV), heron hepatitis B virus
(HHBV), crane hepatitis B virus (CHBV), rose goose hepatitis B virus (RGHV), stork
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Figure 2.4: Circular representation of the hepatitis B virus genome. Figure
was obtained from Wikipedia (http://upload.wikimedia.org/wikipedia/
commons/thumb/0/00/HBV_Genome.svg/2000px-HBV_Genome.svg.png).
hepatitis B virus (STHBV), and parrot hepatitis B virus (PHBV). Orthohepadnaviruses
infect mammals, e.g. primates, rodents, and bats. Rodent hepatitis B viruses include,
for example, ground squirrel hepatitis B virus (GSHV), artic squirrel hepatitis B virus
(ASHV), and woodchuck hepatitis B virus (WHV). Primate hepatitis B viruses include
human HBV and several non-human HBV variants. Throughout the thesis HBV always
refers to human HBV. Figure 2.3 shows a phylogenetic tree of the Hepadnaviridae family.
Hepadnaviruses have a very small genome of only 3000 to 3300 bases. The genome has
the chemical structure of partially double-stranded, relaxed circular (rc) DNA and dupli-
cates through reverse transcription of an RNA intermediate, the pregenomic (pg) RNA.
In general, hepadnaviruses have a narrow host range. The woodchuck hepatitis B virus,
for example, infects only woodchucks but no other mammals while the ground squirrel
hepatitis B virus infects woodchucks and ground squirrels. HBV infects humans and chim-
panzees. The woolly monkey hepatitis B virus (WMHBV), on the other hand, is poorly
infectious for chimpanzees.
In Section 2.2.1 we discuss the coding elements of the HBV genome and detail the
function and structure of the respective proteins. Section 2.2.2 outlines the replication
cycle of HBV. In Section 2.2.3 we discuss the genetic diversity of HBV and in Section 2.2.4
we briefly survey the different hypotheses of the origin of hepatitis B in humans.
2.2.1 Particle, Genome, and Proteins
HBV has the smallest genome of all human pathogenic viruses. The genome has been
subdivided into distinct HBV genotypes (A to J) based on phylogenetic analysis (see
Section 2.2.3). The genomes of all genotypes contain four open reading frames core, surface,
polymerase, and X (Figure 2.4). Every base in the genome codes for at least one viral
protein. About 67% of the genome encode at least two viral proteins. The reading frames
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Genomic region Protein Reading frame Positions
Terminal protein (TP) Polymerase Polymerase 2307-2843
Spacer (SP) Polymerase Polymerase 2844-129
Reverse transcriptase
(RT)
Polymerase Polymerase 130-1161
RNaseH (RN) Polymerase Polymerase 1162-1623
PreS1 LHBsAg Surface 2854-3210
PreS2 LHBsAg, MHBsAg Surface 3211-154
HBsAg LHBsAg, MHBsAg, SHBsAg Surface 155-835
X X X 1374-1900
Precore (PC) HBcAg, HBeAg Core 1814-1900
Core HBcAg Core 1901-2458
Table 2.1: Overview of genomic regions and reading frames in the HBV genome and the
proteins these encode for. Positions are given with respect to reference strain
AM282986.
are overlapping with frame shifts and all regulatory elements, e.g. promoters, enhancers,
and polyadenylation signals, are embedded within coding regions of other genes. The
four open reading frames, which correspond to four genes, encode seven viral proteins.
Alternative transcriptional start sites facilitate different viral proteins to be generated
from a single reading frame. Table 2.1 lists the genomic positions of all relevant coding
regions. We refer to these regions throughout the thesis. In the remainder of this Section
we detail the function and structure of the viral proteins.
Core gene. The core gene encodes two proteins: the hepatitis B core antigen (HBcAg)
and HBeAg. HBcAg is the building block of the HBV capsid. Depending on the HBV
genotype it is formed by 183 or 185 amino acids. Nevertheless, HBcAg is highly conserved
among the different genotypes likely due to structural requirements of capsid assembly
(Chain and Myers, 2005). The N-terminal 149 or 151 amino acids (depending on the geno-
type) are referred to as the assembly domain that forms the protein shell of the capsid. The
remaining amino acids form the so-called protamine domain, which is positively charged
due to a high number of arginine residues. The protamine domain binds to HBV’s prege-
nomic RNA and initiates the packing of the viral genome (Gallina et al., 1989; Zlotnick
et al., 1997).
Based on cryo-electron microscopy and crystallization studies a detailed picture of the
HBV capsid is available (Böttcher et al., 1997; Wynne et al., 1999). The capsid has an
icosahedral structure. It consists either of 120 or of 90 HBcAg homodimers (Figure 2.5).
The capsid configuration that consists of 120 HBcAg homodimers has a symmetry with
triangulation number 4 (T = 4) and is more prevalent in infectious viral particles. The
configuration with 90 HBcAg homodimers has a symmetry with T = 3 and a prevalence
of about 10% (Crowther et al., 1994; Short et al., 2009). The HBcAg homodimer subunits
are paired by forming a four-helix bundle stabilized by an intermolecular disulfide bond
(Böttcher et al., 1997; Conway et al., 1997). The HBcAg homodimers form the spikes of
the surface of the capsid, which are surrounded by flanking pores. The tips of the spikes
display the major immunodominant region on the capsid surface, which is recognized by
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Figure 2.5: Reconstructions of hepatitis B virus capsid based on cryo-electron microscopy.
An epitope (Fab-3120) was used for color labeling. Capsid protein is blue,
Fab-3120 density is pink. (a) Capsid conformation with triangulation number
4 (T = 4). (d) Capsid conformation with triangulation number 3 (T = 3). (b)
and (e) Lattice diagram of single triangular facets of the capsid, as marked on
subplots (c) and (f). (c) and (f) Unlabeled capsids with triangulation number
4 and 3, respectively. The bar in the right bottom corner indicates the scale of
50 Å. Figure was obtained from Conway et al. (2003).
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the adaptive immune system to develop antibodies (anti-HBc) (Wynne et al., 1999). The
antibodies anti-HBc are persistent throughout the infection but do not neutralize HBV.
The pores have a diameter between 12 and 15 Å. They allow for diffusion of nucleotides
and other small molecules into the interior of the capsid (Böttcher et al., 2006; Perlman
et al., 2005).
HBeAg is the second viral protein encoded by the core gene. Its translational start posi-
tion is 29 codons upstream of HBcAg. HBeAg is non-structural but serves as an important
biomarker to monitor the natural progression of hepatitis B as discussed in Section 2.1.3.
The function of HBeAg is not completely understood yet (Walsh and Locarnini, 2012). It is
not required for viral assembly, infection, or replication (Chang et al., 1987). Nevertheless,
it was shown to attenuate the host’s immune response to HBcAg and to downregulate the
innate and adaptive immune system (Chen et al., 2004; Visvanathan et al., 2007). HBeAg
traverses the placenta to induce immune tolerance in utero, which promotes viral persis-
tence following perinatal infection (Milich et al., 1990). Thus, HBeAg plays a key role in
viral persistence and promotes HBV chronicity due to its immunomodulatory effects.
Surface gene. The envelope consists of a host cell-derived phospholipid bilayer and
three viral surface proteins called large (LHBsAg), middle (MHBsAg), and small (SHBsAg)
hepatitis B surface antigen (Schädler and Hildt, 2009). Throughout the thesis we use
HBsAg to refer to either of the three surface proteins. The three proteins have different
start codons but share the same end position in the genome. The coding regions that encode
the surface proteins are named preS2, preS1, and S. SHBsAg is encoded by S alone and
consists of 226 amino acids. SHBsAg contains the immunodominant antigenic determinant
referred to as the “a” determinant. It is located between amino acid positions 124 and 147
of SHBsAg and plays an important role in diagnosis and immunoprophylaxis. Several
immune and vaccine escape mutations have been described within the “a” determinant
(Carman et al., 1990; Chiou et al., 1997; Lee et al., 2001). MHBsAg has 55 amino acids
(encoded by preS1) added to the N-terminus of SHBsAg. PreS2 encodes additional 108,
118, or 119 amino acids (depending on the genotype), which are added to MHBsAg at its
N-terminus. The surface proteins are translocated across the endoplasmic reticulum (ER)
membrane (Eble et al., 1987, 1990). The structural conformation of the surface proteins
with respect to the ER membrane is detailed in the caption of Figure 2.6.
During chronic infection HBsAg is expressed in large amounts (up to 10,000-fold excess
over virions) in the form of quasispherical particles and tubes of variable length (Figure 2.7).
These empty subviral particles are noninfectious and have a diameter of approximately 20
nanometer (Gilbert et al., 2005). They are formed by SHBsAg and LHBsAg in the lumen of
the ER and the ER-Golgi intermediate compartment (Patient et al., 2007). The biological
function of these subviral particles has not been fully understood yet. A study performed
on duck hepatitis B virus suggests that the subviral particles strongly enhance intracellular
viral replication and are required to establish an infection in vivo (Bruns et al., 1998).
Polymerase gene. The polymerase gene, which spans almost 80% of the HBV genome,
encodes a single protein, the HBV polymerase. The polymerase has four functional do-
mains. The terminal protein (TP) domain initiates capsid packing and reverse transcription
by binding to a stem-loop located at the 5′ of the pregenomic RNA, the so-called ε-signal
(Lanford et al., 1997; Wang and Seeger, 1992; Weber et al., 1994). We further detail this
in Section 2.2.2. The reverse transcriptase (RT) domain and the RNaseH domain together
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Figure 2.6: Visualization of the three hepatitis B virus surface proteins (SHBsAg,
MHBsAg, and LHBsAg) integrated into the endoplasmic reticulum membrane.
The first transmembrane region (TM1), located between amino acids 8 and 22
of SHBsAg, initiates the membrane insertion. At amino acid positions 80 to 98
a second transmembrane region (TM2) is located. Position 146 harbors an N-
glycosylation site depicted as asn146. SHBsAg contains one or two additional
transmembrane regions TM3 and TM4 at its C-terminal region. MHBsAg has
55 amino acids added to the N-terminus of SHBsAg, which are located in the
lumen of the endoplasmic reticulum. Aside from this MHBsAg and SHBsAg
share the same topology. MHBsAg contains a glycosylation site at amino acid
position 4 (asn4). LHBsAg has additional 108, 118, or 119 amino acids (de-
pending on the genotype), which are added to MHBsAg at its N-terminus.
LHBsAg has two distinct conformational forms of the N-terminal domain. In
one conformation the topology of LHBsAg differs from the topology of SHBsAg
and MHBsAg in a way that its N-terminus including TM1 is located inside the
cytoplasm. In this conformation LHBsAg establishes the binding to the virus
capsid (Bruss, 1997). In the other conformation, which is topologically similar
to SHBsAg and MHBsAg, the N-terminus is exposed on the surface of virions
and was described to have an important function during cell entry (Prange and
Streeck, 1995). Figure obtained from Schädler and Hildt (2009).
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Figure 2.7: Electron microscopic image of infectious HBV virions and subviral particles.
Infectious HBV virions have a diameter of about 42 nanometer and contain
a genome. Subviral particles, which do not contain a genome and are nonin-
fectious, are either quasispherical particles or tubes of variable length. Subvi-
ral particles have a diameter of approximately 20 nanometer and are formed
by SHBsAg and LHBsAg. Subviral particles are expressed in large amounts
compared to virions. Figure was obtained from Wikipedia (http://upload.
wikimedia.org/wikipedia/commons/1/12/Hepatitis-B_virions.jpg).
perform the reverse transcription of the pregenomic RNA into partially double-stranded,
relaxed circular DNA present in mature particles. The spacer domain was not found to have
a specific function other than to provide a spatially flexible connection between the ter-
minal protein domain and the reverse transcriptase domain (Bartenschlager and Schaller,
1988; Chang et al., 1990).
X gene. The X gene encodes the hepatitis B virus X antigen (HBxAg), which has
central functions in HBV biology and hepatic pathogenesis by modulating many viral and
cellular functions. The X gene is highly conserved among mammalian hepadnaviruses. Its
product, HBxAg, can be observed very early after infection and throughout the chronic
phase. HBxAg has not been identified in mature virions but can be observed throughout
the cytoplasm with accumulation in the perinuclear region. HBxAg consists of 154 amino
acids and has two functional domains, which are critical for its regulatory activity (Kumar
et al., 1996; Martin-Vilchez et al., 2011; Takada and Koike, 1994). One functional site
is at amino acid position 69 and the other is between amino acid positions 110 and 139.
HBxAg does not bind to DNA but regulates transcription of cellular genes, including
oncogenes, cell growth factors, DNA repair genes, and genes associated with apoptosis
(Martin-Vilchez et al., 2011). Several studies investigated protein-protein interactions of
HBxAg with human proteins using screening protocols like the yeast two-hybrid assay or
immunoprecipitation/mass spectrometry approaches. More than 30 human proteins were
reported to interact with HBxAg but the biological significance and mode of action of these
virus-host protein interactions are difficult to determine (Fields et al., 2007; Kumar et al.,
2011). Studies performed with the woodchuck hepatitis B virus showed that a functional
form of HBxAg is required to initiate infections in vivo (Chen et al., 1993; Zoulim et al.,
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Figure 2.8: Replication cycle of the hepatitis B virus. Cell entry and fusion is followed
by transportation of the capsid to the nucleus. (1) After uncoating and up-
take of the HBV genome into the nucleus, partially double-stranded, relaxed
circular DNA is transformed into covalently closed circular DNA. (2) An RNA
intermediate, the pregenomic RNA, is transcribed from the cccDNA. (3) Prege-
nomic RNA is reverse transcribed to DNA and encapsidated. Newly formed
capsids may renter the nucleus or be enveloped by HBV surface proteins in the
endoplasmic reticulum and released. Figure obtained from (Beck and Nassal,
2007).
1994).
2.2.2 Replication Cycle
As mentioned before, HBV replicates through reverse transcription of an RNA interme-
diate. The replication cycle of HBV is summarized in Figure 2.8 and detailed in the
remainder of this Section.
Cell entry. The mechanisms of attachment and productive cell entry, as the initial
step in the HBV replication cycle, are not fully understood yet (Schädler and Hildt, 2009).
According to the general concept of viral infection, cell entry can be divided into three
steps: attachment, fusion, and entry. The interaction of HBV’s surface proteins with a
specific receptor on the host cell membrane mediates the attachment of virions. HBV
uses the carbohydrate side chains of hepatocyte-associated heparan sulfate proteoglycans
as attachment receptors (Leistner et al., 2008; Schulze et al., 2007). It was shown that
this interaction requires the integrity of LHBsAg. The attachment is believed to have low
affinity and to be reversible. Thus, it may or may not be followed by cell fusion (Marsh and
Helenius, 2006). The complete understanding of the fusion of the viral and the cellular
membranes and the subsequent uptake of the virion into the cell is an active research
challenge. Lately, the sodium taurocholate cotransporting polypeptide (NTCP) has been
identified as a cellular entry receptor for HBV (Ni et al., 2014; Yan et al., 2012).
Integration into the nucleus. The HBV replication cycle requires the HBV genome to
be integrated into the nucleus of the host cell. Perinuclear accumulation of the HBV capsid
can be observed already about 15 minutes after insertion into the cytoplasm (Schädler and
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Hildt, 2009; Sodeik, 2000). The transportation of the genome towards the perinuclear area
is a directed process, which utilizes the cellular microtubule system (Rabe et al., 2006).
The uncoating of virions may begin instantly after virus fusion, but this has not been
confirmed yet. Likewise, the mechanisms that mediate entry of the viral genome into
the nucleus of the host cell are still enigmatic. In mature particles the HBV genome
has the chemical structure of partially double-stranded, relaxed circular DNA and has a
HBV polymerase covalently attached to the 5′ end of the (–)-DNA strand. In the nucleus
the HBV genome persists in the form of covalently closed circular (ccc) DNA. cccDNA is
very stable and serves as the central intracellular intermediate during viral replication. As
detailed in the paragraph about reverse transcription in this Section, derivation of cccDNA
from rcDNA requires the cleavage of the HBV polymerase, the completion of the (+)-DNA
strand, the removal of the RNA primer, the cleavage of redundant DNA, and the ligation
of the (+)-DNA and (–)-DNA strands.
Transcription and encapsidation. Transcription of three subgenomic5 RNAs and
one supergenomic6 RNA, the pgRNA, is performed by the cellular RNA polymerase II.
Two of the subgenomic RNAs are coding for surface proteins (2.4 kilobase RNA and 2.1
kilobase RNA) and one is coding for HBxAg (0.7 kilobase RNA) (Schädler and Hildt,
2009). The pgRNA has a length of about 3500 bases. Due to its supergenomic length, it
contains two copies of the direct repeat 1 element (DR1) and two copies of the ε-signal, a
stem-loop structure. It serves as a template for the reverse transcription into rcDNA and as
a template for translation of the HBV polymerase, HBcAg, and HBeAg. The TP domain
of the polymerase binds preferentially to the very same pgRNA molecule from which it
was translated and together they form the pgRNA-polymerase complex (Bartenschlager
et al., 1990). This binding at the 5′ proximal ε-signal initiates encapsidation of the pgRNA
and its reverse transcription (Nassal, 2008) (Figure 2.9). This mechanism ensures that a
single pgRNA molecule and a single polymerase are packaged in each viral particle. The
pgRNA-polymerase complex acts as an anchor for the attachment of HBcAg homodimers
that leads to capsid formation. At a certain rate newly formed capsids reside inside the
cell and reenter the nucleus to increase the number of cccDNA copies available in the cell.
Reverse transcription. The reverse transcription of the pgRNA is a very complex yet
well understood process. In short, first the (–)-DNA strand is formed using the pgRNA
as a template followed by the synthesis of the (+)-DNA strand resulting in rcDNA. The
following outline of the reverse transcription takes reference to Nassal (2008). In detail,
DNA synthesis is initiated by protein-priming (Wang and Seeger, 1992). The HBV poly-
merase uses a bulged region within the 5′ proximal ε-signal stem-loop as a template to
generate a four nucleotide long DNA oligonucleotide, which is then translocated together
with the covalently attached TP domain to the 3′ proximal DR1 (Figure 2.9). Starting
at 3′ proximal DR1 the RT domain synthesizes the (–)-DNA strand until the very 5′ end
of the pgRNA. Simultaneously, the pgRNA template is degraded by the RNaseH domain
but not until the very end. A small RNA oligomer (11 to 16 nucleotides of the pgRNA),
which includes the 5′ proximal DR1 remains (Haines and Loeb, 2007). Next, translocation
of the RNA oligomer to DR2 (which is sequence identical to DR1) creates the primer for
5Subgenomic RNA refers to an RNA molecule that is shorter than the HBV genome.
6Supergenomic RNA refers to an RNA molecule that is longer than the HBV genome. Its transcription
is possible due to the circular structure of the HBV genome.
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Figure 2.9: The pregenomic RNA contains two copies of the ε-signal, a stem loop, and
DR1 (pictured as DR1 and DR1∗). The TP domain of the HBV polymerase
binds to the 5′ end proximal ε-signal and uses its bulge region to create a
four-nucleotide long DNA primer. This DNA oligonucleotide is translocated to
the 3′ proximal DR1 element (depicted as DR1∗), which initiates the reverse
transcription of the pgRNA into the (–)-DNA strand. Permission to use this
figure was granted by Elsevier (Nassal, 2008).
the (+)-DNA strand synthesis. With low frequency the RNA oligomer does not switch
to DR2, in which case (+)-DNA strand synthesis is initiated from DR1. This alternative
route is called in situ priming and results in double-stranded linear DNA, which likely is
nonreplicative. Nevertheless, translocation and priming from DR2 is predominant. Folding
of the (–)-DNA strand facilitates the template switch as it ensures that DR1 and DR2 lie
close together in space (Lewellyn and Loeb, 2007). (+)-DNA strand synthesis is facilitated
by the RT domain starting from DR2 until the very 5′ end of the (–)-DNA strand. Then,
a third translocation of the growing end of (+)-DNA strand mediated by small terminal
repeat elements yields circulation and upon further extension of the (+)-DNA stand results
in rcDNA. The intermediate steps of the reverse transcription of the pgRNA are shown in
detail in Figure 2.10.
Capsid maturation, envelopment, and secretion. As pointed out before, mature
HBV particles predominantly contain partially double-stranded, relaxed circular DNA.
But HBV DNA found in the cytoplasm of infected cells contain equal amounts of partially
double-stranded and single-stranded DNA (Summers and Mason, 1982; Wei et al., 1996).
Thus, the synthesis of the (+)-DNA strand likely triggers modifications on the surface of the
capsid, which facilitate the interaction with HBV’s surface proteins and afford envelopment.
The molecular modifications are suspected to involve changes in the phosphorylation state
of HBcAg (Liao and Ou, 1995). Translocation of the capsid across the ER membrane is
mediated by their interaction with LHBsAg and results in enveloped particles, which are
secreted into the bloodstream (Huovila et al., 1992).
2.2.3 Genetic Diversity and HBV Genotypes
The HBV genome has been classified into eight well characterized genotypes A to H based
on a nucleotide variation threshold of 8% over the entire genome (Arauz-Ruiz et al., 2002;
Naumann et al., 1993; Norder et al., 1994, 2004; Okamoto et al., 1988; Stuyver et al.,
2000) and two additional (very rare) genotypes, namely I (Olinger et al., 2008; Tran et al.,
2008; Yu et al., 2010) and J (Tatematsu et al., 2009). HBV genotypes have been found
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Figure 2.10: Reverse transcription of the pregenomic RNA. (A) The pgRNA is reverse
transcribed into (–)-DNA until the very 5′ end. The RNaseH domain of the
polymerase digests the pgRNA but leaves a short RNA oligomer, which after
translocation to DR2 serves as a primer for the synthesis of the (+)-DNA
strand. (B and C) Translocation of the RNA oligomer is supported by bending
of the (–)-DNA strand facilitated by functional element 5E, M5, 3E, and M3.
(D) The growing end of the (+)-DNA strand is translocated to the 3′ end
of the (–)-DNA strand, which creates the relaxed circular structure of the
HBV genome. The translocation of the growing end is possible due to small
repeat elements 5′r and 3′r. (E and F) Structural representation of partially
double-stranded, relaxed circular DNA, the form of the HBV genome present
in mature particles. Permission to use this figure was granted by Elsevier
(Nassal, 2008).
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Genotype Genome Length (NT) Insertions and Deletions
A 3221 Insertion of two amino acids at position 153 and
154 in HBcAg
B 3215
C 3215
D 3182 Deletion of amino acid 1 to 11 in preS1
E 3212 Deletion of amino acid 11 in preS1
F 3215
G 3248 Insertion of 36 nucleotides after the 5th base in
HBcAg. Deletion of amino acid 11 in preS1
H 3215
I 3215
J 3182 Deletion of amino acid 1 to 11 in preS1
Table 2.2: Hepatitis B virus genotypes and genome lengths. The typical genomes of geno-
types B, C, F, H, and I have a length of 3215 nucleotides. The typical genomes
of genotypes A, D, E, G, and J differ due to genotype specific insertions or
deletions. Summary is based on Schaefer (2007); Tatematsu et al. (2009); Tran
et al. (2008).
to influence the rate of chronicity (Ogawa et al., 2002; Suzuki et al., 2005; Zhang et al.,
2008), the course of the disease (Chan et al., 2004; Kao et al., 2000; Livingston et al.,
2007; Sánchez-Tapias et al., 2002; Thakur et al., 2002; Yuen et al., 2004), and the response
to interferon treatment (Section 2.3.1). HBV genomes of genotypes B, C, F, H, and I
regularly have a length of 3215 nucleotides. The genome of other genotypes differ slightly
due to genotype specific insertions or deletions (Table 2.2).
HBV genotypes are further classified into subgenotypes, which are named according to
the genotype with a numeric appendix. The following outline takes reference to Lin and
Kao (2011). HBV subgenotypes are defined based on a 4% divergence across the com-
plete genome. Genotype A is divided into A1, A2, and A3, which are prevalent in distinct
geographic areas, namely sub-Saharan Africa, Northern Europe, and Western Africa, re-
spectively. Genotypes B and C are the dominant genotypes in Asia. B1 is common in Japan
and B6 is common in indigenous populations in Alaska, Northern Canada, and Greenland.
Subgenotypes B2 to B5, which are prevalent throughout Asia except Japan, have a re-
combinant core gene that partly consists of genotype C. Subgenotypes C1 to C3 are most
prevalent in Taiwan, China, Korea, and Southeast Asia while subgenotype C4 circulates
in Australia. C5 is mainly found in the Philippines and in Vietnam. The subgenotypes
of genotype D (D1 to D5) are widely spread across Eastern Europe, the Mediterranean
region, northern Africa, Russia, the Middle East, and India. To date, no subgenotypes
are defined for genotype E, which is restricted to West Africa. Genotypes F and H are
phylogenetically closely related. Genotype F is divided into subgenotypes F1 to F4 that
are prevalent in Central and South America while genotype H is primarily found in Mexico
and Nicaragua (Devesa and Pujol, 2007). Genotype G is the most uncommon genotype
among the established genotypes (A to H). Isolates were found in France, Germany, and
the United States. Genotype G occurs in persons infected with a second genotype, usually
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genotype A. All genotype G genomes harbor the G1896A stop codon mutation such that
the second genotype is required to express HBeAg (Kato et al., 2002). The newly identified
genotype I was found in Vietnam and Laos. Genotype J was found in one individual that
lived in the Ryukyu Islands in Japan.
HBV dual infections, defined as the simultaneous infection with two heterologous HBV
strains, may lead to the exchange of genetic material between the viral strains. The
resulting hybrids are referred to as recombinant forms or recombinants. Recombination
events may arise at multiple steps during the replication cycle of HBV. Frequent inter-
and intramolecular recombinations were described at RNA and DNA level during either
transcription of cccDNA or reverse transcription of pgRNA (Newbold et al., 1995; Yang and
Summers, 1995). Due to their high prevalence in certain geographic regions recombinant
forms play an important role for the genetic diversity of HBV. Two distinct versions of
C/D recombinants developed into the two most prevalent HBV variants in Tibet (Cui
et al., 2002; Wang et al., 2005a). Subgenotypes B2 to B5, which are prevalent throughout
Asia except for Japan, have a recombinant core gene that partly consists of genotype
C, as mentioned before. A/D recombinants circulate in Italy, South Africa, and India
(Chauhan et al., 2008; Morozov et al., 2000; Owiredu et al., 2001). Two studies analyzed full
genome HBV sequence data and identified eight genomic regions, in which recombination
breakpoints accumulate (Simmonds and Midgley, 2005; Yang et al., 2006).
2.2.4 Origin of Hepatitis B in Humans
The origin of HBV in humans has not yet been resolved (Locarnini et al., 2013). Several
models were proposed but none of these are conclusive and widely accepted.
The so-called “Out of South America” hypothesis proposes that HBV originated in the
New World and spread about 400 years ago in concert with the colonization (Bollyky et al.,
1997). Two lines of arguments contradict this hypothesis. First, this model implies that
genotypes F and H (today common in South America) migrated to Africa and Asia to
develop a large chronic carrier population and diverse into non-F/H genotypes in only 400
years. Second, HBV is widely distributed in wild living non-human primate species such
as chimpanzees and gorillas as well as in gibbons and orangutans (Locarnini et al., 2013).
Following the “Out of South America” hypothesis these infections in primates were caused
by humans. Both implications seem very unlikely.
HBV may have co-evolved with anatomically modern humans as they migrated out of
Africa 100,000 years ago (Norder et al., 1994). As a consequence the genetic relationships
between human subpopulations should be reflected in the genetic diversity of HBV endemic
in the respective human subpopulations. But this is not the case. For example, the
native American population (which is associated with HBV genotype F) is genetically
closely related to “Mongolian” North East Asians associated with genotypes B and C. But
genotypes F is not closely related to genotypes B and C, which contradicts the “Out of
Africa” hypothesis (Locarnini et al., 2013).
Another model proposes several independent transmission events from primates to hu-
mans with several distinct genetic variants (Simmonds, 2001). This hypothesis is similar to
that on the origins of the human immunodeficiency virus (HIV). Phylogenetic studies iden-
tified multiple cross-species transmission events of African non-human primate lentiviruses
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(simian immunodeficiency virus (SIV)) as the origin of HIV. HIV-2 likely emerged from
sooty mangabey (Cercocebus atys) SIV (Hirsch et al., 1989; Gao et al., 1992). Similarly,
several subgroups of HIV-1 can be linked to at least three transmission events of chimpanzee
SIV from an African chimpanzee species to humans (Gao et al., 1999). The cross-species
transmission hypothesis for HBV is supported by the fact that geographic areas of high
HBV prevalence (South America, sub-Saharan Africa, and South East Asia) are those in
which contact of humans with primates are most likely. Nevertheless, the HBV genotypes
present in the respective areas are not particularly closely related to the genomes of the
non-human primate viruses in these regions. Thus, the species involved in the transmis-
sion(s) to humans are still unidentified and likely have become extinct, which makes the
multiple transmissions hypothesis difficult to validate (Locarnini et al., 2013).
2.3 Hepatitis B Therapy
The primary goal of hepatitis B therapy is to prevent the progression of liver degeneration in
form of liver cirrhosis and HCC. The main viral factors associated with disease progression
are persistent presence of HBeAg and persistently high levels of HBV DNA (Chen et al.,
2006; Iloeje et al., 2006; Kwon and Lok, 2011). Thus, long-term suppression of viral
replication and possible treatment induced HBeAg seroconversion have to be achieved.
The level of HBV DNA in serum is the most important indicator of HBV treatment success
or failure. Additionally, normalization of alanine aminotransferase levels, decrease of liver
inflammation, and loss of HBeAg are used in clinical routine to measure treatment outcome.
The ultimate goal of therapy is the clearance of HBsAg and the seroconversion to anti-HBs.
This marks the endpoint of an infection and normally ensures life-long immunity. As of
2014, seven drugs have been approved by the United States Food and Drug Administration
for the treatment of hepatitis B: two variants of interferon (IFN) and five nucleos(t)ide
analogues (NA).
2.3.1 Treatment with Interferon
Interferons are glycoproteins that have strong immunomodulatory, antiviral, and antitumor
activity. Interferons were first described by Isaacs and Lindenmann (1957) who demon-
strated their antiviral activity and named them due to their ability to “interfere” with viral
replication. Interferons are signaling proteins that upregulate the transcription of hundreds
of so-called interferon-stimulated genes, whose protein products mediate immunomodula-
tory, antiviral, and antitumor effects (Fensterl and Sen, 2009).
Standard interferon (interferon α-2b) was the first drug to be approved for the treatment
of hepatitis B. Long-term follow-up studies of interferon responders showed that it reduces
the risk of progression to cirrhosis and HCC for both HBeAg-positive and HBeAg-negative
carriers (Papatheodoridis et al., 2001; van Zonneveld et al., 2004). Nowadays pegylated
interferon α-2a has superseded standard interferon due to higher response rates and the
easier dosing schedule of pegylated interferon (weekly administration instead of daily or
three times a week administration). The process of pegylation adds polyethylene glycol
to interferon, which enhances the half-life compared to native interferon (Lau et al., 2005;
Marcellin et al., 2004).
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Figure 2.11: The diagram allows to compute the expected probability of sustained response
to interferon for HBeAg-positive patients. Permission to use this figure was
granted by Elsevier (Buster et al., 2009).
Standard therapy with pegylated interferon α-2a consists of one year of weekly ad-
ministration. Treatment response is evaluated 24 weeks after the administration of the
last dose, after the so-called follow-up period. Approximately 30% of HBeAg-positive pa-
tients achieve HBeAg seroconversion during the course of the treatment (Chan et al., 2005;
Janssen et al., 2005; Lau et al., 2005). A long-term follow-up study of 172 patients with a
mean observation period of three years revealed HBeAg and HBsAg seroconversion rates
of 37% and 11%, respectively (Buster et al., 2008).
For HBeAg-negative patients the rates of sustained virological response (suppression of
HBV DNA to below 400 copies per milliliter) were 19% after one year of treatment with
pegylated interferon α-2a and 24 weeks of follow-up (Marcellin et al., 2004). After 3 years
of long-term follow-up normal ALT levels were observed in 31% of the patients and 28%
of the cohort showed low HBV DNA levels (below 10,000 copies per milliliter). Loss of
HBsAg, thus cure of hepatitis B, was observed in 8.7% of the cohort.
Interferon facilitates limited treatment durations, but has partly severe side effects. Al-
most all patients experience initial flu-like illness, fatigue, and anorexia. Other common
adverse effects include emotional unstableness, hair loss, and exacerbation of autoimmune
illnesses (Kwon and Lok, 2011). Interferon treatment might accelerate liver inflammation,
thus, it is contraindicated for patients with decompensated cirrhosis or HBV-related liver
failure (Hoofnagle et al., 1993; Kwon and Lok, 2011). Nevertheless, interferon is effective
and safe for patients with compensated cirrhosis.
Low response rates between 19% and 30% in combination with painful and severe side ef-
fects make the prediction of treatment response to interferon based on pretreatment patient
or virus characteristics a clinically relevant research question. High pretreatment serum
alanine aminotransferase levels, low HBV DNA levels, the presence of HBV genotypes A
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and B, and progressed liver inflammation have been associated with higher response rates
for interferon treatment (Lok and McMahon, 2001; Niederau et al., 1996). Buster et al.
(2009) derived an algorithm to compute the expected probability of treatment response to
pegylated interferon based on the treatment history of 721 HBeAg-positive patients (Figure
2.11). Nevertheless, pretreatment parameters provide only limited evidence of treatment
response. Recent research led to the development of so-called response-guided interferon
therapy. During treatment, decline of hepatitis B surface antigen and HBV DNA at week
twelve were shown to be effective predictors of nonresponse to interferon (Chan et al.,
2011; Rijckborst et al., 2010, 2012; Sonneveld et al., 2010, 2013). If no significant decline
of quantitative HBsAg levels and HBV DNA is achieved during the first twelve weeks of
treatment the chances of sustained response are near zero, thus treatment can be stopped.
The underlying determinants of response to interferon, however, may be genetic factors and
immunological disposition of the host as well as genetic factors of the virus itself beyond
HBV genotype (Kamatani et al., 2009).
2.3.2 Treatment with Nucleos(t)ide Analogs
Nucleos(t)ide analogs are the second major treatment option for chronic hepatitis B. These
compounds interfere with the HBV replication cycle by inhibiting the reverse transcrip-
tion. Nucleos(t)ide analogs are chemically similar to deoxynucleotides, the natural building
blocks of DNA. As a consequence the HBV polymerase incorporates nucleos(t)ide analogs
into the DNA chain during reverse transcription of the pregenomic RNA into viral DNA.
Nucleos(t)ide analogs lack a 3′-hydroxyl group, thus they do not allow the formation of a
further 5′-3′ phosphodiester bond needed to extend the DNA chain (chain termination).
This prevents the synthesis of the HBV DNA.
Treatment with nucleos(t)ide analogs effectively blocks viral replication, which lowers
the long-term risk of liver failure. However, this effect lasts only as long as HBV has not
developed resistance to the treatment. Resistance is mediated by suitable mutations in the
reverse transcriptase domain of the polymerase gene. A resistant form of the polymerase
can distinguish nucleos(t)ide analogs from natural deoxynucleotides and incorporates nu-
cleos(t)ide analogs at lower rates compared to wild-type polymerases. Resistance is the
major problem in the long-term treatment of hepatitis B with nucleos(t)ide analogs. Re-
sistance becomes evident as virological breakthrough, which is defined as an increase of
the HBV DNA level of at least one log10 level or the redetection of HBV DNA after it
had become undetectable (Kwon and Lok, 2011). Increase of alanine aminotransferase
levels (biochemical breakthrough) and increased liver inflammation may follow virological
breakthrough if therapy is not adapted.
The five approved nucleos(t)ide analogs are classified into three groups based on their
chemical structure.
• l-nucleosides. Lamivudine (3TC) and Telbivudine (LdT) are enantiomers of the
natural nucleosides and have an inverted configuration at all chiral centers. It was
demonstrated that viral polymerases process l-nucleosides better than the respective
d-enantiomeric counterparts.
• Acyclic nucleoside phosphonates. Adefovir (ADV) and Tenofovir (TDF) have
2.3 Hepatitis B Therapy 25
Amino acid substitutions in the RT domain 3TC LdT ETV ADV TDF
M204I R R I S S
L180M+M204V R R I S S
N236T S S S R I
A181T/V I/R R S R I
L180M+M204I/V±I169T±V173L±M250V R R R S S
L180M+M204I/V±T184G±S202I/G R R R S S
Table 2.3: Drug resistance mutations of all approved nucleos(t)ide analogs with reference
to Zoulim et al. (2009). R indicates resistance, I intermediate resistance, and S
indicates susceptibility. Row five (L180M+M204I/V±I169T±V173L±M250V)
and row six (L180M+M204I/V±T184G±S202I/G) list two disjunct ETV resis-
tance pathways. At least one of the mutations I169T, V173L, M250V, T184G,
or S202I/G together with L180M and M204I/V is required to confer full clini-
cal resistance towards ETV. Positions are numbered with respect to the reverse
transcriptase domain of the HBV polymerase according to the standard notation
(Stuyver et al., 2001).
to be phosphorylated (intracellularily by cellular kinases) before they can interact
with the HBV polymerase.
• d-cyclopentane. Entecavir (ETV) has a D-configured cyclopentyl group that fits
directly into the hydrophobic pocket of HBV polymerase.
Cross resistance is defined as resistance to drugs to which a virus has never been ex-
posed. Resistance to any drug confers at least some degree of cross resistance to other
members of its group, and may reduce effectiveness of nucleos(t)ide analogs from other
groups. Lamivudine and Telbivudine have very similar sets of resistance mutations (Table
2.3). A single nucleotide change is required to confer full clinical resistance. The two
most important resistance mutations rtM204I/V (Isoleucine or Valine at position 204 of
the reverse transcriptase) that confer resistance to Lamivudine and Telbivudine reduce
sensitivity to Entecavir but not to Adefovir or Tenofovir. Multiple mutations in addition
to rtM204I/V are required for high-level resistance to Entecavir (Table 2.3). The resistance
mutations rt181T/V are shared between l-nucleosides and the acyclic nucleoside phospho-
nate Adefovir. The rtN236T mutation, which confers resistance to Adefovir and diminishes
sensitivity towards Tenofovir, does not confer significant cross resistance to l-nucleosides
and Entecavir. Cross resistance is held responsible for the high rate of drug resistance in
patients with previous treatment failure (Rapti et al., 2007; Tenney et al., 2009). As a
consequence, it is advised to start therapy with Tenofovir and Entecavir (European Asso-
ciation for the Study of the Liver, 2012). These drugs are very potent inhibitors of the viral
replication and require multiple nucleotide exchanges to develop resistance. This reduces
the long-term risk of drug resistance in hepatitis B patients.
NAs often have to be administered life-long (Kwon and Lok, 2011). Finite treatment du-
ration might be achievable for HBeAg-positive patients who experience HBeAg seroconver-
sion during NA administration. Treatment should be continued for at least 12 months after
HBeAg seroconversion though. Rates of sustained response (defined as HBeAg-negativity
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and undetectable HBV DNA levels) were found to be as high as 91% after five years of
follow-up if NA treatment was continued for at least 12 months after HBeAg seroconver-
sion (Lee et al., 2010). However, treatment duration with NAs is unpredictable prior to
therapy as it depends on the timing of HBeAg seroconversion.
One year of NA treatment results in undetectable HBV DNA levels in up to 93% of
HBeAg-negative patients (Lai et al., 2007; Marcellin et al., 2008b). Nevertheless, viral
relapse occurs in almost all patients only 24 weeks after the discontinuation of NA ad-
ministration (Lai et al., 2006). After four to five years of NA treatment 67% to 86% of
HBeAg-negative patients show maintained viral suppression after discontinuation of treat-
ment (Hadziyannis et al., 2006; Marcellin et al., 2010). Thus, a treatment pause with tight
patient monitoring might be scheduled after four to five years of NA administration to
evaluate off-treatment suppression of viral replication.
In contrast to treatment with interferon, treatment with nucleos(t)ide analogs is tolerated
quite well (Kwon and Lok, 2011). Adefovir and Tenofovir are known to be associated
with nephrotoxicity and have been reported to cause renal tubular dysfunction, including
Fanconi syndrome (Heathcote et al., 2011; Marcellin et al., 2008a). Children treated with
Tenofovir experienced decrease in bone mineral density (Purdy et al., 2008). One case
of lethal lactic acidosis was reported in a patient who had highly impaired liver function
before treatment (Lange et al., 2009). Nevertheless, nucleos(t)ide analogs show convincing
short-term safety. The long-term safety in terms of decades of administration of these
drugs has obviously not been established yet.
2.4 DNA Sequencing
DNA sequencing is the process of measuring the order of the four types of nucleotides
along a DNA chain molecule. It is the key technology to determine the quasispecies of
HBV. Sanger sequencing (first-generation sequencing) refers to a set of sequencing tech-
nologies, which utilize dideoxynucleotides (chain terminator nucleotides) in a polymerase
chain reaction (PCR) to obtain DNA fragments of different lengths, which are separated
by electrophoresis (Sanger et al., 1977a). Frederick Sanger, who was honored with the
Nobel Prize in Chemistry in 1980 for his work on DNA sequencing, derived the first full
genome DNA sequence of an organism called bacteriophage φX174 using this approach
(Sanger et al., 1977b). Later in 2000, the first draft of the human genome was published
by the use of Sanger sequencing technologies, which by the time had undergone several
significant improvements (Lander et al., 2001; Venter et al., 2001). In the mid-2000’s,
second-generation sequencing (2ndGS) technologies became available and replaced Sanger
sequencing in many applications (Mardis, 2008; Metzker, 2010). With respect to sequenc-
ing of viral populations, Sanger sequencing has several significant limitations: sensitivity
to detect minor variants and the loss of linkage information. Second-generation sequenc-
ing technologies make use of high levels of miniaturization and parallelization to increase
the sequencing throughput and to afford deeper insights into the composition of the viral
quasispecies. Moreover, second-generation sequencing technologies amplify and read-out
individual strands of DNA and, thus provide linkage information over the full read length.
Nevertheless, as of 2014, Sanger sequencing is still used in the clinical routine for the
treatment of hepatitis B due to its wide availability and low cost. In the remainder of
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this Section we briefly introduce the cornerstones of modern Sanger sequencing and two
second-generation sequencing technologies, Roche/454 and Illumina/MiSeq.
2.4.1 Sanger Sequencing
The following outline takes reference to Janitz (2011). Sanger sequencing utilizes a PCR
to facilitate sequencing (Figure 2.12). A primer specific to the DNA substratum to be se-
quenced is required to initiate the PCR. The primer is an oligonucleotide complementary
to a designated region of the DNA substratum. Double-stranded DNA needs to unwind
and separate into single-stranded DNA. This allows the primer to bind to the designated
region, which may be on either of the two complementary DNA strands. The separation
of the two complementary DNA strands is referred to as DNA denaturation, which is
achieved by heating (with a temperature high enough to break the hydrogen bonds be-
tween the complementary strands). In the subsequent PCR the primer is extended by
incorporation of nucleotides according to the DNA substratum. The trick is that a small
portion of dideoxynucleotides in addition to normal nucleotides is included in the reaction.
Dideoxynucleotides are characterized by the absence of the 3′-hydroxyl group, which pre-
vents the binding of another nucleotide at the 3′ end as no phosphodiester bond can be
established (see upper-right corner of Figure 2.12). Dideoxynucleotides are incorporated
during the PCR with a certain rate, which is mainly determined by the biochemical struc-
ture of the DNA polymerase that facilitates the PCR, the DNA sequence context, and the
chemical structure of the dideoxynucleotides. The sporadic incorporation of dideoxynu-
cleotides leads to chain termination at different sequence positions and results in DNA
fragments of different lengths.
Dideoxynucleotides are either labeled with radioactive or fluorescent tags. The latter
technique was introduced in 1986 and allows the PCR to be performed in a single reaction
tube (Smith et al., 1986). Sequencing with radioactive labeled dideoxynucleotides requires
four separate reactions, each enriched with one of the four dideoxynucleotides to determine
the sequence information of the respective base. Radioactively tagged dideoxynucleotides
are localized by X-rays, which stimulate the emission of beta particles. Likewise, a laser
excites the fluorescently tagged dideoxynucleotides and the corresponding light signal is
recorded by a camera module.
Before 1990, DNA fragments of different lengths were separated by electrophoresis using
polyacrylamide gel (PAG) as a medium. The principle of electrophoresis says that charged
particles migrate in an electric field with smaller fragments migrating faster. Thus, the neg-
atively charged DNA fragments are separated by size. Nowadays, capillary electrophoresis
affords faster separation of DNA fragments with higher resolution and better separation
efficiency (Guttman et al., 1990; Luckey et al., 1990; Swerdlow et al., 1990). Capillary
electrophoresis is a miniaturized version of electrophoresis using PAG in a capillary, which
minimizes disturbance by optimizing the surface-area-to-volume ratio.
Another cornerstone of efficient Sanger sequencing is cycle sequencing introduced by
Murray (1989). In cycle sequencing the first steps of the sequencing process (denatura-
tion, primer binding, and chain extension/termination) are repeated 20 to 50 times by
cycling through distinct temperatures optimized to support the respective reactions of the
sequencing process. This improves the sensitivity of the sequencing reaction and permits
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Figure 2.12: Visualization of the four steps of Sanger sequencing. (1) The sequencing reac-
tion mixture includes the DNA substratum to be sequenced, primer to initiate
the polymerase chain reaction, normal nucleotides (dNTPs), and dideoxynu-
cleotides (ddNTPs). (2) Sporadic incorporation of dideoxynucleotides dur-
ing PCR leads to chain termination at different positions and DNA frag-
ments of variable length. (3) Variable-length DNA fragments are separated
by size by the use of capillary gel electrophoresis. (4) Fluorescently tagged
dideoxynucleotides are detected by laser/camera aperture. Fluoresce data is
read-out as a chromatogram. Subsequent computational analysis of the chro-
matogram provides the DNA sequence. Figure was obtained from Wikipedia
(http://en.wikipedia.org/wiki/File:Sanger-sequencing.svg).
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sequencing of small amounts of DNA substrata.
Other very important lines of research that have led to the excellent effectivity and ef-
ficiency of Sanger sequencing today is based on the development of optimized fluorescent
dyes (Ju et al., 1995; Metzker et al., 1996; Rosenblum et al., 1997), optimized dideoxynu-
cleotides (Prober et al., 1987), and polymerases specifically designed for sequencing (Reeve
and Fuller, 1995; Tabor and Richardson, 1989, 1990). All components of the chemistry are
optimized among other properties to provide high physio-chemical stability, equal incorpo-
ration rates of the four dideoxynucleotides, minimally overlapping emission spectra, high
fluorescence intensity, and uniform electrophoretic mobilities. The importance of the opti-
mization of the chemistry to allow efficient read-out of the fluorescence intensity data and
its subsequent transformation into sequence data can not be overestimated.
The raw image data need to be preprocessed to derive sequencing chromatograms, which
consist of deconvolved, smoothed, and noise-reduced fluorescence intensity values at sev-
eral thousand uniformly spaced time points. The sequencing chromatograms are then
translated into a DNA sequence, referred to as base-calling. Base-calling is algorithmi-
cally trivial for ideal data, which is noise-free and in which all peaks are evenly spaced
and non-overlapping. But several experimental and systematic factors lead to impaired
and noisy chromatograms, which are more difficult to interpret (see Ewing et al. (1998)
for a summary of influencing factors). Progress was made in the development of efficient
and error-tolerant algorithms and their implementations to derive and interpret sequencing
chromatograms (Ewing et al., 1998; Flood et al., 2002; Nickerson et al., 1997).
2.4.2 Roche/454 Pyrosequencing
The Roche/454 FLX sequencer was the first commercially available second-generation se-
quencing technology (Margulies et al., 2005). It performs several hundred thousand inde-
pendent pyrosequencing reactions in the wells of a picotiter plate. We now briefly intro-
duce pyrosequencing, a sequencing technology that was developed in the 1990s, and the
Roche/454 miniaturization technique with reference to Mardis (2008).
Pyrosequencing. Pyrosequencing is an implementation of the idea of sequencing-by-
synthesis rather than sequencing by chain termination (Ronaghi et al., 1996, 1998). Given
a single-stranded DNA stratum, the complementary strand is synthesized by repetitively
adding only one of the four possible natural nucleotides at a time. Incorporation of nu-
cleotides by a DNA polymerase results in the release of pyrophosphate, which is converted
to adenosine triphosphate (ATP) by an ATP sulfurylase. ATP is made observable as light
using the firefly luciferase. The number of nucleotides that were added in a row determines
the amount of produced ATP and, thus the intensity of the light emitted. The interpreta-
tion of the sequence of light signals of varying intensity affords the read-out of the DNA
sequence.
Roche/454 pyrosequencing. The pyrosequencing technology was refined and im-
proved by Roche/454 to allow massively parallel sequencing. In the library preparation
preprocessing step, the DNA strata to be sequenced are marked with individual 454-specific
adapter sequences. The sequencing strata are then mixed with agarose beads, which carry
oligonucleotides complementary to the 454-specific adapter sequences on their surfaces.
Each bead is associated with at most one DNA strand of the sequencing stratum. The re-
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sulting complexes of beads and DNA are then isolated into individual water-in-oil emulsion
micelles. Inside the micelles a PCR is initiated that results in approximately one million
copies of each individual DNA strand. The beads are then single-fitted into the wells of
a picotiter plate, where individual pyrosequencing reactions are initiated, maintained, and
monitored. The wells ensure that the beads are fixed to a specific location on the plate.
This allows for the recording of the individual fluorescent emissions of the individual py-
rosequencing reactions and facilitates the determination of the DNA sequences.
2.4.3 Illumina/MiSeq Sequencing
Illumina/MiSeq utilizes a sequencing-by-synthesis approach that makes use of custom chain
terminator nucleotides, derivatives of natural nucleotides in which the 3′-hydroxyl group is
chemically blocked. The blocking of the 3′-hydroxyl group ensures that only one nucleotide
is added at a time. The chain terminator nucleotides are fluorescently labeled such that the
type of nucleotide can be identified upon incorporation. Sequencing takes place in turns.
Each turn consists of three steps. First, all four types of chain terminator nucleotides
are added. Second, incorporation is recorded in the imaging step. Third, the 3′ blocking
component is chemically removed such that further chain extension is feasible.
Before the sequencing reaction, the DNA strata need to be amplified in the so-called
cluster creation phase. Therefore, single-stranded DNA fragments, which were randomly
fragmented and ligated with adapter sequences at both ends, are immobilized on the surface
of a flow cell. Then, solid-phase amplification is initialized that creates approximately one
million copies of each DNA fragment in close proximity to each other (clusters of identical
DNA fragments). Solid-phase amplification was developed as a novel method to amplify
DNA, in which primers are attached to a solid surface (Adessi et al., 2000; Bing et al.,
1996).
2.5 Probabilistic Reasoning and Statistical Learning
Throughout the thesis we make use of probabilistic reasoning and statistical learning meth-
ods to infer information from data. In the following Sections we briefly introduce the basic
rules and notations of probability theory, probabilistic reasoning, and two important sta-
tistical learning models.
2.5.1 Probability Theory and Probabilistic Reasoning
The following introduction to probability theory and probabilistic reasoning has been
adapted from Barber (2012).
Random variables are used to describe possible outcomes of random experiments, e.g.
the experiment of a coin toss, which can result in either “heads” or “tails”. The set of all
possible outcomes or states of a random variable x is referred to as its domain: dom(x).
For now we assume dom(x) to be a finite set. The probability of a random variable x to
be in state a ∈ dom(x) is denoted by P (x = a). P (x = a) takes values between 0 and 1
and quantifies the level of belief that x is in state a. P (x = a) = 1 means that we are
absolutely certain that x is in state a and P (x = a) = 0 means that we are absolutely
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certain that x is not in state a. For P (x = a) we use the short notation P (x) to depict the
probability of any respective state a ∈ dom(x).
The normalization condition ascertains that the probabilities over all states add up to
one: ∑
a∈dom(x)
P (x = a) = 1.
To sum over all possible states of a random variable we usually write
∑
x P (x) instead of∑
a∈dom(x) P (x = a).
Additionally, the rules of probability theory states that for two random variables x and
y the following equation holds:
P (x and y) = P (x) + P (y)− P (x or y).
The notation P (x, y) is used as shorthand to depict P (x and y).
Based on the joint distribution P (x1, . . . , xn) of a set of random variables the distribution
of a subset of these variables can be computed by the process of marginalization.
P (x1, . . . , xi−1, xi+1, . . . , xn) =
∑
xi
P (x1, . . . , xn) (2.1)
After n− 1 steps of marginalization in which all variables except xi have been marginal-
ized P (xi) denotes the marginal distribution of xi with respect to the joint distribution
P (x1, . . . , xn).
If dom(x) is finite, x is called a discrete random variable. For a real-valued random
variable x (dom(x) = R) a probability density function is defined as a function
f(x) : dom(x) 7−→ R
such that
f(x) ≥ 0,∫ ∞
−∞
f(x)dx = 1,
and the probability that x takes a value between a ∈ R and b ∈ R is given by
P (a ≤ x ≤ b) =
∫ b
a
f(x) dx.
The multivariate case f(x1, . . . , xn) is treated analogously with integration over the
respective regions to compute P (a1 ≤ x1 ≤ b1, . . . , an ≤ xn ≤ bn). Note that formally
P (x = a) is zero for any real-valued variable x and all a ∈ R. However, we write P (x) for
both discrete and real-valued variables, thus we do not distinguish between probabilities
and probability density function values. In the real-valued case the expression P (x) can
be considered as a shorthand for
∫
x∈∆ f(x) dx where ∆ is a small region centered around
x. This is well defined in a probabilistic sense and in the limit (∆ being very small),
this would give P (x) ≈ ∆f(x). The same ∆ is then consistently used for all probability
density functions, which results in a common prefactor ∆ in all expressions. Usually the
∆ values can be ignored as they cancel out when computing relative probabilities. In this
way, the standard rules of probability carry over to real-valued variables. Further, we write
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∫
x P (x) dx as a valid expression for real-valued and discrete random variables x assuming
that integrations are replaced by finite summations for discrete random variables.
Next, we introduce conditional probabilities P (x|y). P (x|y) denotes the probability of x
given that we know the state of y. If P (y) > 0 the conditional probability P (x|y) is defined
as:
P (x|y) = P (x, y)
P (y)
. (2.2)
From this definition and the fact that P (x, y) = P (y, x) Bayes’ rule is derived:
P (x|y) = P (x)P (y|x)
P (y)
.
Bayes’ rule. Bayes’ rule plays a key role in probabilistic reasoning. It allows us to
relate P (x|y) with P (y|x). This is useful in the context of a generative model P (D|θ) of
the data D, which depends on a set of model parameters θ. The generative model P (D|θ)
is a hypothesis about how the data D was sampled dependent on θ. Using Bayes’ rule we
compute P (θ|D), which summarizes our knowledge about the distribution of θ after we
have observed data D:
P (θ|D) = P (θ)P (D|θ)
P (D) .
In this context we call P (θ|D) the posterior, P (θ) the prior, P (D|θ) the data likeli-
hood, and P (D) the evidence. The evidence P (D) is defined such that P (θ|D) is a valid
probability distribution and sums up to 1. Thus,
P (D) =
∫
θ
P (θ)P (D|θ) dθ.
The process of probabilistic reasoning may be reduced to the computation of θ∗, which is
the value of θ that maximizes the posterior distribution:
θ∗ = arg max
θ
P (θ|D).
θ∗ is the so-called maximum a posteriori probability (MAP) estimate, which is an rea-
sonable estimate for θ incorporating prior knowledge and observed data.
The application of Bayes’ rule requires the quantification of the prior belief of the dis-
tribution P (θ). If P (θ) assigns equal probability to all values of θ (a so-called flat prior)
the MAP estimate reduces to the maximum likelihood estimate, which solely maximizes
the data likelihood P (D|θ).
Model selection. Bayes’ rule is also applied when comparing alternative generative
models P (D|M1, θ1), . . . , P (D|Mm, θm). Each model Mi has a prior probability P (Mi)
and its own set of parameters θi with a prior distribution P (θi|Mi). We are interested in
the models’ posterior probabilities, which are given by
P (Mi|D) = P (Mi)P (D|Mi)∑m
j=1 P (Mj)P (D|Mj)
where
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P (D|Mi) =
∫
θi
P (θi|Mi)P (D|Mi, θi) dθi. (2.3)
Two models Mi and Mj are compared by computing the posterior Bayes’ factor which
is the ratio of the models’ posterior probabilities:
P (Mi|D)
P (Mj |D) =
P (Mi)
P (Mj)
· P (D|Mi)
P (D|Mj) .
The quantities P (D|Mi) are called the marginal model likelihoods. In case of flat model
priors P (Mi), model selection is reduced to comparing the marginal model likelihoods,
which do account for model complexity by averaging P (θi|Mi) ·P (D|Mi, θi) over the whole
parameter space of θi (equation (2.3)). Model selection in Chapter 4 is based on the
marginal model likelihoods.
To summarize, probabilistic reasoning requires a two step approach. First, one considers
a finite set of models M1, . . . ,Mm. Each model is specified by the model prior P (Mi),
the data likelihood function P (D|Mi, θi), and a prior for the model parameters P (θi|Mi).
Model selection is carried out by computing the models’ posterior probabilities P (Mi|D).
These quantities are often computationally expensive to obtain as their computation re-
quires to integrate over the set of model parameters according to equation (2.3). The
model Mi that maximizes P (Mi|D) might be selected, but P (Mi|D) is not straightforward
to interpret. Model posterior probabilities have to be interpreted in the context of the
finite set of models M1, . . . ,Mm that were considered from the beginning. Ideally, one
would need to consider all possible models and compute the models’ posterior probabilities
based on this infinite set of models. This, of course, is usually not feasible. Therefore,
certainty of model selection is expressed in terms of posterior Bayes’ factors, which are
easier to interpret. In the second step of probabilistic reasoning, Bayes’ rule allows us to
infer the posterior distribution of the respective model parameters.
2.5.2 Hidden Markov Models
Hidden Markov models (HMMs) are specific forms of probabilistic models that have been
used extensively in bioinformatics. HMMs can be applied to infer the sequence of internal
(hidden) states using a sequence of observed symbols. In particular, they have been used
in protein secondary structure prediction (Won et al., 2007), gene prediction (Munch and
Krogh, 2006), pairwise and multiple sequence alignments (Durbin et al., 1998; Pachter
et al., 2002), and many more applications (Yoon, 2009). We employ HMMs in Chapter 3
to infer the HBV genotypes and the recombination breakpoints of HBV sequence data. In
the following, we briefly lay out the formal representation of HMMs and the algorithms
required to perform inference in HMMs. We stick close to the systematic and the notation
used in Durbin et al. (1998).
Suppose we are given a finite sequence of hidden states pi = pi1, . . . , piL with pii ∈ A
and a finite sequence of observed symbols x = x1, . . . , xL with xi ∈ B, where each state
or symbol belongs to a respective finite set A or B. The sequence pi is assumed to have
the Markov property: the probability of pii only depends on the previous state pii−1. The
transition from pii−1 to pii is characterized by a set of parameters akl.
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P (pii = l|pii−1 = k) = akl
Additional parameters are the transition probabilities a0k from a virtual start state 0 to
state k. In other words, a0k is the probability to start in state k.
It is further assumed that the observed symbol xi only depends on the hidden state pii via
so-called emission probabilities. The emission probabilities ek(b) are additional parameters
of the model that specify the conditional probabilities P (xi|pii).
P (xi = b|pii = k) = ek(b)
Based on this model description, several distinct statistical inference problems can be
addressed. In the remainder of this Section, we lay out the statistical problems together
with the respective algorithms to perform efficient inference.
input : ek(b), akl, xi
output: pi∗
Initialization:
vk(0) = a0k for k ∈ A
Recursion:
for i = 1, . . . , L do
vl(i) = el(xi) maxk(vk(i− 1)akl), for all l ∈ A
ptri(l) = arg maxk(vk(i− 1)akl), for all l ∈ A
end
Termination:
pi∗L = arg maxk(vk(L))
Traceback:
for i = L, . . . , 1 do
pi∗i−1 = ptri(pi
∗
i )
end
Algorithm 1: Viterbi algorithm
Optimal hidden state sequence. A very important statistical inference problem is
to find the most probable sequence of hidden states pi∗ given a sequence of symbols x, the
transition probabilities alk, and the emission probabilities ek(b). More formally, we are
interested in:
pi∗ = arg max
pi
P (pi|x).
pi∗ can be computed using the Viterbi algorithm, a dynamic programming algorithm. The
key idea is very simple. Let vl(i) be the probability of the most probable subsequence
pi1, . . . , pii such that pii = l. Then, for any state l the quantities vl(i+ 1) can be computed
using all predecessor states k ∈ A:
vl(i+ 1) = el(xi+1) max
k
vk(i)akl. (2.4)
Starting with vl(0) = a0k, the most probable path vl(L) ending at the last position L
in state l can be computed with L iterations using equation 2.4. Then, pi∗L is given by
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arg maxk vk(L) and pi∗i−1 for i = L, . . . , 2 is given by the backtracking pointers ptri(pi
∗
i ),
which are computed simultaneously with vl(i). The Viterbi algorithm is listed as Algorithm
1.
Sequence probability. To compute the probability P (x) of a sequence of symbols x,
the different paths of states pi need to be taken into account. According to the marginal-
ization rule of probability (equation 2.1):
P (x) =
∑
pi
P (x, pi).
The size of the summation grows exponentially with the length of the sequence x. Thus,
enumeration of all possible paths pi does not allow for efficient computation of P (x). The
forward algorithm can compute P (x) in polynomial time. It is a slight modification of the
Viterbi algorithm, in which the maximization steps are replaced with summation steps.
Let fl(i) be the probability of the subsequence x1, . . . , xi with pii = l.
fl(i) = P (x1, . . . , xi, pii = l)
Then, fl(i + 1) can be computed by summation over the quantities el(xi+1)fk(i)akl for
all predecessor states k ∈ A. The forward algorithm is detailed as Algorithm 2.
input : ek(b), akl, xi
output: P (x), fk(i)
Initialization:
fk(0) = a0k for k ∈ A
Recursion:
for i = 1, . . . , L do
fl(i) = el(xi)
∑
k∈A fk(i− 1)akl, for all l ∈ A
end
Termination:
P (x) =
∑
k∈A fk(L)
Algorithm 2: Forward algorithm
Posterior state probability. The computation of the most probable path pi∗ using the
Viterbi algorithm does not provide uncertainty information. The position-specific posterior
probability of a state l given the observed sequence P (pii = l|x) quantifies the belief that
observation xi originating from state k and is of interest in many applications. The position-
specific posterior can be computed by the forward-backward algorithm. This algorithm
requires the quantities fl(i) derived from the forward algorithm and the quantities bl(i)
computed by the backward algorithm. The term bl(i) is defined as the probability of the
subsequence xi+1. . . . , xL given that xi is emitted from state l:
bl(i) = P (xi+1. . . . , xL|pii = l).
The quantities bl(i) are computed backwards (from i = L− 1 to i = 1) using a summation
recursion formula (see Algorithm 3).
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input : ek(b), akl, xi
output: P (x), bli
Initialization:
bk(L) = 1 for k ∈ A
Recursion:
for i = L− 1, . . . , 1 do
bl(i) =
∑
k∈A alkek(xi+1)bk(i+ 1), for all l ∈ A
end
Termination:
P (x) =
∑
k∈A a0kek(x1)bk(1)
Algorithm 3: Backward algorithm
Using the definition of conditional probabilities (equation 2.2) the posterior probability
P (pii = l|x) can be expressed as
P (pii = l|x) = P (x, pii = l)
P (x)
. (2.5)
We rewrite P (x, pii = l) using, first, the definition of conditional probabilities and, second,
the Markov property that the probability of the subsequence xi+1, . . . , xL depends only on
the state pii. Thus,
P (x, pii = l) = P (x1, . . . xi, pii = l)P (xi+1, . . . , xL|x1, . . . xi, pii = l)
= P (x1, . . . xi, pii = l)P (xi+1, . . . , xL|pii = l).
(2.6)
Note that P (x, pii = l) is the product of fl(i) and bl(i). Together with equation (2.5) this
gives rise to the forward-backward algorithm to compute the position-specific posterior.
P (pii = l|x) = fl(i)bl(i)
P (x)
(2.7)
To sum up, the forward-backward algorithm requires the execution of the forward algo-
rithm, the backward algorithm and, finally, the application of equation (2.7).
2.5.3 Support Vector Machines
Support vector machines (SVMs) are a set of supervised learning algorithms, algorithms to
solve supervised learning problems. SVMs are very popular in bioinformatics and in many
areas of machine learning due to their high prediction performance (Wang, 2005b). We
use SVMs to predict treatment response to interferon in Chapter 6. The following outline
is adapted from Hastie et al. (2009).
In supervised learning problems we are given joint observations of two random variables
x and y, thus data points that consist of pairs (x1, y1), . . . , (xn, yn) with xi ∈ Rp and
yi ∈ R. The general goal of supervised learning is to derive a function f(x) that predicts
the value of y given the value of x. We refer to x1, . . . , xn as the input (input data) of
the learning algorithm and to y1, . . . , yn as the output (output data) or the labels. The p
dimensions of x1, . . . , xn ∈ Rp are called the features or the feature set.
Supervised learning problems are divided into two groups:
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Figure 2.13: Support vector machines with perfect separation (left) and soft margin
(right). Permission to reuse this figure was granted by Springer (Hastie et al.,
2009).
(i) Regression problems, in which case the labels y are quantitative (continuous).
(ii) Classification problems, in which case the labels y are qualitative (categorical).
The distinct values of y are called classes. Binary (or 2-fold) classification problems,
in which y can take exactly two different values −1 and +1, are of special importance.
In the following we briefly describe linear soft-margin SVMs used for binary classification.
The goal is to find a linear function
f(x) = βTx+ β0
to estimate the label y. y is set to class −1 if f(x) < 0 and to class +1 otherwise. Suppose
the input data of the two classes can be perfectly separated by many different hyperplanes
(see left side of Figure 2.13). In such cases Vapnik (1996) suggested, in order to construct
a more accurate classifier, to select the hyperplane which is maximally far away from any
data point, the hyperplane which maximizes the so-called margin7. The concept of soft-
margin SVMs generalizes this idea to the case of non-separable classes (right side of Figure
2.13). Here data points are allowed to reside on the wrong side of the hyperplane (Boser
et al., 1992; Cortes and Vapnik, 1995). In order to find the optimal soft-margin separating
hyperplane the following optimization problem needs to be solved.
minimize
{β,β0}
1
2
||β||2 + C
n∑
i=1
ξi
subject to yi(xTβ + β0) ≥ 1− ξi, i = 1, . . . , n
ξi ≥ 0, i = 1, . . . , n
(2.8)
C > 0 denotes a regularization parameter which trades off model complexity for pre-
diction accuracy on the training data. A solution is obtained by the use of the Lagrange
multiplier method. This method introduces Lagrange multipliers αi ≥ 0, i = 1, . . . , n
7The margin is defined as the distance of the hyperplane to the closest point from either class.
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and µi ≥ 0, i = 1, . . . , n associated each with one constraint, such that the problem
reformulates to minimize the Lagrange primal function.
minimize
{β,β0,α}
1
2
||β||2 + C
n∑
i=1
ξi −
n∑
i=1
αi[yi(x
T
i β + β0)− (1− ξi)]−
n∑
i=1
µiξi
subject to αi ≥ 0, i = 1, . . . , n
µi ≥ 0, i = 1, . . . , n
(2.9)
Setting the partial derivatives for β, β0, and α to zero provides.
β =
n∑
i=1
αiyixi (2.10)
0 =
n∑
i=1
αiyi (2.11)
αi =C − µi, i = 1, . . . n (2.12)
Equations (2.10) to (2.12) together with the positivity constraints αi, µi, ξi ≥ 0 can be
substituted into (2.9) to obtain the Lagrange dual problem.
maximize
α
n∑
i=1
αi − 1
2
n∑
i=1
n∑
j=1
αiαjyiyjx
T
i xj
subject to
n∑
i=1
αiyi = 0,
0 ≤ αi ≤ C, i = 1, . . . , n
(2.13)
The Karush-Kuhn-Tucker conditions based on the Lagrange dual formulation provides
the following constrains (Karush, 1939; Kuhn and Tucker, 1951).
0 = αi[yi(x
Tβ + β0)− (1− ξi)], i = 1, . . . n (2.14)
0 = µiξi, i = 1, . . . n (2.15)
0 ≤ yi(xTβ + β0)− (1− ξi), i = 1, . . . n (2.16)
Finally, equations (2.10) to (2.12) together with equations (2.14) to (2.16) uniquely char-
acterize the solution to the primal and dual problem and facilitate its efficient computation.
3 The Dual Infection Model
Remember that all models are wrong; the practical question is how
wrong do they have to be to not be useful.
(George E.P. Box, 1987)
The impact of the HBV genotype on the natural progression of chronic hepatitis B and on
treatment response is discussed in Sections 2.2.3 and 2.3. Whether or not to determine the
genotype before start of therapy is a matter of debate (reviewed in Cooksley (2010); Lin
and Kao (2011)). The three major regional liver associations, the American Association for
the Study of Liver Disease (AASLD) (Lok and McMahon, 2009), the European Association
for the Study of Liver (EASL) (European Association for the Study of the Liver, 2012),
and the Asian Pacific Association for the Study of Liver (APASL) (Liaw et al., 2008) do
not recommend genotyping in their respective guidelines. Nevertheless, several European
treatment guidelines recommend genotyping before therapy, e.g. the German guidelines
(Cornberg et al., 2011), the Swedish guidelines (Lindh et al., 2008), and, if treatment
with interferon is considered, also the Dutch guidelines (Buster et al., 2012). Interferon
treatment affords finite duration therapy of only 48 weeks, which is an important advantage
compared to treatment with nucleos(t)ide analogues (Section 2.3). Sustained response
to interferon strongly depends on the HBV genotype with which the patient is infected.
Patients infected with genotype A and genotype B, the two genotypes that show good
response to interferon, may benefit greatly from interferon therapy.
Several methods have been developed to determine the HBV genotype based on a patient
serum sample. Phylogenetic analysis of the entire viral genome derived by population-
based Sanger sequencing remains the gold standard. Additionally, other computational
approaches were proposed to identify the genotype or a recombination of genotypes using
full- or sub-genome sequence data (Alcantara et al., 2009; Myers et al., 2006; Rozanov
et al., 2004; Schultz et al., 2006; Struck et al., 2010).
The importance and high prevalence of recombinant forms of the HBV genome is dis-
cussed in Section 2.2.3. Genotyping of recombinant forms have been addressed either by
applying an existing genotyping method to individual sliding windows along the genome
(Myers et al., 2006; Rozanov et al., 2004; Alcantara et al., 2009) or, more involved, by
hidden Markov models (Schultz et al., 2006; Zhang et al., 2006). A prerequisite for recom-
bination events is the simultaneous infection with two heterologous HBV strains referred to
as HBV dual infection. Dual infections can be either coinfections or superinfections. Coin-
fection indicates a situation in which a patient was infected with two heterologous strains
either simultaneously or within a brief period of time. According to the definition, the
infection with the second strain occurs prior to the immune response to the first infection.
Superinfection describes an infection with a second strain, which occurs after the initial
infection and after immune response to it (Smith et al., 2005). Despite several studies on
the natural progression of dual infections, their clinical implications are largely unknown
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(Kao et al., 2001; Michitaka et al., 2005). Nevertheless, the importance of identifying and
genotyping dual infections correctly to quantify the risk of interferon therapy failure was
shown by Hannoun et al. (2002).
In this Chapter we focus on the identification and genotyping of intra- and intergenotype
dual infections using population-based sequence data. In the presence of multiple heterol-
ogous viral strains population-based sequence data contains a high number of ambiguous
sequence positions, which hamper state-of-the-art genotyping methods. The correct classi-
fication of patient sequence data is impaired and respective patients are at risk of receiving
suboptimal treatments. We describe an extended version of the work presented in Beggel
et al. (2012). The study was executed in cooperation with Jens Verheyen from the Uni-
versity of Cologne who provided the patient data from routine diagnostics and with Maria
Neumann-Fraune from the University of Cologne who produced clonal sequence data to
validate model predictions. This Chapter is structured as follows. Section 3.1 discusses
in silico genotyping approaches and Section 3.2 summarizes in vitro methods to genotype
HBV dual infections. Section 3.3 outlines the dual infection model and the validation
procedure. Results on synthetic and patient data are presented in Sections 3.4 and 3.5,
respectively. Section 3.6 provides a discussion and final remarks.
3.1 Genotyping HBV in silico
HBV genotypes are defined based on clusters in phylogenetic analysis of full genome se-
quences. However, the proper construction of phylogenetic trees is non-trivial, computa-
tionally intensive, and often requires visual inspection and verification. Thus, in application
scenarios where thousands of sequences need to be genotyped, phylogenetic methods are
not easy to be applied. Methods based on scoring functions were developed to overcome
the limitations of phylogenetic methods and are described in the remainder of this Sec-
tion. We discuss genotyping methods based on sequence similarity and those that utilize
position-specific scoring matrices.
3.1.1 Genotyping by Sequence Similarity
A set of simple yet effective genotyping methods uses sequence similarity measures. Given
a set of reference sequences for each genotype, the approach consists of computing the
similarity of the input sequence to each reference sequence. The input sequence is then
assigned to the genotype of the reference with highest sequence similarity measure unless
the similarity score is less than a given threshold. Similarity measures often require a
precomputed sequence alignment. The National Center for Biotechnology Information
(NCBI) genotyping service bypasses this computationally expensive precondition by the
utilization of BLAST similarity scores (Altschul et al., 1990; Rozanov et al., 2004). In
order to determine and genotype recombinant forms, the sequence similarity methodology
is applied to sliding windows along the input sequence. Rozanov et al. (2004) uses 300 bases
long windows with an overlap of 100 bases. This gives rise to several windows covering each
sequence position. Multiple genotype predictions may be processed to compute position-
wise confidence scores.
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3.1.2 Genotyping by Position-specific Scoring Matrices
Sequence similarity methods utilize only a small set of reference sequences. Detailed ge-
netic information, for instance on conserved or variable regions in the viral genome, which
nowadays can be extracted from large sequence databases, is neglected. A different set of
approaches is based on position-specific scoring matrices. Large sets of reference sequences
are employed to compute the distribution of nucleotides or amino-acids per sequence po-
sition with respect to a precomputed alignment. HBV STAR is based on position-specific
distributions on the amino-acid level (Gale et al., 2004; Myers et al., 2005, 2006). HBV
STAR genotypes an input sequence by rating each amino-acid position independently and
summing up position-specific scores. Each amino-acid aj in the amino-acid input sequence
ai, . . . , ai+n is classified to either have a positive discriminant with respect to each geno-
type, if the odds ratio
genotype-specific frequency of aj
genotype-independent frequency of aj (whole data set)
is greater than one or to have a negative discriminant otherwise. The quotient of the
number of positive discriminants divided by the number of negative discriminants yields
an overall discriminant odds ratio score for each genotype that summarizes all amino-acid
positions. The genotype with the largest overall discriminant odds ratio score indicates
the most likely genotype of the input sequence.
3.1.3 Detection of Recombinants by Position-specific Nucleotide Distributions
Position- and genotype-specific nucleotide distributions (PGSNDs) were combined in a
concise probabilistic framework to genotype HBV, hepatitis C virus (HCV), and HIV
(Schultz et al., 2006, 2009, 2012; Zhang et al., 2006). The basic idea reads as follows. Let
{g1, . . . , gl} be a finite set of genotypes and letA be a multiple sequence alignment of a set of
genotype-annotated reference sequences. The PGSNDs pgj , where g ∈ {g1, . . . , gl} denotes
the genotype and j denotes the sequence position within the multiple sequence alignment
A, are derived by counting base frequencies. The PGSNDs encode the distribution of
genotype-specific polymorphisms at the nucleotide level and, thus, harbor information on
conserved or variable regions within the genome. In this approach pgj represent multi-
nomial distributions over the alphabet {A,C,G,T} consisting of the four bases found in
DNA Adenine, Cytosine, Guanine, and Thymine. The model assumes that pgj [b] is the
probability of observing base b ∈ {A,C,G,T} at sequence position j of an input sequence
ri, . . . , ri+n (for which we assume it is aligned with respect to the alignment A) subject to
the condition that the sequence is of genotype g. Thus,
P (rj = b|g) = pgj [b].
Recombinant detection is implemented by modeling the genotype as the hidden state
of a hidden Markov model. Figure 3.1 illustrate the so-called jumping profile hidden
Markov model. The emission probabilities of the HMM are given by the PGSNDs pgj .
State/genotype transitions are allowed at any position in the model. Transitions between
genotypes are referred to as jumps and allow for transitions if the input sequence shows
local similarity to different genotypes. Jumps need to have relatively high transition costs
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Figure 3.1: Simplified topology of the jumping profile hidden Markov model. The geno-
types g1, . . . , gl correspond to hidden states of a hidden Markov model. Thick
arrows indicate intragenotype transitions whereas thin arrows indicate transi-
tions between genotypes. For simplicity insertions and deletions are not visu-
alized. Figure is based on Schultz et al. (2006).
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(low transition probabilities) to prevent overfitting (high frequency of genotype changes).
This penalty parameter was optimized using cross validation on synthetic data sets. The
prediction of genotypes and recombination breakpoints is then carried out by comput-
ing the Viterbi path, which provides the most probable path of hidden states through
all sequence positions (see Section 2.5.2). Note that such a path assigns one particular
state and, thus, exactly one genotype to each sequence position of the input sequence.
The forward-backward algorithm for hidden Markov models, which computes the position-
specific posterior of the hidden state variable, was employed to assign confidence values to
the genotype predictions (Schultz et al., 2009).
3.2 Genotyping HBV Dual Infections in vitro
Clonal analysis of the viral quasispecies is the widely accepted gold-standard method to
identify and genotype dual infections. Amplicons, derived from primers designed to bind to
all known HBV genotypes, are cloned in a plasmid vector and transfected into Escherichia
coli. After the bacteria are cultivated, a number of individual bacteria are picked from
the Petri dish to sequence the contained DNA fragments. The resulting sequences are
clonal, represent the composition of the viral quasispecies, and are further analyzed by
phylogenetic or other genotyping methods. The number of clones selected and sequenced is
a crucial parameter that determines the sensitivity of the analysis. The minority genotype
might be overlooked if the number of clones is too low. High numbers of clones increase the
lab work and lab costs. A binomial model can be applied to relate the number of clones to
the expected sensitivity. In case of varying affinity of the primers to the respective genetic
variants present in the sample the binomial model might underestimate the number of
required clones.
Other methods to identify intergenotype dual infections, which are more cost-effective
than clonal analysis, were developed. For example, Naito et al. (2001) designed genotype-
specific primers to extract amplicons of genotype-specific length, which can be separated
using gel electrophoresis. Genotyping by the use of DNA fragments, which are comple-
mentary to genotype-specific conserved regions within preS1 or HBsAg, are another cost-
effective and sensitive method to identify intergenotype dual infections (Kato et al., 2003;
Osiowy and Giles, 2003). An enzyme-linked immunosorbent assay (ELISA) for genotyping
was developed by Usuda et al. (1999). In this assay five monoclonal antibodies identify
the genotype by selective binding to corresponding epitopes on the product of the preS2
region. ELISA is available as a commercial kit, which makes it interesting for large-scale
surveys.
3.3 Materials and Methods
3.3.1 Data Likelihood of Single and Dual Infections
We now briefly introduce the dual infection model, a statistical model to identify and
genotype intra- and intergenotype dual infections using population-based sequence data.
Let pgj denote PGSNDs for the HBV genotypes g ∈ {A, . . . ,H} and sequence positions
j in a given multiple sequence alignment A of a set of reference sequences. Let M be
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the set of all model alternatives, which are the single infection models {A, . . . ,H} that
correspond to the HBV genotypes and the dual infection models {A-A,A-B, . . . ,H-H} that
consist of all unordered pairwise combinations of the single genotype models. For each
model M ∈ M the position-wise data likelihood of an input sequence represented by
ri, . . . , ri+n needs to be specified. Each rj corresponds to one sequence position j with
respect to the alignment A and comprises either a single DNA base (rj ∈ {A,C,G,T})
or an International Union of Pure and Applied Chemistry (IUPAC) ambiguity code of
DNA bases (rj ∈ {K,M,R, S,W,Y,B,D,H,V,N}). The ambiguity codes, extracted from
population-based sequence data, indicate the presence of multiple genetic variants at a
single genome position.
Single infection likelihood. For the single genotype models, the likelihood of an
unambiguous sequence position rj = b is computed by
P (rj = b|g) = pgj [b].
As introduced before, pgj [b] denotes the fraction of base b being observed at position j for
genotype g and therefore is used to compute the likelihood of base b given genotype g.
For an ambiguous sequence position rj = (b1, b2) where b1 and b2 are two divergent bases
the likelihood of the sequence position is computed as
P (rj = (b1, b2)|g) = pgj [b1] · pgj [b2].
Ambiguous positions for a single genotype model can be explained by the concept of viral
quasispecies. Some strains within a patient might exhibit mutations at certain positions.
Nevertheless, all strains originate from the same initial viral variant with which the patient
was infected.
Dual infection likelihood. A dual infection is manifested by a combination of two,
not necessarily different genotypes g, h ∈ {A, . . . ,H}. The likelihood of the input sequence
is computed using the assumption that population-based sequencing provides the union of
the bases of the two underlying viral strains as shown in Figure 3.2. Thus, if the sequence
position rj is unambiguous, there is only a single base b at position j in both strains.
This case is not unusual since the overall intergroup divergence of genotypes is in the
range between 8% and 17% (Arauz-Ruiz et al., 2002). The likelihood of an unambiguous
sequence position is computed as
P (rj = b|g, h) = pgj [b] · phj [b].
The case of an ambiguous sequence position of cardinality two rj = (b1, b2) is difficult to
interpret because the phase information of the two bases is lost in the sequencing process,
i.e. we do not know to which genotype, g or h, each of the two bases, b1 and b2, belong.
This corresponds to two biological events: in the first, b1 is present in a strain of genotype
g and b2 is present in a strain of genotype h, in the second, b1 is present in a strain of
genotype h and b2 is present in a strain of genotype g. The likelihood of the first event
is given by pgj [b1] · phj [b2], while the likelihood of the second event is pgj [b2] · phj [b1]. As
these events are mutually exclusive, the likelihood of an ambiguous sequence position is
obtained by summation:
P (rj = (b1, b2)|g, h) = pgj [b1] · phj [b2] + pgj [b2] · phj [b1].
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Sequence position  1 2 3 4 5 6 7 8 9 10 11 12 13 
Strain 1 A T C A A C G A A T G G A 
Strain 2 A T T A A C G G A T G A A 
Population-based 
sequencing read  
A T CT A A C G AG A T G AG A 
Figure 3.2: Dual infection with two viral strains both of which occur at frequencies above
the detection threshold of the sequencing technology. Population-based se-
quencing provides the position-wise union of the two, not necessarily distinct
bases of the two viral strains. This gives rise to sequencing ambiguities wher-
ever the viral strains differ.
Regularization. The likelihood computation is extended by a regularization procedure
that accounts for sequencing errors in the input sequence and inaccuracies in the PGSNDs.
The adjusted position-wise likelihood P ∗ of a sequence position given any model M ∈ M
is computed as
P ∗(rj |M) = perror · kj + (1− perror) · P (rj |M),
where kj equals 1/4 if rj ∈ {A,C,G,T} is unambiguous and 1/6 if rj ∈ {K,M,R,Y, S,W}
is ambiguous with cardinality two. Ambiguous sequence positions with cardinality greater
than two are not included in the likelihood computation. The error constant perror is set to
1%, the reported error rate of Sanger sequencing (Keith et al., 1993). Sequence positions
known to be associated with drug resistance (see Table 2.3) are excluded from the analysis
as they might bias the evaluation.
Maximum likelihood principle. The complete input sequence ri, . . . , ri+n is classified
to be either a single infection or a dual infection of the respective genotype(s) using the
adjusted total likelihood P ∗(ri, . . . , ri+n|M), M ∈M that comprises all adjusted position-
wise likelihoods:
P ∗(ri, . . . , ri+n|M) =
i+n∏
j=i
P ∗(rj |M). (3.1)
Equation (3.1) together with the maximum likelihood principle facilitate the analysis of
short sequence fragments but fail in situations in which recombinant forms are involved. To
analyze recombinant forms it is not sufficient to compute P ∗(ri, . . . , ri+n|M) as different
single or dual infection models need to be applied for different sequence positions.
Detection of recombinants. The jumping profile hidden Markov model was applied
in combination with the dual infection model to address complex dual infections with at
least one recombinant sequence involved. The resulting model, which again is a HMM,
is visualized in Figure 3.3. The single and dual infections models M ∈ M correspond to
the set of hidden states of the HMM. The input sequence ri, . . . , ri+n corresponds to the
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Figure 3.3: Topology of the combination of the dual infection model with the jumping
profile hidden Markov model. Each model m1, . . . ,ml refers to either a single
infection model {A, . . . ,H} that correspond to the HBV genotypes or to a dual
infection model {A-A,A-B, . . . ,H-H} that correspond to unordered pairwise
combinations of HBV genotypes. The models m1, . . . ,ml define position-wise
probability distributions that emit HBV sequence data. Thick arrows indi-
cate intra-model transitions whereas thin arrows indicate transitions between
models. Figure is based on Schultz et al. (2006).
sequence of observed symbols. Emission probabilities eM (rj) depending on the model M
and the sequence position j are given by the adjusted position-wise likelihoods:
eM (rj) = P
∗(rj |M).
Transition probabilities aMkMl from model Mk ∈ M to model Ml ∈ M depend on the
regularization parameter pjump:
aMkMl =
{
pjump ifMk 6= Ml
1− (|M| − 1) · pjump ifMk = Ml.
The regularization parameter pjump prevents frequent model changes and was set to 10−7
(according to Schultz et al. (2012)). Inference in the HMM is performed by computing
the most probable sequence of hidden states using the Viterbi algorithm (Section 2.5.2).
Confidence of predictions are visualized using the position-specific posterior distributions
of the hidden states, which were computed using the forward-backward algorithm (Section
2.5.2).
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3.3.2 Training and Test Data
GenBank Data-set
The dual infection model utilizes PGSNDs derived from genotype-annotated sequence data.
3796 HBV full genome sequences were downloaded from GenBank (Benson et al., 2012).
The sequence meta-information was parsed to annotate the genotype. Genotypes I and
J were excluded from the data set as only very few of these sequences are available. Se-
quences without genotype annotation were excluded along with sequences whose annota-
tions included the keywords “defective”, “non-functional”, or “recomb”. Additionally, the se-
quences with accession numbers AB486012, AF461362, AY293309, EF103284, EU305546,
EU939634, GQ377573, GU357844, and HQ231877 to HQ231885 were removed from the
data set due to evidence from the NCBI genotyping web-service implicating recombinants
or false genotype annotations. Duplicate sequences were also removed. The goal of the fil-
tering steps was to obtain a data set of high quality, non-redundant, and non-recombinant
sequences with correct genotype annotation that could be used to train and to validate our
genotyping methodology. This procedure resulted in 1791 genotype-annotated sequences
(270 for genotype A, 339 for genotype B, 636 for genotype C, 304 for genotype D, 159
for genotype E, 54 for genotype F, 12 for genotype G, and 17 for genotype H). Subgeno-
type predictions were based on sequence data and subgenotype annotations supplied in
the literature (Norder et al., 2004; Tallo et al., 2008). Pairwise alignments of the 1791
GenBank sequences with the reference strain AM282986 form the alignment A. PGSNDs
were obtained by counting the frequencies of Adenine, Cytosine, Guanine, and Thymine
per reference sequence position and genotype.
Synthetic Test Data
Synthetic test data was generated based on sequence data of known genotype from the
GenBank data set. Dual infections were simulated by constructing the position-wise union
of sequence bases after alignment to the reference strain AM282986. This position-wise
union of two sequences emulates the perception of how population-based sequence data
of patients with HBV dual infections arise, when both strains are above the sequenc-
ing detection sensitivity (see Figure 3.2). This procedure generated sequence data with
high numbers of ambiguities representing dual infections that simulate population-based
sequence data of in vivo dual infections. In total three test sets (TS1 to TS3) were gener-
ated. TS1 contains single infections and synthetic intra- and intergenotype dual infections
for the genomic regions TP, RT, RN, HBsAg, X, and Core (see Table 2.1 for a description
of the genomic regions). TS2 consist of HBsAg sequences only. This part of the genome
is sequenced during routine diagnostics and enables the evaluation of the dual infection
model in a clinical setting. The sequences in TS2 were impaired by random noise. TS3
consists of full genome sequence data and addresses the ability of the model to genotype
complex dual infection including recombinant forms. We now detail the generation of the
three test sets.
TS1. TS1 consists of all 1791 GenBank sequences, which we assume represent single
infections, and 3600 synthetic intra- and intergenotype dual infections per genomic region
(TP, RT, RN, HBsAg, X, and Core). For each of the six genomic regions and for each
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combination of genotypes A to H, 100 test sequences were created by randomly selecting
two sequences of the respective genotypes. The procedure generated 3600 (36 combinations
times 100 samples) test sequences, of which 800 were intragenotype (e.g. A and A) and
2800 were intergenotype (e.g. A and B) for each genomic region.
TS2. The impact of sequencing errors on the identification and genotyping of dual in-
fections was analyzed. TS2 was created sampling randomly 100 single infection HBsAg
sequences, 100 intragenotype dual infection HBsAg sequences, and 100 intergenotype dual
infection HBsAg sequences from TS1. Each sequence was modified by either adding (for sin-
gle infection sequences) or removing (for intra- and intergenotype dual infection sequences)
ambiguities to simulate sequencing errors. For each sequence, random ambiguities at rates
of 1%, 2%,. . ., 70% were added or removed at random positions. This in total gave rise to
3 times 100 times 70 equals 21000 test sequences in TS2.
TS3. TS3 consists of full genome test sequences. This test set addresses the ability of
the model to genotype complex dual infections including recombinant sequences. 1000 test
sequences were generated by combining three full genome sequences of distinct genotype
from the GenBank data set. To account for an uneven distribution of the genotypes
in the GenBank data set, three distinct genotypes were sampled with equal probability.
Then, three sequences corresponding to the three distinct genotypes were sampled. Two of
the three sequences were used to build a recombinant sequence with three recombination
breakpoints each. The three recombination sites were randomly placed in the genome
with only one limitation: the recombination breakpoints had to be at least 300 bases
apart from each other and from the beginning and the end of the genome. The random
placement ensures that recombination breakpoints are placed in different genes at different
positions and cover highly variable and highly conserved regions of the HBV genome.
The recombinant sequence was then combined with the third sequence to simulate dual
infections. The process of generating TS3 is visualized in Figure 3.4.
Performance assessment. Computational experiments based on the GenBank se-
quence data (TS1 - TS3) were performed with five-fold cross-validation. The PGSNDs
were computed on the respective training sequences and the test sequences were generated
using the respective test folds of the data sets. Accuracy, sensitivity, and specificity were
used to assess prediction quality.
Genotype references. Reference sequences X02763, D00329, X01587, V01460, X75657,
X75658, AF160501, and AY090460 were used for HBV genotypes A to H (Arauz-Ruiz et al.,
2002; Stuyver et al., 2001).
Patient Test Data
HBV sequences from routine diagnostics performed between 2002 and 2010 at the Institute
of Virology (University of Cologne) were employed. The HBV genome region encoding
partly the polymerase and HBsAg were amplified and sequenced according to Schildgen
et al. (2004).
Clonal analysis. The oligonucleotides HBrt-AccIII-fw (GTCACTTCCGGAGACTAC-
TGTTGTTAGACGACG) and HBrt-RsrII-rev (GCGCATCGGTCCGGCAGATGAGAA-
GGC) were used to amplify the HBV polymerase of patient isolates from the original serum
samples. The amplification products and the vector pCH9-3091 were cut with AccIII and
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Sequence a 
Sequence c 
Sequence b 
Sequence c 
Recombination sites 1, 2 and 3 
Recombinant sequence a/b 
Dual infection of recombinant a/b sequence 
and sequence c 
(A) 
(B) 
(C) 
Figure 3.4: The figure visualizes the generation of synthetic test data in test set TS3. (A)
Three full genome sequences of distinct genotype are randomly selected from
the GenBank data set. (B) Sequence a and b are combined to a recombinant
sequence a/b with three randomly placed recombination sites. (C) A dual
infection of recombinant sequence a/b and sequence c is simulated by building
the positions-wise union of the respective bases according to Figure 3.2.
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Type of Infection Measure TP RT RN HBsAg X Core
Single infection Accuracy 99.8% 100.0% 99.8% 100.0% 99.8% 99.6%
Intergenotype DI Accuracy 99.4% 100.0% 99.7% 100.0% 98.8% 98.5%
Intragenotype DI Accuracy 47.8% 48.6% 47.5% 42.2% 44.7% 45.0%
Intragenotype DI Accuracy∗ 99.9% 100.0% 100.0% 100.0% 99.1% 99.5%
Table 3.1: Prediction performance on TS1. TS1 consists of single infection sequences
and synthetic intra- and intergenotype dual infections. The measure Accuracy∗
considers an intragenotype dual infections to be correctly genotypes if either
the intragenotype dual infections with the correct genotype is identified or if a
single infection with the correct genotype is predicted. The genomic regions TP,
RT, RN, HBsAg, X, and Core are detailed in Table 2.1.
RsrII preceding a ligation step. After transformation using JM109 (Promega) clones were
picked and analyzed by sequencing. All sequencing was performed using oligonucleotides
HBsAg-KpnI-fw (gtcactggtaccatggagagcacaacatcaggattc), HBsAg-MHL-fw (gtcactcatat-
gctcttcatcctgctgctatgcc), and HBV S6antisense (cKttgacaDactttccaatcaatag). The prod-
ucts were sequenced with the ABI PRISMTM 3130xl and edited with DNASTAR Laser-
gene. The lab work to derive the clonal sequences was carried out by Maria Neumann-
Fraune at the Institute of Virology (University of Cologne). The resulting sequences were
analyzed using the NCBI genotyping and the jumping profile hidden Markov model web-
services (Rozanov et al., 2004; Schultz et al., 2009).
3.4 Evaluation based on Synthetic Data
The dual infection model was derived from position- and genotype-specific nucleotide dis-
tributions, which were computed using full genome sequence data from GenBank annotated
with genotype. The dual infection model was applied to three data sets of synthetic data
(TS1 to TS3) and to clinical patient sequences to identify and genotype HBV dual infec-
tions.
Performance on TS1. Synthetic inter- and intragenotype dual infections were created
by randomly combining pairs of sequences of the respective genomic regions. Depending
on the genomic region, between 98.5% to 100% of the intergenotype dual infections were
correctly identified including the correct combination of genotypes (Table 3.1). Intrageno-
type dual infections were correctly identified as such by the dual infection model in 42.2.%
to 48.6% of the cases. Nevertheless, for 99.1% to 100% of the intragenotype infections the
correct genotype was identified, which means that only the intragenotype dual infection
could not be inferred. Additionally, the dual infection model genotyped 99.6% to 100% of
the GenBank data set correctly.
Performance on TS2. Model predictions were very robust with respect to randomly
added or removed ambiguities. Randomly added ambiguities in the range of 1% to 32%
did not lead to any falsely positive predicted intergenotype dual infection for single infec-
tion sequences (Figure 3.5A). False positive intragenotype dual infections were observed
depending on the level of noise. For example, 15% ambiguities resulted in 14 (14.0%) out
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Figure 3.5: Prediction performance on TS2. TS2 consists of (A) single infection sequences,
(B) intragenotype dual infection sequences, and (C) intergenotype dual infec-
tion sequences that were altered by increasing level of noise displayed on the
x-axis.
of 100 false positive intragenotype predictions and 30% ambiguities resulted in 71 (71.0%)
out of 100 false positive intragenotype predictions. Adding more than 32% ambiguities led
to rare false positive intergenotype dual infection predictions.
Randomly removing 1% to 10% of the ambiguities of intragenotype dual infection se-
quences did not decrease notably the number of correctly genotyped sequences (Figure
3.5B). Nevertheless, removing more than 10% of the ambiguities hampered the correct
identification of intragenotype dual infections.
The correct genotyping of intergenotype dual infection sequences was also not sensitive
to randomly removing ambiguities. Removing up to 40% of the ambiguities did not lead
to any false genotyping result (Figure 3.5C).
Performance on TS3. The utilization of the jumping profile hidden Markov model in
combination with the dual infection model facilitated the accurate genotyping of complex
dual infections that involved recombinant forms. Figure 3.6 shows a sample solution derived
from this approach. Of the 1000 synthetic test sequences 96.4% were genotyped correctly.
The accuracy at the position level was 98.4%. 98.0% of the simulated recombination
breakpoints were identified correctly (correct model change and recombination site within
100 bases from the true location) with a median deviation from the ground truth location
of 5 bases.
Performance of baseline method. Previous authors identified intergenotype dual
infections using a dissimilarity score and a set of genotype reference sequences. The se-
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Figure 3.6: The plot shows the position-wise posterior probability of the two models C-D
(dual infection of genotypes C and D) and D-G (dual infection of HBV geno-
types D and G). This result indicates a dual infection with a genotype D strain
and a C/G recombinant strain. Three recombination sites are indicated by
the changing posterior probabilities of the two models from approximately zero
to approximately one. The ground truth recombination site locations are in-
dicated on the x-axis at positions 516, 897, and 2640. The model estimated
recombination sites positions 517, 895, and 2638, respectively. These positions
differ from the ground truth in this case by only one, two, and two bases,
respectively.
quence dissimilarities of the input sequence to the set of genotype reference sequences were
computed and if all dissimilarity scores exceed a cutoff value of 6.0%, the input sequence
was considered to represent an intergenotype dual infection (Mallory et al., 2011). We ap-
plied this method to our synthetic data set TS1 of synthetic intra- and intergenotype dual
infection sequences. The resulting sequence dissimilarities for intragenotype vs. intergeno-
type dual infections showed distinct distributions but overlapped for each genomic region
(Figure 3.7). Thus, the utilization of the dissimilarity score did not facilitate complete
separation, and inferred neither intragenotype nor intergenotype dual infections. Addi-
tionally, we found that the 6.0% dissimilarity cutoff proposed by Mallory et al. (2011) was
too high for optimizing accuracy on TS1. For example, only 61.4% of the HBsAg intergeno-
type sequences exceeded this cutoff. In contrast, a cutoff of 3.0% sequence dissimilarity
yielded sensitivity in the identification of intergenotype dual infections of 99.8%, specificity
of 84.9% and the accuracy amounted to 92.4%, while a cutoff of 5.0% yielded sensitivity of
83.7%, specificity of 94.6%, and accuracy of 89.2%. Table 3.2 summarizes the performance
evaluation of the sequence dissimilarity method for all genomic regions. Suitable cutoffs
were found to depend on the genomic region. We also applied the dissimilarity measure
to our test set with randomly introduced ambiguities (TS2) and obviously found that,
as soon as the percentage of generated ambiguities exceeded the dissimilarity cutoff, all
sequences were classified as intergenotype dual infections. These evaluations show that,
on our synthetic data set, methods based on the sequence dissimilarity score could not
identify intergenotype dual infections as accurately as the dual infection model and easily
get hampered in the presence of sequencing noise.
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Figure 3.7: Distribution of sequence dissimilarities to the closest genotype reference se-
quence for single infections (GenBank data set) vs. intragenotype vs. intergeno-
type dual infections (data set TS1). Sequence dissimilarity scores overlap for
all genomic regions TP, RT, RN, HBsAg, X, and Core (see Table 2.1). Thus,
the sequence dissimilarities as a baseline method to identify intergenotype dual
infections do facilitate separation of intra- and intergenotype dual infections
with limited accuracy.
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Method Measure TP RT RN HBsAg X Core
DS 3%
Sensitivity 99.9% 100.0% 100.0% 99.8% 100.0% 99.9%
Specificity 35.3% 41.3% 32.0% 90.3% 34.8% 31.9%
Accuracy 69.6% 72.4% 68.1% 95.4% 69.4% 68.0%
DS 4%
Sensitivity 99.9% 100.0% 100.0% 95.5% 99.8% 99.2%
Specificity 44.9% 63.5% 58.5% 99.0% 62.0% 46.4%
Accuracy 74.1% 82.9% 80.5% 97.2% 82.1% 74.4%
DS 5%
Sensitivity 99.9% 100.0% 99.9% 84.0% 97.8% 97.9%
Specificity 53.8% 83.3% 74.6% 99.9% 81.1% 61.2%
Accuracy 78.3% 92.2% 88.0% 91.5% 89.9% 80.7%
DS 6%
Sensitivity 99.9% 100.0% 96.4% 59.7% 92.7% 95.3%
Specificity 63.7% 95.3% 90.6% 100.0% 87.3% 73.3%
Accuracy 82.9% 97.8% 93.7% 78.7% 90.2% 85.0%
DI model
Sensitivity 99.7% 100.0% 100.0% 100.0% 99.9% 99.4%
Specificity 99.9% 100.0% 100.0% 100.0% 99.0% 99.6%
Accuracy 99.8% 100.0% 100.0% 100.0% 99.5% 99.5%
Table 3.2: Predictions performance of the sequence dissimilarity score (DS) method with
cutoff values of 3%, 4%, 5%, and 6% and the dual infection (DI) model to sepa-
rate intragenotype vs. intergenotype dual infections on synthetic data set TS1.
To allow a direct comparison of the dual infection model with the dissimilarity
score method, sensitivity, specificity, and accuracy refers only to the identifi-
cation of intergenotype dual infections and does not account for the correct
identification of the involved genotypes. Thus, accuracy results differ from the
values presented in Table 3.1.
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3.5 Evaluation based on Patient Data
We employed sequence data obtained from chronically infected patients (n = 241) who
were diagnosed within the routine diagnostics at the Institute of Virology (University of
Cologne) to evaluate the dual infection model. A population-based sequencing procedure
covered the reverse transcriptase domain from amino-acid position 88 (median value) to
position 235 (median value) with a median sequence length of 454 bases. Patient sequences
were genotyped and screened for dual infections by, first, applying the dual infection model
and, second, by applying the baseline method based on sequence dissimilarity scores (Table
3.3). The dual infection model identified eight intergenotype dual infections (one A-D, six
A-G, and one D-G) and four intragenotype dual infections (one A-A, two D-D, and one
E-E). In contrast, the dissimilarity score method with a 5% dissimilarity cutoff labeled
seven samples as intergenotype dual infections, five of which were classified as genotype D
single infections by the dual infection model. The 3% dissimilarity cutoff was exceeded by
51 of 241 (21.1%) patient sequences, eleven of which matched with the predictions of the
dual infection model.
Dual infection model Dissimilarity score
A B C D E F G Mixture
A 72 0 0 0 0 0 0 0
A-A 1 0 0 0 0 0 0 0
A-D 0 0 0 0 0 0 0 1
A-G 0 0 0 0 0 0 5 1
B 0 13 0 0 0 0 0 0
C 0 0 6 0 0 0 0 0
D 0 0 0 103 0 0 0 5
D-D 0 0 0 2 0 0 0 0
D-G 0 0 0 0 0 0 1 0
E 0 0 0 0 8 0 0 0
E-E 0 0 0 0 1 0 0 0
F 0 0 0 0 0 1 0 0
G 0 0 0 0 0 0 21 0
Table 3.3: The table contains the counts of patient sequences per genotyping result using
the dual infection model (rows) and the sequence dissimilarity score method
(columns). For example, as indicated in the first row and the first column,
72 patient sequences were genotypes as a single infection with genotype A by
the dual infection model and by the sequence dissimilarity score method. The
dual infection model identified eight intergenotype and four intragenotype dual
infections. The sequence dissimilarity score method with a 5% dissimilarity
cutoff labeled seven patient samples as intergenotype dual infections of which
only two coincide with the predictions of the dual infection model.
Validation using sets of clonal sequences. To validate the predictions of the dual
infection model, cloning experiments were performed. In three of twelve suspected cases of
HBV dual infections a total number of 54 clones were picked, sequenced and genotyped by
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the National Center for Biotechnology Information genotyping web-service. In nine cases
a shortage of material or insufficient polymerase chain reaction amplification obviated po-
tential experiments. For the first patient sample (A-G dual infection, accession number
JQ776529) 21 clones were successfully sequenced of which 19 were of genotype G, one was
of genotype A, and one clone was an A/G recombinant. The recombinant sequence was
analyzed with the jumping profile hidden Markov model that inferred two breakpoints.
The sequence was estimated to be of genotype G between nucleotide positions (with re-
spect to AM282986) 131 and 375 and between 726 and 1053 and of genotype A between
nucleotide positions 376 and 725. For the second patient sample (A-G dual-infection, ac-
cession number JQ776530) 17 clones were sequenced of which 14 were of genotype G, two
were of genotype A, and one was a recombinant of genotypes A and G. The jumping pro-
file hidden Markov model estimated that nucleotide positions 226 to 518 were of genotype
A and nucleotide positions 519 to 998 were of genotype G. For the third patient sample
(A-G dual infection, accession number JQ776532) a number of 16 clones were successfully
sequenced. 13 were of genotype G and three were found to be A/G recombinants. The
three recombinant sequences covered nucleotide positions 388 to 1132, 402 to 1171, and
389 to 1093 with estimated breakpoints at nucleotide positions 725, 765, and 782. To
summarize, the predictions of the dual infection model were confirmed in vitro for these
three patient samples as clonal HBV variants of the predicted genotypes were found in
the respective patient sera. The three original patient sequences did not exceed the 5%
dissimilarity cutoff and were falsely classified as genotype G by the use of the dissimilarity
score method.
Intragenotype dual infections. Three of the four putative intragenotype dual infec-
tions showed evidence of multiple subgenotypes. Predictions were further investigated by
a follow-up analysis in which subgenotype-specific nucleotide distributions were employed
by the dual infection model. The A-A dual infection sequence (JQ776527) was identified as
an A1-A2 intersubgenotype dual infection. The sequence contained 19 of 454 (4.2%) ambi-
guities at the nucleotide level which implies the presence of two subgenotypes. Further, its
HBsAg sequence contained the ambiguities sS207SN and sL209LV which are characteristic
for the presence of subgenotypes A1 and A2. A1 usually encodes Asparagine at position
207 and Leucine at position 209 and A2 usually encodes Serine at position 207 and Valine
at position 209 (Norder et al., 2004). Both D-D dual infections were classified as D2-D3
intersubgenotype dual infections. The first of these two sequences (HM174233) contained
two different serotypes ayw2 and ayw3 as Arginine was encoded at position 122, Lysine
at position 160, Glycine at position 159, and Threonine at position 140 in addition to the
HBsAg ambiguity sP127PT (Purdy et al., 2007). In this sequence, Alanine was present
at position 128, while the other sequence (HM174239) expressed Alanine and Valine at
position 128 and Threonine at position 127 of HBsAg. In both patient samples, Alanine
and Threonine were present at position 118 and Methionine and Threonine were expressed
at position 125. Thus, the HBsAg amino-acid sequences were in 100% accordance with the
conserved amino-acid residues of a combination of the subgenotypes D2 and D3 (Tallo et al.,
2008). The sequence HM174233 contained 16 of 394 (4.1%) and the sequence HM174239
contained 13 of 469 (2.8%) ambiguous sequence positions at the nucleotide level.
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3.6 Discussion
Taking into account position- and genotype-specific differences in nucleotide distributions
can help to identify and genotype HBV dual infections in silico from population-based
sequencing data. The approach was verified in silico with synthetic dual infection data
and in vitro with clonal experiments of patient samples.
Synthetic data. We showed that the dual infection model has high genotyping accuracy
on all genomic regions based on the GenBank sequence data set. This is in concordance
with the known fact that HBV facilitates accurate genotyping on all genomic regions due
to conserved genetic differences (Myers et al., 2006; Norder et al., 2004). Experiments with
synthetic inter- and intragenotype dual infection sequence data showed that intergenotype
dual infections can be identified and genotyped with nearly 100% accuracy. Very rare
false positive intergenotype dual infections were observed when the model was tested with
simulated sequencing errors. HBV genotypes express genotype specific polymorphisms.
Consequently, a dual infection with two different genotypes expresses specific combinations
of polymorphisms, which are distinct from random noise. Our model based on position- and
genotype-specific nucleotide distributions accurately identified these characteristic patterns
of ambiguities.
The dual infection model is also capable of identifying intragenotype dual infections. On
our synthetic data set these dual infections were identified in 42.2% to 48.6% of the cases
depending on the genomic region. The model’s ability to distinguish between intragenotype
dual infections and sequencing noise was demonstrated by a false positive rate of only 14.0%
for intragenotype dual infections in the presence of a very high level of sequencing noise
(15% sequence ambiguities).
The dual infection model was combined with the jumping profile hidden Markov model
to genotype complex dual infections that involve recombinant sequences. This approach
identified 96.4% of the complex synthetic dual infections correctly. The accuracy at the po-
sition level was 98.4%. 98.0% of the simulated recombination sites were identified correctly
with a median deviation from the ground truth location of 5 bases.
Patient data. The dual infection model identified eight (3.3%) intergenotype and four
(1.7%) intragenotype dual infections in our patient cohort (n = 241). The majority of the
intergenotype cases were A-G and D-G dual infections. This confirms previous reports that
genotype G frequently co-occurs with other genotypes (Kato et al., 2002; Osiowy et al.,
2008). Additionally, one A-D dual infection was identified (JQ776528). This sequence
was classified as genotype A by standard genotyping web-services (Myers et al., 2006;
Rozanov et al., 2004) in which case the risk of interferon treatment failure would have
been underestimated due to the overlooked presence of a genotype D strain. Datta et al.
(2009) identified and validated five dual infection sequences (four A-D and one A-C) with
accession numbers EU275341, EU275342, EU275344, EU275345, and EU275338. These
sequences display the same inaccurate classification by standard genotyping methods but
are identified correctly by the dual infection model. The NCBI web-service classifies all
five as genotype A and HBV STAR classifies the four A-D dual infections as genotype A
and the A-C dual infection remains undetermined.
Validation of our predictions with clonal experiments from the original patient material
confirmed three out of three predictions. Clonal HBV variants of the predicted genotypes
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were found in the respective patient samples. No prediction was falsified. But only few
samples could be investigated in vitro due to the shortage of original patient material. The
analysis of the clonal data using the NCBI genotyping web-service and the jumping profile
hidden Markov model for HBV revealed complex quasispecies compositions as two of the
three samples contained genotype A variants, genotype G variants, and A/G recombinants.
The detailed composition of the viral populations obtained by the clonal experiments could
not be elucidated by the use of the dual infection model alone. First, the dual infection
model does not account for mixtures of more than two viral strains. Second, the original
patient sequences acquired for routine diagnostics were significantly shorter (median length
of 454 bases) than the clonal data (median length of 818 bases).
We predicted four cases of intragenotype dual infections within our patient cohort. The
intragenotype predictions are inherently difficult to validate and might only reflect the viral
quasispecies within the patient. For three of the four predicted cases we have strong evi-
dence of intersubgenotype dual infections. First, the total number of ambiguous sequence
positions was high (13, 16 and 19). Second, the observed amino-acids were in concor-
dance with the conserved residues of the combination of subgenotypes predicted by the
dual infection model. Compared to the alternative it seems more likely that the observed
combinations of amino-acids result from a dual infection with existing subgenotypes. The
alternative would be that intra-patient evolution developed the very same combinations of
polymorphisms, which are conserved in the subgenotypes. The fourth intragenotype case
(E-E dual infection) remains unresolved. It might be a false positive prediction or there
might be two distinct genotype E strains present.
Baseline method. The dual infection model outperformed the identification of dual
infections based on sequence dissimilarity scores, a baseline method proposed by Mallory
et al. (2011). Our model achieved higher accuracy on synthetic data (100% vs. 89.2%
with 5% dissimilarity cutoff) and was more robust with respect to sequencing errors (with
10% sequencing noise: 0% false positive intergenotype dual infections vs. 100% false
positive intergenotype dual infections). Using the 5% dissimilarity cutoff the baseline
method identified (in our patient cohort) only two of the eight intergenotype dual infections
reported by the dual infection model. Three validated dual infections did not exceed the
5% dissimilarity cutoff. Lower cutoffs were not suitable for our patient cohort either, due
to false positive intergenotype predictions. Other standard genotyping methods do not
account for dual infections and, thus bear the risk of leading to suboptimal treatment
decisions when present genotypes are overlooked.
Conclusions. The dual infection model provides an in silico alternative to labor- and
money-intensive clonal experiments. It requires only HBV sequences obtained by routine
diagnostics. Alternatives such as second-generation sequencing are able to analyze this
problem with higher sensitivity with respect to minor sub-populations, but none of the
systems is expected to replace population-based sequencing in the clinical routine within
the near future due to cost reasons.
In summary, we developed the first in silico genotyping method that can identify and
genotype HBV intergenotype dual infections reliably. The method can elucidate the fre-
quency of dual infections in the routine diagnostics and can be helpful in optimizing an-
tiviral therapy. It was integrated into the web-service geno2pheno[HBV] in the scope of a
Bachelor’s thesis (Döring, 2011) and is freely available.
4 Linkage Information from Sequencing
Chromatograms
I’ll fetch what you wish, and I’ll fetch more:
Easy it’s true, but then easy things weigh more:
It’s there already, yet how we might achieve it,
That’s the tricky thing, knowing how to seize it.
...
And so it goes on, yesterday and today.
Still buried in the earth, why, there it is:
The earth is the Emperor’s, so it’s his.
(J. W. von Goethe, Faust Part II, translation by A. S. Kline)
Population-based Sanger sequencing is a cheap and widely used Population-based Sanger
sequencing is a cheap and widely used sequencing technology but suffers from low sensi-
tivity regarding the detection of minor variants and from the loss of linkage information.
In Chapter 3 we developed a model to identify and to genotype dual infections. In the
case of an intra- or intergenotype dual infection we showed that the composition of the
viral quasispecies can be elucidated using genotype- and position-specific nucleotide dis-
tributions derived from reference sequences annotated with genotype. In this Chapter we
show that short-range linkage can be inferred from population-based Sanger sequencing
data in a general scenario. While this might seem promising, we will see that the linkage
information available from Sanger sequencing data is limited. Our method has signifi-
cant restrictions with respect to the distance over which linkage can be inferred and with
respect to accuracy. However, short-range linkage is of special interest. In the case of
two ambiguous sequence positions within the same codon (Figure 4.1), the amino-acids
present in the mixture cannot be determined precisely due to the lack of linkage informa-
tion. Such short-range linkage information is of clinical relevance as treatment decisions,
for instance for human immunodeficiency virus and hepatitis B patients, are often based
on population-based Sanger sequencing data of the viral genome (Lengauer and Sing, 2006;
Lengauer et al., 2007; Zoulim et al., 2009).
Notable attempts have been made to infer linkage information from Sanger sequencing
data of the human genome (Dmitriev and Rakitov, 2008; Flot et al., 2006; Flot, 2007;
Seroussi and Seroussi, 2007; Sousa Santos et al., 2005). These methods are tailored to
genomes that contain a mixture of two different sequences (diploid genomes), one of which
harbors an insertion or deletion. The chromatogram downstream of the insertion or dele-
tion shows a high number of double peaks as the two genetic variants are superimposed
with a phase shift. These methods rely on additional information, i.e. a reference se-
quence, a set of possible single nucleotide polymorphisms (SNPs), or the availability of
both the forward and the reverse chromatogram. Otherwise, these methods can only be
applied in situations in which the two mixture sequences are sufficiently similar and the
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Figure 4.1: The sequencing chromatogram shows two nearby ambiguous sequence positions
610 and 612. At position 610 adenine and guanine are present. At position
612 adenine and thymine are present. Positions are numbered with respect to
the reverse transcriptase of the hepatitis B virus genome. This chromatogram
raises the question which of the bases at positions 610 and 612 are present in
the same clonal variant.
analyzed fragment is significantly longer than the insertion or deletion (Dmitriev and Rak-
itov, 2008). The method we present here does not rely on diploid genomes that contain
a heterozygous insertion or deletion. It is tailored to viral genomes that can have a more
complex quasispecies without insertions or deletions. Additionally, we explore a source of
information that is encoded in the peak heights of the sequencing chromatograms and has
not been considered so far.
Modern Sanger sequencing chromatograms exhibit heterogeneous peak heights that re-
sult from different affinities of the polymerase for dideoxynucleotides rather than natural
nucleotides during PCR amplification (Lee et al., 1992; Li et al., 1999; Tabor and Richard-
son, 1995). The rate of incorporation has been found to also depend on the up- and
downstream subsequence (Kwok et al., 1994; Parker et al., 1996). This effect is referred
to as sequence context-dependent incorporation of dideoxynucleotides. Some methods for
estimating the frequencies of two alleles present at an ambiguous sequence position account
for this effect by comparing the observed peak heights to the peak heights of reference chro-
matograms (Carr et al., 2009; Kwok et al., 1994). We explore this effect to infer short-range
linkage information.
The key assumption of our method is that the collection of peak heights of a mixture of
clonal variants (which are called haplotypes, in the following) is the proportion-weighted
mixture of the peak heights of the underlying haplotypes. The underlying physico-chemical
reasoning is as follows: context-dependent incorporation of dideoxynucleotides resulting
in context-dependent peak heights occurs at the level of each polymerase molecule that
incorporates dideoxynucleotides with an affinity depending on the DNA subsequence it is
processing. The intensity level of the fluorescence observed in the sequencing chromatogram
is the sum of all individual molecular fluorescence impulses. Thus, knowing the peak heights
of all possible haplotypes present in a mixture, given that these show distinct patterns,
renders the determination of the haplotype composition feasible. As context-dependent
incorporation of dideoxynucleotides is a local effect, our methodology will only infer linkage
information over a short genomic region, maybe up to five bases. A Gaussian noise model
was added to the mixture assumption to account for variation in peak heights. Marginal
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model likelihoods in combination with the posterior marginals of the model parameters are
used for model selection.
This Chapter is structured as follows. First, we describe related work, methods to
estimate relative allele frequencies based on sequencing chromatograms. In this context we
present a preliminary analysis that has motivated our work (Section 4.2). In Section 4.3
we lay out the methodical details and in Section 4.4 we analyze prediction results based
on in silico and in vitro data. We conclude the Chapter with a discussion (Section 4.5).
Note that this Chapter elaborates on work initially presented in Beggel et al. (2013b). The
study was performed in cooperation with Maria Neumann-Fraune from the University of
Cologne who helped with the design of the study and performed the laboratory work.
4.1 Quantifying Allele Frequencies
Sanger sequencing chromatograms facilitate the estimation of the relative allele frequencies
at ambiguous sequence positions (Carr et al., 2009; Kwok et al., 1994; Manion et al., 2009;
Qiu et al., 2003). The reasoning is straightforward: given an ambiguous sequence position
(double peak) each peak height gives the amount of fluorescently tagged dideoxynucleotides
that was incorporated at this position. Thus, the quotient of the peak heights reflects the
relative allele frequencies of the two bases at the ambiguous site in the DNA substratum,
assumed that there are no biases. Three types of biases hamper the direct interpretation
of the peak heights as allele frequencies:
• During the sequencing amplification (which essentially is a PCR as discussed in
Section 2.4.1), the relative frequencies of different DNA variants in the sequencing
substratum might not be conserved. The chromatogram can only reflect the mixture
fractions of the sequencing substratum after the amplification step, which might not
reflect the true mixture fractions of the original sample. The parameters of the PCR
should be adapted to minimize such distortions as discussed in Carr et al. (2009).
• Different amounts of natural nucleotides and dideoxynucleotides for the four bases
contained in the reaction tube lead to altering peak heights. The peak heights need
to be normalized using other peaks of the corresponding base prior to interpretation.
A base-specific linear scaling transformation is used for this purpose. We refer to
these scaling factors as the normalization parameters γA, γC , γG, γT .
• Peak heights observed in chromatograms depend on the sequence context as dis-
cussed in the introduction of this Chapter (effect of sequence context-dependent
incorporation of dideoxynucleotides). Existing methods to quantify the relative al-
lele frequencies of SNPs based on chromatograms can be divided into two groups:
reference-based methods, which account for this effect and try to correct for the
corresponding bias, and reference-free methods, which do not.
We now briefly introduce a reference-free method (Qiu et al., 2003) and a reference-
based method (Carr et al., 2009). Given a sequencing chromatogram of a mixture of at
least two genomic variants that has at least one ambiguous sequence position with two
alleles present (we refer to these as base 1 and base 2), let p1 and p2 denote estimates for
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the relative frequencies of the two alleles at the ambiguous position under analysis. Qiu
et al. (2003) compute the base-specific normalization parameters γA, γC , γG, γT such that
the base-specific average height of all peaks in the chromatogram is 1000. Then, p1 is
computed as:
p1 =
h1
h1 + h2
. (4.1)
Here h1 and h2 are the peak heights of base 1 and base 2 after normalization. Equation
(4.1) ensures that p1 + p2 = 1 if p2 is computed accordingly. Thus, equation (4.1) provides
consistent estimates for the two allele frequencies p1 and p2.
Carr et al. (2009) compute the normalization parameters locally using up to four neigh-
boring positions of the base under inspection. Then, to compute p1, a reference chro-
matogram is required that has base 1 at the ambiguous position and the same sequence
as the mixture otherwise. The peak height of base 1 in the mixture chromatogram is
compared to the peak height of base 1 in the reference chromatogram. Thus,
p1 =
h1
h∗1
. (4.2)
Here h1 and h∗1 refer to the peak heights of base 1 in the mixture and in the reference
chromatogram, respectively. p2 is computed as p2 = h2/h∗∗2 , where h∗∗2 is the peak height
of base 2 in a reference chromatogram that has base 2 at the ambiguous position and is
sequence identical to the mixture otherwise. Note that this may provide estimates p1 and
p2 that do not need to fulfill p1 + p2 = 1. Carr et al. (2009) do not explain how divergent
estimates p1 and p2 may be interpreted.
Reference-based methods have several drawbacks compared to reference-free methods.
First and foremost, these methods require at least one reference template to determine the
unambiguous peak height. Second, it is unclear how to apply reference-based methods in
the context of several nearby ambiguous positions. Third, reference-based methods may
provide inconsistent estimates p1 and p2 with p1 + p2 6= 1. Reference-free methods do not
face these difficulties and, due to their simplicity, a reference-free method for quantification
of ambiguous positions was integrated into a commercial sequence editing software (Man-
ion et al., 2009). On the other hand, reference-free methods might be not as accurate as
reference-based methods as they do not account for sequence context-dependent incorpo-
ration of dideoxynucleotides. Despite major improvements in the 1990s with respect to the
sequencing chemistry (see Section 2.4.1) which have led to quite balanced chromatograms,
peak heights might still differ by up to 20%. This is reflected in limited quantification
accuracy of reference-free methods, which strongly depend on the genomic position being
analyzed.
4.2 Preliminary Analysis
In a preliminary study we analyzed a set of sequencing chromatograms from three dilu-
tion series published in Carr et al. (2009). This motivated the mixture assumption and
provided evidence that sequencing chromatograms contain linkage information and that
reconstructing the haplotype composition might be feasible. Each dilution series was cre-
ated by mixing different pairs of DNA fragments that differ at a single nucleotide position.
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Figure 4.2: The figure shows the median normalized peak heights of the chromatograms of
a dilution series (dilution series 1, obtained from Carr et al. (2009)) sorted by
nominal mixture proportion. The normalized peak heights before the ambigu-
ous sequence position are almost identical for all nominal mixture proportions.
At the ambiguous sequence position and at two to four bases downstream of
the ambiguous sequence position a smooth and apparently linear transition be-
tween the peak heights of the samples with nominal mixture proportions 10:0
and 0:10 can be observed. The colors indicate the bases: Adenine is green,
Cytosine is blue, Guanine is black, and Thymine is red.
Experimental mixture proportions were 10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, and
0:10. Thus, eleven samples per dilution series were available. Each sample was amplified
and sequenced three times.
In the analysis we were interested in changes of peak heights near the ambiguous sequence
positions and found that the normalized peak heights upstream of the ambiguous sequence
positions were almost identical for all nominal mixture proportions. At the ambiguous
sequence position and at the two to four bases downstream we observed a smooth and
almost linear transition of the peak heights between the samples with nominal mixture
proportions 10:0 and 0:10 (Figure 4.2). This gave rise to the mixture assumption: the peak
heights of a mixture of haplotypes are the proportion-weighted mixtures of the peak heights
of the underlying haplotypes. The mixture assumption is commonly accepted for the
ambiguous sequence position in a dilution series. Reference-based methods for quantifying
allele frequencies rely on this principle (Carr et al., 2009; Kwok et al., 1994). We found
that the hypothesis is true for all peak heights. The mixture assumption becomes evident
near ambiguous sequence positions where the peak heights of the underlying haplotypes
differ due to the effect of sequence context-dependent incorporation of dideoxynucleotides.
Figure 4.2 shows that there are informative dependencies between peak heights at different
positions within sequencing chromatograms, e.g. given the peak height at positions 2,
the relative frequency of the bases present at the ambiguous sequence position can be
estimated. This source of information might be used to infer linkage information from
sequencing chromatograms.
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Haplotype Position 610 Position 612 Position 614 Comment
v1 Adenine Guanine Adenine Wild-type
v2 Guanine Guanine Adenine rtM204V
v3 Adenine Thymine Adenine rtM204I
v4 Guanine Thymine Adenine rtM204V
v5 Adenine Guanine Thymine Wild-type
v6 Guanine Guanine Thymine rtM204V
Table 4.1: Six clonal hepatitis B virus genomes (haplotypes) were created by varying three
nearby nucleotide positions. Haplotypes v1, v2, v3, v4 express all possible combi-
nations of two variants Adenine and Guanine present at position 610 and two
variants Guanine and Thymine present at position 612. These nucleotide vari-
ants are clinically relevant as they represent two primary resistance mutations
rtM204I and rtM204V (see Section 2.3.2). Haplotypes v1, v2, v5, v6 express all
possible combinations of two variants Adenine and Guanine present at posi-
tion 610 and two variants Adenine and Thymine present at position 614. The
mutation at position 614 is clinically not relevant. It was introduced to test
our approach with two ambiguities that are three bases apart from each other.
Positions are numbered with respect to the reverse transcriptase domain.
4.3 Materials and Methods
4.3.1 In vitro Experimental Setup
To evaluate the mixture assumption we designed and created two in vitro test sets, each
consisting of four clonal HBV variants that differ at two nucleotide positions along with
two sets of in vitro mixtures of the four respective haplotypes.
The wild-type HBV plasmid vector pCH9-3091 was modified by site-directed mutage-
nesis. This resulted in a set of six clonal HBV variants (Table 4.1). The clonal variants
v1, v2, v3, v4 represent all possible haplotypes for the two ambiguous positions 610 and
612 in the reverse transcriptase domain shown in Figure 4.1. Likewise, the haplotypes
v1, v2, v5, v6 represent all possible haplotypes for two SNPs at positions 610 and 614. Test
set 1 (TS1) consists of 29 in vitro mixtures of the four haplotypes v1, v2, v3, v4 and test
set 2 (TS2) consists of 42 in vitro mixtures of the four haplotypes v1, v2, v5, v6. Mixtures
were prepared by mixing equal amounts of DNA of the respective haplotypes. The in vitro
mixtures were submitted to independent sequencing reactions, each with the same set of
oligonucleotides.
Clonal variants or mixtures of clonal variants were amplified and sequenced using two
distinct established protocols and sequencing machines. TS1 and TS2 were prepared ac-
cording to Schildgen et al. (2004) and Zhang et al. (2007), respectively. Sequencing of TS1
was performed on ABI 3130xl using BigDye version 1.1 while TS2 was sequenced on ABI
3730 using BigDye version 3.1. The use of two different sequencing protocols was due to
interim technological development and not originally intended in the design stage of the
study. However, incorporating two technologies enables us to document the robustness of
our approach with respect to sequencing protocols. The use of standard sequencing proto-
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cols, which are also used in routine diagnostics at the Institute of Virology, University of
Cologne, allows us to evaluate our method in a setting close to the clinical routine. Nev-
ertheless, as these standard sequencing protocols are not optimized to preserve mixture
fractions, we focus on predicting mixture components.
4.3.2 In silico Test Data
An in silico test set of 1771 samples was created using all possible mixture fractions on a
grid with precision 0.05 using the set of haplotypes v1, v2, v3, v4. Test chromatograms were
computed using the mixture assumption according to equation (4.4).
4.3.3 Data Likelihood Computation
The computational approach requires repetitive sequencing of all possible clonal variants
in the mixture as training data. Each haplotype has its own characteristic sequencing
chromatogram profile due to the effect of context-dependent incorporation of dideoxynu-
cleotides. Then, the chromatogram of a mixture of haplotypes is the proportion-weighted
combination of these haplotype-specific profiles (with some variance). The haplotype-
specific profiles are similar to the reference chromatograms used in reference-based methods
to quantify relative allele frequencies. Haplotype-specific profiles are derived from several
sequencing repetitions of a single template to average out noise and obtain more accurate
reference peak heights.
In a preprocessing step all sequencing chromatograms were normalized using a sequence
region (called the normalization region) upstream from the region under analysis. Each
DNA base (A, C, G, T) requires its own normalization parameter. These four parameters
were set such that the average peak height of each base in the normalization region is 1000.
Let cjki denote the normalized peak heights of the sequencing chromatograms of the four
haplotypes with j = 1, ..., 4 indexing a set of haplotypes (either v1, v2, v3, v4 or v1, v2, v5, v6),
k = 1, ..., q indicating the sequencing replicate, and i = 1, ..., n representing all nonzero
peak heights in a window of 20 bases around the ambiguous positions. This includes all
positions, both ambiguous and non-ambiguous. Thus, n = 22. Note that i does not index
sequence positions, i indexes nonzero peak heights. The haplotype-specific profiles pji were
computed as the median normalized peak heights of the sequencing replicates:
pji = median(cj1i, ..., cjqi). (4.3)
Given the fractions α1, α2, α3, α4 (with αj ≥ 0 and
∑
j αj = 1) of a mixture of four
haplotypes the corresponding mixture profile mi was computed in terms of the weighted
sum of the peak heights of the individual haplotype-specific profiles. Here the weights are
the fractions of the haplotypes:
mi =
∑
j
αj · pji. (4.4)
The likelihood of an observed chromatogram with peak heights D = {hi, i = 1, ..., n}
given a mixture profile mi is specified using the following conditional distribution as-
sumption: given normalization parameters γA, γC , γG, γT for each DNA base, the mixture
components M ⊆ {1, ..., 4}, and the corresponding mixture fractions αj , the normalized
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peak heights γB[hi] · hi are assumed to be normally distributed with mean equal to the
mixture profile peak heights mi and constant variance σ2:
P (γB[hi] · hi|M,α) =
1
σ
√
2pi
· e−
(γB[hi]
·hi−mi)2
2σ2 . (4.5)
Here B[hi] denotes the DNA base of peak height hi. The variance σ2 reflects sequencing-
dependent variations in peak heights, which were estimated using sequencing replicates of
clonal variants.
In order to apply equation (4.5) (to compute the data likelihood P (D|M,α)) the normal-
ization constants γA, γC , γG, γT need to be estimated. Therefore, the data D is partitioned
into the distinct union of D = Deval∪˙Dfit. Deval contains all ambiguous and Dfit the re-
maining peak heights. γA, γC , γG, γT are estimated on Dfit using the maximum likelihood
principle given the conditional distribution assumption (4.5) and the mixture profile mi.
Fitting each normalization constant is an ordinary least-square regression problem for each
mixture profile mi. The likelihood of the observation P (D|M,α) is then computed using
equation (4.6). Thus, we evaluate P (D|M,α) by computing P (Deval|M,α,Dfit). After the
normalization constants γA, γC , γG, γT have been estimated using Dfit, the peak heights
of Deval can be assumed to be independent given the conditional distribution assumption.
This allows the likelihood function to be factorized:
P (D|M,α) = P (Deval|M,α,Dfit)
=
∏
h∈Deval
P (γB[h] · h|M,α). (4.6)
4.3.4 Model Selection
The primary goal is to determine the haplotypes M ⊆ {1, ..., 4} represented by a given
chromatogram. Maximum likelihood estimates derived from the conditional distribution
assumption overfit and likely produce point estimates indicating that all four haplotypes
are present. In order to guard against overfitting regularization is employed by computing
the marginal model likelihoods with uniform priors P (α|M) according to the principals
of probabilistic reasoning as introduced in Section 2.5.1. Given a model M the marginal
model likelihoods are computed as:
P (D|M) = P (Deval|M,Dfit)
=
∫
P (Deval|M,α,Dfit) · P (α|M) dα.
(4.7)
For the setting with two ambiguous sequence positions seven alternative models need to
be considered, which areM1+4,M2+3,M1+2+3,M1+2+4,M1+3+4,M2+3+4, andM1+2+3+4.
Thus, inferring the haplotype composition is a 7-fold classification problem. The notation
M1+4 is used to indicate a mixture of haplotypes 1 and 4, M1+2+3 is used to indicate a
mixture of haplotypes 1, 2 and 3, etc.. Other subsets of {1, ..., 4}, e.g. {1, 2}, do not exhibit
two ambiguous positions in the chromatogram and therefore can be excluded.
To improve model selection, the modes β1, . . . , β4 of the posterior marginals of the model
parameters α1, . . . , α4 of the full model M1+2+3+4 are computed. For each j ∈ {1, 2, 3, 4}
let αj denote all αi with i 6= j.
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βj = arg max
αj
P (αj |D,M1+2+3+4)
= arg max
αj
∫
[0,1]3
P (α|D,M1+2+3+4) dαj
= arg max
αj
∫
[0,1]3
P (α|M1+2+3+4) · P (D|M1+2+3+4, α) dαj
(4.8)
A model M ⊆ {1, ..., 4} is considered to be inconsistent with β1, . . . , β4 given a certain
cutoff value t if there exists j ∈ M with βj ≤ t and (in case M 6= M1+2+3+4) if there
is k /∈ M with βk > t. In words, there is a haplotype j indicated by the model with
low βj and a haplotype k not present in the model with high βk, which together indicate
a strong contradiction of the model with the parameter marginals. The latter condition
that haplotype k is not present in the model even though βk > t can and need only to be
fulfilled if the model under consideration is not the full model (M1+2+3+4). Models that
are inconsistent with the modes of the parameter marginals are excluded from the model
selection procedure. We refer to this as the application of the consistency rule. The cutoff
t used to evaluate the prediction performance on TS1 was chosen to optimize accuracy on
TS2 and vice versa.
The integrals (4.7) and (4.8) were approximated using a grid of α values of precision
0.025. This resulted in 12341 parameter configurations, for which the log-likelihoods were
computed and summed up to compute the marginal model likelihoods and the posterior
marginal parameter distributions.
4.3.5 Performance Evaluation
Haplotype reconstruction for two ambiguous sequence positions is a 7-fold classification
problem. Prediction performance at the model level is measured in terms of accuracy.
Prediction performance is also evaluated at the clonal level. For this purpose, each 7-
fold classification problem is interpreted as four 2-fold classification problems defined by
the prediction of the presence or the absence of each of the four possible haplotypes.
Confidence of predictions is expressed in terms of an uncertainty cutoff. Each prediction
is either correct, incorrect, or unassigned. A sample remains unassigned if the marginal
likelihood of the best model divided by the marginal likelihoods of all other models falls
below the uncertainty cutoff.
4.4 Results
4.4.1 Application to Dilution Series
The mixture assumption was employed to estimate the mixture fractions of three dilution
series obtained from Carr et al. (2009). The maximum likelihood estimates for the mixture
fractions derived from the chromatograms were close to the nominal mixture fractions for
dilution series 1 and 2 with average absolute errors of 0.01 and 0.03, respectively (Figures
4.3A and 4.3B). Dilution series 3 exhibited a nonlinear relationship between nominal and
estimated proportions, resulting in an average absolute error of 0.14 (Figure 4.3C). This
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nonlinear relationship is likely caused by varying amplification efficiencies of the differ-
ent clonal variants. Almost identical results for these data were reported by Carr et al.
(2009). Note that the variance in the estimates originates from repetitive amplification and
sequencing of the same in vitro mixture. The experiment described above was repeated
while blanking out the ambiguous positions. Thus, we employed only sequence positions
-2, -1, 1, and 2 (see Figure 4.2) to estimate the mixture fractions. This resulted in fraction
estimates with higher average errors of 0.05, 0.08, and 0.26 and higher variances (Figures
4.3D-4.3E). The mixture assumption facilitates the estimation of the fractions of a mixture
without using the ambiguous positions. Previous methods that quantify mixture fractions
based on sequencing chromatograms only consider ambiguous positions and neglect the in-
formation provided by surrounding peaks (Carr et al., 2009; Kwok et al., 1994; Qiu et al.,
2003).
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Figure 4.3: All plots show nominal mixture fractions versus estimated mixture fractions
for three dilution series. (A-C) uses all peak heights and provides proportions
estimates with low error and low variance. (D-F) ignores the peak heights at the
ambiguous positions and tries to estimate the mixture proportions only based
on the surrounding peak heights of the unambiguous positions. The resulting
fraction estimates show higher errors and higher variances. The blue lines are
fitted by local polynomial regression lines (LOESS), grey areas indicate 95%
confidence intervals.
4.4.2 Complexity of Haplotype Reconstruction
We now focus on the problem of haplotype reconstruction based on sequencing chro-
matograms in the special case of two ambiguous sequence positions. For this problem
four possible haplotypes 1, . . . , 4 with fractions α1, . . . , α4 need to be considered. Table
4.1 rows 1 to 4 lists the four possible haplotypes for the combination of two important
HBV drug resistance mutations within the reverse transcriptase domain. The haplotype
reconstruction problem has three degrees of freedom α1, α2, α3, which determine α4 due
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to
∑
j αj = 1. An estimate of the fraction of the first ambiguous position p1 gives rise to
α1 +α3 = p1 as haplotype 1 and 3 are wild-type at the first ambiguous position. Similarly,
an estimate p2 of the fraction of the second ambiguous position provides α1 + α2 = p2.
These frequency estimates can be derived from the chromatograms, thus reducing the com-
plexity to one degree of freedom. This implies that the peak heights of the two ambiguous
positions impose strong constraints that limit the space of possible solutions to approxi-
mately a straight line in the three-dimensional simplex of all possible solutions. Within
this set of possible solutions we face the problem of model selection. Further evidence from
the surrounding peaks or slightly different configurations of the four ambiguous peaks are
required to localize the correct solution.
4.4.3 In silico Experiment
To study elementary properties of our approach we created a set of in silico test samples.
1771 artificial chromatograms were created for the set of haplotypes v1, . . . , v4 (see Table
4.1) based on equation (4.4) using a grid of α values with grid size 0.05. Test data were
generated without adding a noise component. The noise-free setting provides an upper
bound on the model performance to be expected on real-world data and simplifies the
analysis of model characteristics and limitations. Mixture chromatograms were truncated
to nucleotide positions 600 to 620. Positions 610 and 612 were employed to compute the
data likelihoods. The value of the standard deviation σ was estimated using the sequencing
repetitions of the haplotypes. σ was set to 20.94. As peak heights were normalized to have
an average height of 1000, a standard deviation of 20.94 implies variation of peak heights
of approximately 2.1%.
Only 867 (49%) of the 1771 in silico test samples were predicted correctly. Figure 4.4
visualizes all incorrectly predicted test cases separately for each falsely predicted label. The
four surfaces of the simplex correspond to the four 3-mixture models M1+2+3, M1+2+4,
M1+3+4, and M2+3+4. Test samples that lie in the interior of the simplex but close to
one of its faces display mixtures of all four haplotypes of which one haplotype has low
frequency (Figures 4.4A-4.4D). These test samples were regularized towards the surface
of the simplex by using the marginal likelihoods for model selection. This reveals the
first major restriction of the model in terms of sensitivity, which is that low frequency
haplotypes in a mixture of four haplotypes can not reliably be detected.
The test set can be divided into two groups: those samples that contain at least one
haplotype with a fraction of no more than 10%, and those for which each present haplotype
occurs in a fraction higher than 10%. The samples of the first group were predicted correctly
in 383 (32.0%) of 1200 cases. The samples of the second group (all present haplotypes
exceed a fraction of 10%) were predicted correctly in 484 (85%) of 571 cases.
Figure 4.4E indicates a second systematic failure, which is that 46 test samples (34
M1+2+3+4, 5 M1+2+3, and 7 M2+3+4) were incorrectly predicted as mixtures of haplotypes
1 and 4. All of these samples satisfied the set of linear constraints α2−α3 ≤ 0.05, α2 ≤ 0.35,
and α3 ≤ 0.35. These misclassifications occur due to model regularization as detailed in
Section 4.5. Similarly, 41 test samples (32 M1+2+3+4, 5 M1+2+4, and 4 M1+3+4) were
falsely predicted as mixtures of haplotypes 2 and 3 (Figure 4.4F). These samples satisfied
the constraints 2α1 +α2 +α3− 1 ≤ 0.05, α1 ≤ 0.30, and α4 ≤ 0.30. To improve prediction
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Figure 4.4: 1771 in silico test chromatograms were created by computing the mixture
profiles on a grid of α values with grid size 0.05. The plots show all falsely
classified samples separately for each falsely predicted label. Six major cases of
misclassification can be observed. Plots A-D show test samples, which consist
of four haplotypes, at least one of which having low proportion. Plots E and
F show test samples that were predicted as mixtures of haplotypes 1 and 4 or
as mixtures of haplotypes 2 and 3. The data points of plot E satisfy the linear
constrains α2 − α3 ≤ 0.05, α2 ≤ 0.35 and α3 ≤ 0.35 and data points of plot F
satisfy 2α1 + α2 + α3 − 1 ≤ 0.05, α1 ≤ 0.30 and α4 ≤ 0.30, respectively.
performance we analyzed the marginal posterior distributions of the fraction parameters
α1, . . . , α4. For example, for all of the seven M2+3+4 test samples that were misclassified
as M1+4 we observed that the modes of the posterior marginal distributions of α1 were
zero while the modes of α3 had a mean of 0.22 ± 0.07. Thus, the modes of the posterior
marginals were clearly inconsistent with the model predictions based on the marginal model
likelihoods. By checking the consistency of the model predictions with the modes of the
posterior marginals using a cutoff of 10% (as described in Section 4.3.4) all misclassified
3-mixture test samples could be corrected. Nevertheless, the consistency rule does not
improve prediction performance on the 4-mixture test samples. The inability of the model
to distinguish between 2-mixture and 4-mixture test samples (if one of two sets of linear
constraints is fulfilled) is the second major limitation of the model in terms of accuracy.
4.4.4 In vitro Validation
Our hypothesis was that the haplotype composition of arbitrary mixtures can be recon-
structed using information from the ambiguous and the surrounding peak heights. To test
this hypothesis, we created two in vitro training sets, each composed of six sequencing
repetitions of the underlying haplotypes (Table 4.1) to compute the individual haplotype
profiles and a respective test set of in vitro mixtures. Test set 1 (TS1) based on haplotypes
v1, v2, v3, v4 contained 29 mixtures and test set 2 (TS2) based on haplotypes v1, v2, v5, v6
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contained 42 mixtures. When model selection was solely based on the marginal model
likelihoods, prediction accuracy at the model level was 96.6% on TS1 and 47.6% on TS2.
By application of the consistency rule as described in Section 4.3.4, prediction accuracy
improved to 71.4% on TS2 and remained unchanged on TS1. The respective cutoff used to
evaluate the prediction performance on TS1 was chosen to optimize accuracy on TS2 and
vice versa. A cutoff of 10% was used for both data sets. Note that model selection in this
setting is a 7-fold classification problem and the accuracy expected by chance amounts
to only 14.3%. Prediction performance was also evaluated at the clonal level. In this
evaluation scheme we treated the 7-fold classification problem as four 2-fold classification
problems that amounted to the prediction of the presence or the absence of each of the
four possible haplotypes. Using this evaluation we could study the accuracy of the model
predictions in more detail compared to the assessment of accuracy in terms of 0-1 error
at the model level. For instance, the incorrect classification of a M1+2+3+4 test sample
as M1+2+3 would result in an accuracy of 75% as three of four haplotypes were predicted
correctly. Clonal level prediction accuracy was 97.4% for TS1 and 84.5 % for TS2. Figure
4.5 summarizes the prediction performances on TS1 and TS2 both at the model level and
at the clonal level. Additionally, we present the results as a function of the prediction
confidence expressed by the uncertainty cutoff. For example, at an uncertainty cutoff of
4.0, which means that the marginal likelihood of the best model is at least 4.0 times as high
as the marginal likelihood of the second-best model, only 2.6% (5.4%) of the predictions
at the clonal level were incorrect, 14.6% (30.4%) were unassigned and 82.8% (64.2%) of
the predictions were correct on TS1 (respectively TS2).
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Figure 4.5: The figure shows the prediction accuracy on test sets TS1 (subplots A and B)
and TS2 (subplots C and D). Prediction accuracy was evaluated both at the
clonal and at the model level. Each test sample is predicted either correctly
or incorrectly, or is classified as unassigned. The latter happens when the
marginal likelihood of the best model divided by the marginal likelihood of the
second-best model falls below the uncertainty cutoff displayed on the x-axis.
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4.5 Discussion
We described the first attempt, to our knowledge, to use peak heights from sequencing
chromatograms to infer linkage information about nearby ambiguous positions. A gener-
ative model describes the expected peak heights of a mixture of haplotypes by combining
the chromatograms of the underlying haplotypes. The model was motivated by visual in-
spection of the peak heights of a dilution series. Our model is a generalization of previous
methods for estimating the fractions of one ambiguous sequence position (Carr et al., 2009;
Kwok et al., 1994). The main difference is that we employed a generative model, whose
parameters are estimated by probabilistic inference rather than by comparing observed
peak heights to template peak heights. Previous methods neglected nearby peak heights
as they are usually influenced by the ambiguous peaks to be analyzed. In contrast, we
exploit this interaction effect to infer linkage information.
Prediction accuracy. The high prediction accuracy of our method on two in vitro test
sets of 29 and 42 mixture samples shows that sequencing chromatograms do contain linkage
information. The prediction accuracy on TS1 was 97.4% at the clonal level and 96.6% at
the model level while the accuracy on TS2 was 84.5% at the clonal level and 71.4% at the
model level. We found that the posterior marginal distributions of the model parameters αj
are informative of the mixture compositions as prediction performance at the model level
increased from 47.6% to 71.4% on TS2. The probabilistic framework provides confidence
values for the predictions in terms of posterior distributions, which can be applied to reduce
the number of false predictions at the cost of a higher number of unclassified samples.
Model limitations. The evaluation of the model on a set of 1771 in silico test sam-
ples revealed several limitations of our approach. First, the model cannot reliably detect
minor populations with frequency of no more than 10%. In such cases, the predictions are
regularized towards simpler models, which do not contain the low-frequency haplotype.
Second, we found that if the mixture fractions αj satisfy one of two sets of linear con-
straints, the mixture is always predicted to be either a mixture of the haplotypes 1 and 4
or a mixture of haplotypes 2 and 3. The true mixture components in the former case are
M1+4, M1+2+3, M2+3+4, andM1+2+3+4 and in the latter case areM2+3, M1+2+4, M1+3+4,
and M1+2+3+4. This becomes plausible by looking at the proportion estimates p1 and p2
of the two ambiguous positions. If p1 and p2 are equal (p1 = p2), then the observed peak
heights can be interpreted to originate from a mixture of haplotypes 1 and 4 with α1 = p1
and α4 = 1− p1. From p1 = p2 follows α1 + α3 = α1 + α2 and immediately α2 − α3 = 0.
If additionally α2 and α3 have low frequency (below 35%), we obtain the set of linear con-
straints that are fulfilled by all in silico test cases, which were falsely classified as mixtures
of haplotypes 1 and 4 (Figure 4.4E). The presence of haplotypes 2 and 3 does not become
strongly evident by looking at the surrounding peaks due to their low frequency. Similarly,
if the frequency estimates at the two ambiguous positions fulfill p1 = 1 − p2, the mixture
can be interpreted to contain only the haplotypes 2 and 3 with α2 = p2 and α3 = p1. From
p1 = 1− p2 follows α1 +α3 = 1−α1−α2 and immediately 2α1 +α2 +α3− 1 = 0, which is
the constraint satisfied by all in silico test cases that were falsely predicted as a mixture
of the haplotypes 2 and 3. This observation is reflected in the in vitro test set TS2, in
which four samples (9.5%) were incorrectly classified at an uncertainty cutoff of 4.0. Three
samples were M1+2+3+4 mixtures misclassified as M2+3 with 2α1 +α2 +α3− 1 amounting
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to 0.0, 0.0, and 0.025, respectively. Additionally, one M1+2+3 sample was misclassified as
M1+4 with α2 − α3 equal to 0.025.
To summarize, we think that the misclassifications do not result from inaccurate like-
lihood computations, but rather from the model regularization. Simpler models are pre-
ferred, if the peak heights at the ambiguous positions do not imply a more complex model.
This is the case, in particular, when one haplotype in a mixture of four haplotypes has low
frequency (misclassified as a mixture of three haplotypes), when p1 ≈ p2 (misclassified as
M1+4), or when p1 ≈ 1− p2 (misclassified as M2+3).
Applicability. We evaluated our hypothesis to perform inference on the haplotype com-
positions for only two sets of sequence positions within the reverse transcriptase domain
of the HBV genome. Nevertheless, peak heights usually display very distinctive patterns.
Thus, we assume the approach will also work in other settings. Two different amplification
and sequencing protocols in concert with two different sequencing machines were employed
to generate the two test sets. This indicates the robustness of the method with respect
to sequencing protocols. The reasoning that the problem is essentially one-dimensional
after the mixture fractions are estimated implies that the model very likely cannot suc-
cessfully be extended to infer the haplotype composition in the presence of more than two
nearby ambiguities. Additionally, the locality of the effect of sequence context-dependent
incorporation of dideoxynucleotides limits the capacity of the approach to infer linkage in-
formation of ambiguous positions that are more than a few bases (up to five bases, at most)
apart from each other. On test set TS2, in which the two ambiguous positions were three
positions apart from each other, prediction accuracy was already impaired in comparison
to TS1, in which the two ambiguous positions were only separated by a single base.
Second generation sequencing. The advent of second-generation sequencing tech-
nologies has superseded Sanger sequencing in many applications (Mardis, 2008; Metzker,
2010). 2ndGS technologies offer increased sequencing depth and speed through a high
degree of parallelization and miniaturization and allow for the detection of minor vari-
ants with relative frequencies of as low as 10−4 (Gerstung et al., 2012). 2ndGS data also
naturally provide linkage information over the whole read length, which may further be ex-
tended by the use of paired-end reads (Chaisson et al., 2009). Compared to our approach,
2ndGS technologies are far more sensitive and accurate in determining the haplotype com-
position of mixtures and can deliver long-range linkage. Nevertheless, Sanger sequencing is
cheaper than 2ndGS and 2ndGS will not be accessible in many laboratories for some time
to come. Considering this, certain applications, in which the limitations of our approach
in terms of sensitivity, accuracy, and limited range are acceptable, may not require 2ndGS.
Conclusions. We have developed and validated an approach to compute the peak
heights of a mixture of haplotypes based on the chromatograms of the underlying haplo-
types. The model can be used to infer the haplotypes present in a mixture and therefore the
short-range linkage for two ambiguous sequence positions. The effect of sequence context-
dependent incorporation of dideoxynucleotides, an effect that was previously regarded as
detrimental, was employed. The effectiveness of our method shows that short-range linkage
information can be inferred from sequencing chromatograms with no further assumptions
on the mixture composition. The model also allows the estimation of the fractions of nearby
ambiguities and therefore overcomes the limitations of Carr et al. (2009). As a major lim-
itation to its widespread applicability, the model requires the sequencing chromatograms
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of all possible haplotypes in the mixture. The source code of our method is available at
http://bioinf.mpi-inf.mpg.de/publications/beggel/linkageinformation.zip.
5 G-to-A Hypermutation of the HBV Genome
Real biologists who actually do the research will tell you that they
almost never find a phenomenon, no matter how odd or irrelevant it
looks when they first see it, that doesn’t prove to serve a function.
The outcome itself may be due to small accidents of evolution.
(E. O. Wilson)
The immune response to infections with the hepatitis B virus is a complex and not well
understood system that involves the development of specific antibodies (anti-HBs, anti-
HBc, and anti-HBe) and the activation of a broad set of restriction factors within the
response of the innate immune system. Understanding this system might lead to a better
understanding of the four phases of the natural progression of chronic hepatitis B infections
as the phases are mainly determined by the state of the immune system (see Section
2.1.3), and, as a consequence, to new antiviral strategies. An important part of the innate
immune system are APOBEC3 (A3) proteins, a subgroup of the APOBEC (apolipoprotein
B mRNA-editing enzyme catalytic polypeptide-like) protein family. All members of the
APOBEC family are cytosine deaminases, which catalyze the hydrolytic deamination of
cytosine to uracil (Figure 5.1B). A3 deaminases gained a lot of attention since the gene
of the most prominent member of this subgroup, APOBEC3G (A3G), was identified by
Sheehy et al. (2002). A3 deaminases have the ability to mutate the HBV genome and
the genome of other DNA and RNA viruses. The deamination of cytosine mediated by
APOBEC proteins is referred to as editing. Chelico et al. (2006) provided a detailed
analysis of the molecular mechanisms of the editing activity of A3G, which was shown to
bind to single-stranded DNA and to mutate cytosine to uracil while moving from 3′ to
5′. During completion of the complementary plus strand, deamination of the (–)-DNA
strand results in the translation of uracil into guanine, which becomes visible as G-to-A
mutations. Viral genomes with an unexpected high number of G-to-A mutations were first
observed in HIV patients (Vartanian et al., 1991; Wain-Hobson et al., 1995). The term
G-to-A hypermutation is used to describe the phenomenon of up to 80% of guanines being
mutated to adenines (G-to-A mutations) in a short sequence region of about 100 bases.
The work described in this Chapter was funded by the Forschungskommission of the
Heinrich-Heine-University, Düsseldorf. Project partner Prof. Andreas Erhardt, (formerly
Heinrich-Heine-University, Düsseldorf, currently Petrus Hospital, Wuppertal) designed the
study and provided patient data. Prof. Carsten Münk, Heinrich-Heine-University, Düssel-
dorf supported and guided the analysis. The work was initially published in Beggel et al.
(2013a). We present a detailed analysis of the G-to-A hypermutation pattern of the com-
plete HBV genome on the basis of second-generation sequencing data of 80 treatment-naïve
patients (47 HBeAg-positive and 33 HBeAg-negative). We found that the intensity of G-
to-A hypermutation depends on various factors, especially the position along the genome,
the HBeAg status, and the state of fibrosis. Additionally, we found that the prevalence
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of HBsAg and HBeAg escape mutations are statistically significantly associated with G-
to-A hypermutation. We start this Chapter with a short history of the discovery of A3G
(Section 5.1.1) and a summary of the APOBEC protein family members (Section 5.1.2).
Then, we review the effects of APOBEC proteins on HBV (Section 5.1.3). Section 5.2
presents the methodical background of our study. The results of our analysis are outlined
in Section 5.3. In Section 5.4 we conclude with summarizing remarks and a classification
of our results with respect to the published knowledge about hypermutation of the HBV
genome.
5.1 Biological and Clinical Background
5.1.1 Discovery of APOBEC3G
The study of the APOBEC proteins is closely related to the study of Vif, one of HIV-1’s
accessory regulatory proteins. HIV-1 belongs to the genus Lentivirus, which in turn is
part of the family of retroviruses. The genome of retroviruses contains the reading frames
Gag, Pol, and Env encoding the viral matrix protein, the viral enzymes, and the surface
proteins, respectively. Lentiviruses encode several additional (essential or accessory) reg-
ulatory proteins, which in case of HIV-1 are Tat, Rev, Nef, Vif, Vpr, and Vpu. During
knock-out experiments performed to study the function of the regulatory proteins, it was
observed that Vif-deleted (∆Vif) HIV-1 variants cannot spread in primary CD4 T-cells
and macrophages (Gabuzda et al., 1992; Sova and Volsky, 1993; von Schwedler et al.,
1993). To be more precise, a collection of cell lines, so-called nonpermissive cells, can be
infected with ∆Vif HIV-1 variants but produce noninfectious HIV-1 particles. Other cell
lines (e.g. Jurkat and SupT1), so-called permissive cells, enable ∆Vif HIV-1 to replicate in
the absence of Vif. This suggests two possibilities for the role of Vif in HIV-1 replication:
either permissive cells express a protein similar to Vif, which can perform the function of
Vif in the HIV-1 replication cycle, or Vif counteracts a cellular restriction factor that is
only present in nonpermissive cells. A3G was identified to be the counteracting restriction
factor in a study conducted by Sheehy et al. (2002), in which two very similar cell lines,
one permissive and one nonpermissive, were analyzed using subtractive hybridization tech-
niques. Shortly thereafter, several other members of the APOBEC family were described
(Chiu and Greene, 2008).
5.1.2 APOBEC Protein Family
The human APOBEC protein family consists of eleven members: APOBEC1, APOBEC2,
activation-induced cytidine deaminase (AID), APOBEC3A-APOBEC3H (A3A-A3H), and
APOBEC4 (Jarmuz et al., 2002; Liao et al., 1999; Rogozin et al., 2005). All of these have
the ability to edit DNA or RNA by performing the hydrolytic deamination of cytosine to
uracil (Figure 5.1B). The seven A3 deaminases (A3A, A3B, A3C, A3DE, A3F, A3G, and
A3H) are arranged in a tandem gene array on chromosome 22, which implies that they
likely have a common ancestor and arose from successive gene duplication events.
The active sites of the APOBEC proteins, which are involved in DNA and RNA editing,
are characterized by a conserved zinc-binding motif His-X-Glu-X23−28-Pro-Cys-X2−4-Cys
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Figure 5.1: (A) Location of the active sites of the members of the APOBEC protein family.
The numbers state the first and last amino acids of the cytosine deaminases.
The back region indicates the location of the conserved zinc-dependent cytosine
deaminase active sites with the amino-acid motif shown at the bottom. (B)
Deamination of cytidine (cytosine if incorporated into DNA) to uracil. Per-
mission to reuse this figure was granted by John Wiley & Sons (Janahi and
McGarvey, 2013).
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(Jarmuz et al., 2002; Wedekind et al., 2003). Of note, A3B, A3DE, A3F, and A3G have
two copies of this catalytic site (Figure 5.1A).
The members of the APOBEC family have very distinct biological functions. APOBEC1,
AID, and APOBEC3(A-H) are well characterized, while the functions of APOBEC2 and
APOBEC4 are not well understood. APOBEC1 mediates the deamination of a specific
cytosine at position 6666 in the messenger RNA of apolipoprotein B into uracil-6666, which
creates an in-frame stop codon. The truncated (apoB48) and untruncated (apoB100)
versions of the apolipoprotein B protein were described to have distinct functions in the
lipid metabolism (Mehta et al., 2000; Teng et al., 1993). APOBEC1, in contrast to the
other members of the APOBEC family, primarily edits RNA rather than DNA.
The catalytic activities of AID are crucial for the development of mature and diverse
antibody responses. AID is expressed in germinal centre B-lymphocytes, where it facilitates
cytosine-to-uracil mutations of the immunoglobulin gene. This random deamination of
cytosines is referred to as somatic hypermutation of the immunoglobulin gene and aims
to increase the diversification of the immunoglobulin gene and facilitates antibody class
switches (e.g. from immunoglobulin M to immunoglobulin G) (Muramatsu et al., 1999,
2000).
A3 deaminases are part of the innate immune system and act against exogenous viruses
(Delebecque et al., 2006; Yu et al., 2004) and endogenous retroelements (Bogerd et al.,
2006; Kinomoto et al., 2007). A3 deaminases inhibit a broad range of viruses, for instance
HIV-1, HBV, HCV, human papillomavirus (HPV), herpes simplex virus type 1 (HSV-1),
and Epstein-Barr virus (see Vieira and Soares (2013) for a recent review). It is important
to note that the antiviral activity of A3 deaminases only partly relies on their ability to edit
viral genomes. A3 deaminase-inactive variants were shown to inhibit e.g. HIV-1 with a
deaminase-independent mode of action (Bishop et al., 2006, 2008). G-to-A hypermutation
of the HCV genome has not been described yet while A3G was shown to be a strong
inhibitor of HCV replication in vitro (Peng et al., 2011).
Not all members of the A3 subgroup inhibit all exogenous viruses or endogenous retroele-
ments, which can partly be explained by different localizations. A3D, A3F, and A3G are
mainly observed in the cytoplasm (Bennett et al., 2008; Kinomoto et al., 2007), A3B is al-
most exclusively located in the nucleus (Lackey et al., 2012), and A3A, A3C, and A3H are
found both in the nucleus and in the cytoplasm (Kinomoto et al., 2007; Li and Emerman,
2011).
5.1.3 APOBEC and HBV
Hypermutated HBV genomes were already observed in vivo by Günther et al. (1997), but
the molecular mechanisms of hypermutation were unknown. Hypermutated genomes oc-
cur in vivo at low frequency (below 1%), which makes them difficult to observe and to
analyze (Noguchi et al., 2009; Suspène et al., 2005b). Thus, intensive studies could only be
performed after the APOBEC genes were identified, which allows specific over- and under-
expression of APOBEC genes, and 3D-PCR, a differential DNA amplification technique,
became available (Sheehy et al., 2002; Suspène et al., 2005a). 3D-PCR utilizes the fact that
AT-rich DNA melts at a lower temperature than GC-rich DNA. This allows hypermutated
genomes to be selectively amplified and facilitates the analysis of hypermutated genomes
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despite their low frequency.
In vitro. In vitro studies showed that the HBV genome is susceptible to editing by
APOBEC1 (Gonzalez et al., 2009), AID (Vartanian et al., 2010), and all A3 deaminases
except for A3DE (Baumert et al., 2007; Henry et al., 2009; Köck and Blum, 2008; Rösler
et al., 2005; Suspène et al., 2005b). HBV’s (–)-DNA strand is the preferred editing template
resulting in G-to-A hypermutated genomes, which occur in frequencies of 10−5 to 10−2
depending on the A3 deaminase (Henry et al., 2009). Rare C-to-T hypermutated genomes
or G-to-A + C-to-T mixed hypermutated genomes were observed in vitro in A3B, A3F, and
A3G overexpressed cells, which suggests (+)-DNA strand editing (Suspène et al., 2005b).
It is not well understood how A3 proteins can edit HBV’s (+)-DNA strand. It might
be that the (+)-DNA and (–)-DNA strands temporarily separate, which would enable A3
binding and editing.
Inhibition. Intensive hypermutation of the HBV genome leads to deleterious muta-
tions, which result in non-functional proteins and, obviously, in inhibition of the replica-
tion. Furthermore, DNA that has undergone intensive editing (uracil-rich DNA) might
be recognized as degraded and might be digested by the combined action of uracil DNA
glycosylases and apurinic-apyrimidinic endonuclease (Schröfelbauer et al., 2005; Sova and
Volsky, 1993). By the use of deamination-inactive variants it was shown that A3B, A3G,
and likely other A3 deaminases inhibit HBV in a deamination-independent mode of action.
Deamination-inactive A3G inhibits HBV with the same strength as wild-type A3G, which
indicates that the contribution of hypermutation to its inhibitory effect is likely minimal
(Noguchi et al., 2007). Subsequently, it was pointed out that A3G is a strong inhibitor
of HBV but leads to a relatively low number of edited genomes while A3C, on the other
hand, has only little inhibition activity but leads to a high number of mutated genomes
(Baumert et al., 2007; Köck and Blum, 2008). A study that focused on A3B showed
that the inhibitory effect of deamination-inactive A3B is reduced to approximately 40%
compared to its wild-type counterpart (Bonvin and Greeve, 2007). Both of A3B’s active
sites (see Figure 5.1A) contribute to its antiviral effect, while only the C-terminal active
site has deamination activity. The deamination-independent mode of inhibition is not yet
fully understood. A3 deaminases are likely incorporated into the HBV capsid and prevent
the completion of capsid formation or the reverse transcription of the pregenomic RNA
(Nguyen et al., 2007; Rösler et al., 2005).
Dinucleotide context. APOBEC proteins exhibit context-specific editing profiles
(Henry et al., 2009; Suspène et al., 2005b; Vartanian et al., 2010). APOBEC1 shows a
preference for GA-to-AA mutations and an aversion against GC-to-AC mutations (Gon-
zalez et al., 2009; Vartanian et al., 2010). AID prefers G-to-A mutations in the GC and
GT context, which leads to GC-to-AC and GT-to-AT mutations, respectively (Beale et al.,
2004; Vartanian et al., 2010). In contrast to APOBEC1 and AID, all A3 deaminases pre-
fer editing in the GG and GA context. A3G shows strong preference towards GG-to-AG
mutations while A3A, A3B, A3C, and A3F have a more balanced dinucleotide preference
(Henry et al., 2009; Suspène et al., 2005b). The number of mutations in the GG and GA
context vs. the number of mutations in the GC and GT context is used in in vivo studies
to discriminate between reads edited by APOBEC1/AID and those edited by A3 deami-
nases (Suspène et al., 2011; Vartanian et al., 2010). Additionally, a very high number of
GG-to-AG mutations indicates A3G activity due to A3G’s strong preference for mutations
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in the GG dinucleotide context. Using the dinucleotide context it was shown that the vast
majority of hypermutated genomes observed in vivo were edited by A3 deaminases.
Interferon stimulation. Primary human hepatocytes of healthy individuals express
low levels of the messenger RNAs of A3B to A3G but the expression of A3B, A3C, A3F, and
A3G can be upregulated by interferon stimulation. Upregulation of interferon leads to a sig-
nificant reduction of HBV replication (Bonvin et al., 2006; Jost et al., 2007; Noguchi et al.,
2005; Tanaka et al., 2006). Nevertheless, blocking A3B, A3F, and A3G while upregulating
interferon does not abrogate the inhibitory effect of interferon on HBV. Thus, A3B, A3F,
and A3G likely contribute only minimally to the antiviral effect of interferon (Jost et al.,
2007).
Clinical implications. Despite the importance of A3 deaminases for the innate immune
response and the strong antiviral activity of e.g. A3G in vitro, relatively little is known
about the clinical relevance of A3 deaminases for the natural progression of hepatitis B.
Only a small number of studies tried to relate hypermutation to the clinical course of
hepatitis B patients. Noguchi et al. (2009) observed that a combined increase of ALT
levels and hypermutation levels was associated with a reduction of the viral load. In the
same study four cases of spontaneous HBeAg seroconversion were observed after an increase
of the number of hypermutated genomes. It is quite natural to link G-to-A hypermutation
to HBeAg-negative chronic hepatitis: the most frequent HBeAg escape variant G1896A is a
GG-to-AG mutation and GG is the preferred editing dinucleotide of A3G. Several authors
hypothesized that A3-mediated hypermutation might play an important role in the natural
course of HBV infections (Noguchi et al., 2009; Turelli et al., 2004; Vartanian et al., 2010).
For example, A3 deaminases were linked to disease progression towards cirrhosis as these
are upregulated in cirrhotic liver tissue from HBV single infected and HBV+HCV dual
infected patients (Vartanian et al., 2010).
5.2 Patients and Sequencing Data
We now focus on the methodical details of our study, which aimed to utilize second-
generation sequencing data to analyze the phenomenon of G-to-A hypermutation of HBV
and to relate hypermutation to fundamental characteristics of patients with chronic hep-
atitis B.
Patients. The cohort consists of 47 HBeAg-positive and 33 HBeAg-negative treatment-
naïve patients. Patients were enrolled in a multicenter, randomized, partially double-blind
study that analyzed the effectiveness and safety of pegylated interferon α-2a treatment in
HBeAg-positive patients (Lau et al., 2005) and HBeAg-negative patients (Marcellin et al.,
2004). Patient characteristics including liver biopsy as well as virological and serological
parameters were obtained according to the study protocols. Patient characteristics (de-
tailed in Table 5.1) exhibit statistically significant differences between HBeAg-positive and
HBeAg-negative patients with respect to age, ethnicity, HBV genotype, and viral load.
Viral DNA isolation, amplification, and Roche/454 pyrosequencing. Viral
DNA was extracted from 200 microliter serum using the QIAamp blood mini-kit. DNA
bar-coded primer pairs were designed to generate seven overlapping amplicons (amplicon
1 - 7) covering the whole HBV genome (see Table 5.2). Viral DNA was amplified using a
touch-down PCR protocol.
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Characteristic All patients
(n=80)
HBeAg-
positive
patients
(n=47)
HBeAg-
negative
patients
(n=33)
P-value
Age, years [mean (range)] 37.2 (18-70) 32 (18-65) 44.6 (20-70) < 0.001∗
Male sex [n (%)] 68 (85%) 42 (89.4%) 26 (78.8%) 1.0∗∗
Ethnicity [n (%)] 0.01∗∗
Caucasian 67 (84.8%) 35 (74.5%) 32 (97.0%)
Other 13 (16.2%) 12 (25.5%) 1 (3.0%)
HBV genotype [n (%)] <0.001∗∗
A 39 (48.8%) 33 (70.2%) 6 (18.2%)
D 41 (51.2%) 6 (29.8%) 21 (81.8%)
ALT [mean (range)] 97 (14.6-300) 98.4 (29.2-
300)
94.9 (14.6-
300)
0.87∗
HBV DNA [median (range)] 9.2 (6.3-14.5) 10.1 (7.7-
14.5)
8 (6.3-10.3) <0.001∗
Degree of Fibrosis 0.35∗∗∗
F0 10 (12.5%) 7 (14.9%) 3 (9.0%)
F1 27 (33.8%) 16 (34.0%) 11 (33.3%)
F2 28 (35%) 18 (38.3%) 10 (30.3%)
F3 7 (8.8%) 4 (8.5%) 3 (9.1%)
F4 8 (10%) 2 (4.3%) 6 (18.2%)
Table 5.1: The table provides a summary of the patient characteristics. P-values were
obtained by ∗ Wilcoxon rank-sum test, ∗∗ Fishers exact test, or ∗∗∗ t-test for the
respective parameter to be zero in a linear model. ALT levels are provided in
terms of international units (IU) per milliliter and HBV DNA levels are provided
in terms of copies per milliliter. F0 to F4 indicates the state of fibrosis with
F0 and F1 denoting absent or mild fibrosis and F2 to F4 denoting significant
fibrosis.
82 5 G-to-A Hypermutation of the HBV Genome
Amplicon Genomic region
1 57 to 709
2 524 to 1197
3 1093 to 1660
4 1524 to 2113
5 1956 to 2485
6 2297 to 2990
7 2820 to 199
Table 5.2: Sequencing amplicons.
Amplicons were purified using Agencourt CleanSeq beads on a BioMek NX workstation
(Beckman Coulter) and quantified fluorometric on a FluoStar Optima (BMG Labtech,
Cary, NC, USA). For the emulsion PCRs the amplicons of ten patient samples each were
pooled equimolarly. After recovery of the beads and enrichment, approximately 790,000
beads per pool were loaded on one region of a GS FLX PicoTiterPlate and subdivided
with a 4-lane gasket. Sequencing was performed on a Genome Sequencer FLX Titanium
(Roche-454 Life Sciences).
Sequence data preprocessing. Sequence reads were clipped using phred-equivalent
quality scores (with a cutoff value of ten) or clipped after 400 bases at latest. The SMALT
program (Wellcome Trust Sanger Institute) was used to map the reads to the AM282986
reference strain. Mapped reads shorter than 100 bases were removed from the data set.
In total, 1,360,551 reads were successfully mapped with an average sequence length of 375
± 56 bases. The number of reads per patient exhibited a heterogeneous distribution and
ranged from 7,047 to 61,623 with a mean of 17, 006±7, 332. The median coverage (number
of reads per patient sample and nucleotide position) had a mean of 1,480 ± 601. In the
following we refer to the set of clipped, filtered, and mapped reads as the 454-data.
Hypermutation rates. Several scoring schemes were proposed to identify hypermu-
tated reads. The G-to-A preference was defined as proportion of G-to-A mutations divided
by the total number of mutations in the read (Rose and Korber, 2000). The total num-
ber of G-to-A mutations was also used as indicator of hypermutation. Mutations were
evaluated with respect to the sample consensus sequence based on the 454-data, which in-
cluded every base with frequency of at least 10%. Each read can be classified as normal or
hypermutated based on the number of G-to-A mutations and the G-to-A preference with
individual cutoffs. The quotient of the G-to-A hypermutated reads divided by the total
number of reads in any genomic region is referred to as the hypermutation rate (HMR).
5.3 G-to-A Hypermutation Pattern
HBeAg status. The 454-data were scanned to identify G-to-A hypermutated genomes.
Hypermutation rates were computed with a combination of two hypermutation criteria (at
least four G-to-A mutations and G-to-A preference of at least 70%) for non-overlapping
100-base windows along the genome (Figure 5.2). Median hypermutation rates per 100-base
window varied between 0.0% and 0.047% for HBeAg-positive and between 0.0% and 0.69%
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Figure 5.2: Analysis of G-to-A hypermutation rates along the hepatitis B virus genome.
The scatter plots show per-patient hypermutation rates across the genome for
HBeAg-positive (A) and HBeAg-negative (B) patients. Each point corresponds
to one patient and one 100-base window. The hypermutation criterion requires
at least four G-to-A exchanges and a G-to-A preference of at least 70% within
each 100-base window. The local polynomial regression lines (LOESS) indicate
that hypermutation rates for HBeAg-negative patients are higher, on average,
than for HBeAg-positve patients. Positions are with respect to reference strain
AM282986. The HBV genomic regions were added to plots A and B.
for HBeAg-negative patients, respectively. Thus, the highest median hypermutation rate
for HBeAg-negative patients was 14.6 times higher than that of HBeAg-positive patients.
Genomic regions. Hypermutation was nonuniformly distributed across the genome
(Figure 5.2). The highest hypermutation rates were observed between nucleotide positions
600 and 1800 of the HBV genome. In this genomic region the average hypermutation
rate was 0.067 ± 0.2% for HBeAg-positive and 0.35 ± 0.6% for HBeAg-negative patients,
respectively. Intermediate hypermutation rates were observed between nucleotide positions
1 and 600 with an average hypermutation rate of 0.03± 0.01% and 0.1± 0.2% for HBeAg-
positive and HBeAg-negative patients, respectively. Between nucleotide positions 1800
and 3221 the observed average hypermutation rates were of 0.01± 0.07% and 0.05± 0.2%
for HBeAg-positive and HBeAg-negative patients, respectively. The peak location of high
hypermutation rates was independent of the applied combination of hypermutation criteria,
e.g. an analysis in which a cutoff value of ten G-to-A mutations was used yielded very
similar results.
Dinucleotide context. The dinucleotide context of the G-to-A hypermutations indi-
cated preferred editing in the GA and the GG context and little editing in the GT context
for amplicons 1 to 4 (Figure 5.3). For amplicons 5 to 7 the data was very sparse, as the
median hypermutation rates were near zero in this genomic region. A3 deaminases prefer
to cause mutations in the GG and the GA dinucleotide context. Clonal analysis of the
hypermutated sequences revealed that, depending on the genomic region (amplicons 1 to
7), 74% to 89% of the hypermutated sequences mapped to the editing dinucleotide contexts
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Figure 5.3: Hypermutated sequences were analyzed with respect to the dinucleotide con-
text, in which the G-to-A mutations were found. Hypermutation was defined
by at least four G-to-A mutations per read and a G-to-A preference of at least
70%. The actual number of mutations (black) that occurred in the dinucleotide
contexts GA, GG, GC, and GT was compared to the relative frequency of the
respective dinucleotides in the reference strain AM282986 (grey).
of typical A3 deaminases (Figure 5.4). Thus, after accounting for dinucleotide frequencies
in the reference sequence editing was observed more frequently in the GG and the GA
context than in the GC and GT context.
Correlation with patient characteristics. Hypermutation rates were correlated
with important patient characteristics. The results of the statistical tests are summarized
in Table 5.3. Hypermutation rates were computed using sequence data from amplicon 3
(nucleotide positions 1093 to 1660) which overlaps with the peak location of hypermutation.
We found that G-to-A hypermutation rates were significantly correlated with the degree
of fibrosis for HBeAg-negative patients (P = 0.004). This did not hold for HBeAg-positive
patients (P = 0.09). Figure 5.5 shows increasing hypermutation rates for both HBeAg-
positive and HBeAg-negative patients with increasing degree of fibrosis. Additionally, we
found that G-to-A hypermutation rates are correlated with the patients age for HBeAg-
negative patients (P = 0.04). Nonetheless, in a multivariate analysis including degree
of fibrosis, age, and hypermutation rates age was no longer significantly associated with
hypermutation rates (P = 0.07). Other patient characteristics including sex, ethnicity,
HBV genotype, ALT, and viral load did not reveal significant associations.
Correlation with escape mutations. Several studies suggested that G-to-A hyper-
mutation might be one of the driving forces of HBeAg seroconversion due to mediation of
escape mutations (Noguchi et al., 2009; Turelli et al., 2004; Vartanian et al., 2010). We
found that the relative prevalence of the G1764A (P = 0.0002) mutation was significantly
associated with G-to-A hypermutation rates, which again were computed using amplicon
3 sequences only, in HBeAg-positive patients; no association was found for the muta-
tions G1896A (P=0.8) and A1762G (P = 0.4). G-to-A hypermutation was also suspected
to be relevant for the development of immune escape in the “a” determinant of HBsAg,
e.g. mutations sG145R or sG145E (both mediated by G-to-A transitions) (Turelli et al.,
2004; Vartanian et al., 2010). We found that for HBeAg-positive patients the relative
prevalence of these mutations was strongly correlated with G-to-A hypermutation rates
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Figure 5.4: Hypermutated sequences were analyzed at the single-read level with respect
to the dinucleotide context in which the G-to-A mutations were found. Hyper-
mutation was defined by at least four G-to-A mutations per read and a G-to-A
preference of at least 70%. Each dot in the scatterplot refers to one hyper-
mutated sequence in the 454-data. The x-axis denotes the number of G-to-A
mutations in the GC and GT dinucleotide context per read and the y-axis dis-
plays the number of G-to-A mutations in the GA and GG context. The diagonal
lines extending from the origin account for the frequencies of the dinucleotides
in the reference strain AM282986 of the respective genomic region (amplicons 1
to 7) and separate the scatterplot into an upper-left region, in which mutations
in the GA and GG context are more prevalent than expected, and a lower-right
region, in which mutations in the GC and GT context are more prevalent than
expected. The percentage numbers give the fraction of sequence reads in the
respective genomic regions that express higher mutation rates in the GA and
GG context and, thus have likely been edited by A3 deaminases.
Patient characteristic
HBeAg-positive HBeAg-negative
P-value P-value P-value P-value
(HMR1) (HMR2) (HMR1) (HMR2)
Age 0.442 0.701 0.043 0.161
Sex 0.794 0.844 0.365 0.448
Ethnicity 0.613 0.161 0.495 0.189
HBV genotype 0.787 0.876 1.000 0.709
ALT 0.150 0.093 0.881 0.890
HBV DNA 0.425 0.481 0.974 0.871
Degree of Fibrosis 0.087 0.106 0.004 0.016
Table 5.3: Hypermutation rates associated with patient characteristics. HMR1: hyper-
mutation defined by at least four G-to-A mutations and G-to-A preference of at
least 70% (amplicon 3 reads only). HMR2: hypermutation defined by at least
ten G-to-A mutations and G-to-A preference of at least 70% (amplicon 3 reads
only).
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Figure 5.5: Hypermutated reads were defined by at least four G-to-A mutations and a
G-to-A preference of at least 70% (amplicon 3 sequences only). Hypermuta-
tion rates increase with more severe fibrosis indicating higher activity of A3
deaminases in fibrotic patients.
(P<0.0001). For HBeAg-negative patients absent or weaker correlations were observed for
sG145R (P=0.9) or sG145E (P=0.01), respectively.
5.4 Discussion
By analyzing second-generation sequencing data of the complete HBV genome of 47 HBeAg-
positive and 33 HBeAg-negative treatment-naïve patients, we identified a nonuniform dis-
tribution of G-to-A hypermutations across the genome and significantly different hypermu-
tation rates for HBeAg-positive and HBeAg-negative patients. We also found that hyper-
mutation rates were significantly correlated with the degree of fibrosis in HBeAg-negative
hepatitis.
Dinucleotide context. Hypermutated sequence reads were analyzed at the clonal level
with respect to the dinucleotide context of the observed G-to-A exchanges. Depending on
the genomic region we observed that 74% to 89% of the hypermutated reads contain more
GG-to-AG and GA-to-AA mutations compared to GC-to-AC and GT-to-AT exchanges
than one would expect based on the dinucleotide frequencies of the HBV genome. This
indicates that the majority of hypermutations is due to the action of A3 deaminases which
display the respective editing profile.
Distribution across the genome. A peak location of hypermutated reads was ob-
served between nucleotide positions 600 and 1800 (see Figure 5.2), which does not result
from uneven coverage during sequencing but correlates with the replication cycle of HBV as
proteins of the APOBEC family prefer to deaminate single-stranded DNA. In fact, mature
HBV particles contain a genome in which nucleotide positions between approximately 138
and 947 are partially single-stranded and nucleotide positions from 947 to the (+)-DNA
strand synthesis primer site are almost exclusively single-stranded. The predominant (+)-
DNA strand primer site of HBV is the direct repeat element DR2 (nucleotide positions
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1824 to 1834). Thus, the detected hypermutation rates (Figure 5.2) are consistent with the
prevalence of single-stranded DNA in vivo: high hypermutation rates were found where
HBV DNA is almost exclusively single-stranded (between nucleotide positions 947 and
DR2) and intermediate hypermutation rates were observed where HBV DNA is partially
single-stranded (between nucleotide positions 138 and 947). Hypermutated genomes with
low frequency were also located between nucleotide positions 1800 to 3221. This might hint
at APOBEC activity on the HBV genome before the synthesis of the (+)-DNA strand,
thus before envelopment. This situation is in contrast to e.g. editing the genome of the
human immunodeficiency virus, which can only be targeted after cell entry and reverse
transcription of the viral RNA.
HBeAg status. A key finding of our study is that the median G-to-A hypermutation
rates of HBeAg-negative patients were more than 10-fold higher than those of HBeAg-
positive patients. This finding is likely due to the fact that HBeAg-negative patients
have undergone HBeAg seroconversion implying previous mature immune system activ-
ity. Alternatively, suppression of the immune modulator HBeAg may have resulted in
increased immune pressure. Our finding contradicts a study based on cloning and con-
ventional sequencing of ten chronically infected patients in which hypermutated genomes
were only found in HBeAg-positive but not in HBeAg-negative patients (Noguchi et al.,
2005). Increasing hypermutation rates in HBeAg-positive chronic hepatitis were previously
associated with HBeAg loss (Noguchi et al., 2009). Interestingly, we found a significant
correlation of the hypermutation rates with the relative prevalence of the G1764A mutant
but not with the G1896A precore stop codon mutation. The G1764A mutation, which is
known to be an early indicator of HBeAg loss, is located within the genomic region of high
hypermutation rates but the G1896A precore stop codon mutation is not (Chu et al., 2003;
Hussain et al., 2003). Thus, our data substantiate the hypothesis that the activity of A3
deaminases supports the emergence of HBeAg escape mutations and might drive HBeAg
seroconversion.
Fibrosis. Several cytosine deaminases including A3B, A3C, A3G, A3H, and AID are
upregulated in HBV associated cirrhotic liver tissue (Vartanian et al., 2010). Our data
indicate that upregulation of these genes results in a significantly increased number of
mutated genomes in sera of HBeAg-negative patients. This association was not significant
for HBeAg-positive patients but a similar trend was observed (Figure 5.5).
Conclusions. Our data provide new insights into the G-to-A hypermutation patterns
of the HBV genome. Hypermutation significantly depends on the genomic region, the pa-
tients’ HBeAg and fibrosis status. The observation that hypermutation rates are 10-fold
higher in HBeAg-negative patients and that the relative prevalence of the core promoter
mutation G1764A correlates with hypermutation rates for HBeAg-positive patients indi-
cates an important association of hypermutation mediated by A3 deaminases with the
natural progression of chronic hepatitis B infections both in term of HBeAg seroconversion
and disease progression towards cirrhosis.
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6 Predicting Treatment Response to Interferon
In science it often happens that scientists say, “You know that’s a
really good argument; my position is mistaken,” and then they would
actually change their minds and you never hear that old view from
them again. They really do it. It doesn’t happen as often as it
should, because scientists are human and change is sometimes
painful. But it happens every day. I cannot recall the last time
something like that happened in politics or religion.
(Carl Sagan, 1987)
Interferons facilitate finite treatment durations of only 48 weeks, while treatment duration
with nucleos(t)ide analogues is unpredictable and nucleos(t)ide analogues often require life-
long administration. This benefit of interferon is accompanied by two major downsides.
First, almost all patients treated with interferon experience severe adverse effects, for
instance fatigue, anorexia, emotional lability, hair loss, and exacerbation of autoimmune
illnesses. Second, sustained response is only achieved in a fraction of patients. Rates of
sustained response vary between 19% and 30% depending on the patients’ HBeAg status
and the definition of sustained response. Thus, predicting the probability of response
before start of treatment is of high clinical relevance. We review the state of the art of
predicting treatment response to interferon in Section 2.3.1. In short, high serum alanine
aminotransferase levels, low HBV DNA levels, the presence of HBV genotypes A or B, and
progressed liver inflammation are pretreatment indicators of sustained response but provide
only limited evidence. On-treatment indicators have been shown to be more informative.
Patients that do not exhibit a significant decline of HBsAg and HBV DNA levels after
twelve weeks of treatment have very low probability of achieving sustained response. Thus,
interferon therapy should be stopped for these patients as the treatment will likely not be
successful.
In Chapter 5 we analyzed G-to-A hypermutation patterns using full-genome second-
generation sequencing data. We saw that G-to-A hypermutation can be associated with
the natural course of hepatitis B. In this Chapter we use the exact same data obtained
from 47 HBeAg-positive and 33 HBeAg-negative carriers to investigate whether or not
pretreatment G-to-A hypermutation patterns are informative of sustained response to in-
terferon. We hypothesized that G-to-A hypermutation might serve as a surrogate marker
for assessing the activity of the innate immune system, which may further be stimulated by
treatment with interferon. We found that only the prevalence of hypermutated genomes
with a GG-to-AG preference correlated highly with treatment response for HBeAg-negative
carriers. This finding could not successfully be verified on a validation cohort. Thus, G-
to-A hypermutation rates are not predictive of treatment response.
This Chapter is structured as follows. In Section 6.1 we present the methodical details
of our study. In particular, we explain the approach used to derive features based on
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G-to-A hypermutated genomes and the supervised learning algorithm we employed. In
Section 6.2 we discuss the results of our analysis (referred to as the original study) and
derive a prediction model for HBeAg-negative patients. The model was not predictive
on a validation cohort (referred to as the validation study), as detailed in Section 6.3.
We conclude this Chapter with a discussion in Section 6.4. The work presented in this
Chapter was joint work with Prof. Andreas Erhardt (formerly Heinrich-Heine-University,
Düsseldorf, currently Petrus Hospital, Wuppertal) who designed the study and provided
patient data of the original study, and Prof. Carsten Münk (Heinrich-Heine-University,
Düsseldorf) who supported and guided the analysis. Patient data and material for the
validation study was supplied by André Boonstra and Harry L. A. Janssen (both Erasmus
MC-University Medical Center, Rotterdam).
6.1 Material and Methods
Original study. Second-generation sequencing (Roche/454 pyrosequencing) was per-
formed on pretreatment serum samples from 47 HBeAg-positive and 33 HBeAg-negative
patients treated with pegylated interferon α-2a (Lau et al., 2005; Marcellin et al., 2004).
Duration of therapy was 48 weeks. After 24 weeks of follow-up, sustained response was eval-
uated according to the study protocol: HBV DNA level below 20,000 copies per milliliter,
normalization of ALT (below 30 international units per milliliter), and in case of HBeAg-
positive patients HBeAg seroconversion. Patient characteristics are detailed in Table 5.1.
Validation study. To verify the prediction model that was developed based on the
results of the original study a validation study was performed. 45 treatment-naïve HBeAg-
negative patients were enrolled in the validation study. Patients were treated with pegy-
lated interferon α-2a at the Erasmus MC-University Medical Center in Rotterdam. Dura-
tion of therapy and definition of sustained response was in accordance with to the original
study.
Sequencing data. Preparation of sequencing data for the original study is discussed
in Section 5.2. Sequencing for the validation study was performed using Illumina/MiSeq
sequencing. Two amplicons per patient sample covering NT positions 57 to 1824 were
prepared as in Zhang et al. (2007). Preparation of sequencing libraries involved equimolar
pooling of amplicons, which were fragmented and tagged using a Nextera DNA sample
preparation and index kit from Illumina. The resulting sequencing libraries were quantified
on a 2100 Bioanalyzer (Agilent Technologies) and diluted to 10 picomole per liter for
amplification and sequencing on an Illumina/MiSeq sequencer using the 2 times 250 bases
paired-end sequencing protocol. A cutoff value of 25 for the phred-equivalent quality scores
was used to clip parts of the raw sequence data of inferior quality. Otherwise pre-processing
of sequencing data was performed in the same manner as for the 454-data (Section 5.2).
Hypermutation grid. Each sequencing read was classified as normal or hypermu-
tated based on the G-to-A preference (proportion of G-to-A mutations divided by the total
number of mutations) and the number of G-to-A mutations with individual cutoffs. Dif-
ferent cutoff values 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% for the G-to-A
preference and 2, 3, 4, 5, 6, 7, 8, 9, and 10 for the minimum number of G-to-A muta-
tions were tested. Each preference cutoff was combined with each number of mutations
cutoff, resulting in 81 definitions of hypermutation. These combinations of criteria were
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evaluated on multiple window sizes along the reads (25, 50, 75, 100, 200, 300 bases, and
full read length), resulting in 567 definitions of HMRs. A read was classified as hypermu-
tated if there was at least one window of the respective size along the read for which both
hypermutation criteria were fulfilled.
Hypermutation context. Proteins of the APOBEC family display different dinu-
cleotide preferences for cytosine deamination (Section 5.1.3). Therefore, extensions of the
G-to-A preference statistic were implemented to account for the dinucleotide context. For
each nucleotide X (A, C, G, or T) the GX-to-AX preference was computed and combined
with the cutoff values discussed before.
Feature selection. An univariate scoring scheme based on subsampling identified the
hypermutation rates that best correlated with treatment response (Guyon and Elisseeff,
2003). 50% of the training data were sampled 200 times without replacement. For each
iteration the association of each HMR with the response was measured in terms of the area
under the receiver operating characteristic curve (AUC). The final ranking was performed
using the frequency of the HMRs in the top 5% of the AUC-ranked list. The four top-
scoring hypermutation rates were used in the subsequent prediction. The exact number of
selected HMRs was not critical. Almost identical results were obtained with three to nine
HMRs.
Clinical features. In addition to the top-ranked hypermutation rates other clinical
parameters, such as pretreatment HBV DNA levels and pretreatment ALT levles, were
used as relevant indicators of treatment response.
Performance assessment. The performance of the statistical preciction procedure
was evaluated using 20 times ten-fold cross validation. Feature selection, as described
above, was performed within each fold using only the current training data. All features
were normalized to have zero mean and standard deviation one. A linear support vector
machine model (as introduced in Section 2.5.3) was trained using the selected features to
predict the test data of the current fold. Class weights were computed within each fold and
passed to the SVM to account for unbalanced class distributions. Nested cross validation
was implemented to regularize model complexity. For each patient the probability of
treatment success was predicted. Finally, the AUC was computed and used as primary
quality criterion. Treatment predictions were made by computing the maximum distance
of all nonresponders (of the current training data) to the separating hyperplane. The
current test data was classified using this decision boundary. These predictions were used
to compute the prediction accuracy.
6.2 Original Study
Baseline characteristics. Sustained response to pegylated interferon α-2a in the HBeAg-
positive and HBeAg-negative cohort was achieved by six of 47 patients and by eight
of 33 patients, respectively. The responders in the HBeAg-positive cohort showed non-
significantly lower pretreatment HBV DNA levels (P = 0.80, Wilcoxon rank-sum test) and
significantly higher pretreatment ALT levels (P = 0.04, Wilcoxon rank-sum test) compared
to the nonresponders. In the HBeAg-negative cohort pretreatment HBV DNA levels were
significantly lower for the responders (P = 0.05, Wilcoxon rank-sum test), while pretreat-
ment ALT levels were non-significantly higher (P = 0.98, Wilcoxon rank-sum test). The
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Figure 6.1: Prediction results for HBeAg-negative and HBeAg-positive cohort with respect
to the genomic region and the GX-to-AX hypermutation features. The dashed
lines indicate the performances of the baseline methods in terms of AUC.
dependency of HBV DNA on the sustained response to pegylated interferon α-2a for the
HBeAg-negative patients in terms of the AUC was 0.73 and for HBeAg-positive patients
the dependency of ALT with the sustained response in terms of the AUC was 0.76. These
associations represent baseline models for the prediction of treatment response. The predic-
tion performance may further be improved using features extracted from second-generation
sequencing data based on the hypermutation patterns.
Prediction of sustained response. To predict sustained response, we computed
various hypermutation rates using a combination of criteria: the number of G-to-A mu-
tations and the GX-to-AX preference evaluated on various window sizes along each read.
We then used the subsampling-based feature selection algorithm to identify relevant defi-
nitions of hypermutation rates and calculated SVM models to predict sustained response.
The analysis was performed with eight different subsets of the sequence data. We used
sequence data that was generated using each amplicon (1 to 7, see Table 5.2) separately
and, in addition, the set of all available sequence data (full genome). Additionally, separate
models were calculated for the five (di)nucleotide motifs (G-to-A, GA-to-AA, GC-to-AC,
GG-to-AG, and GT-to-AT). This gave rise to eight times five equals 40 configurations for
both the HBeAg-positive and the HBeAg-negative cohorts. Each configuration used 567
hypermutations rates based on the combination of hypermutation criteria as described in
the Methods section. Figure 6.2 summarizes the prediction performances for both patient
cohorts with each of the 40 configurations in terms of the AUCs.
HBeAg-positive cohort. The features based on hypermutation rates did not fa-
cilitate the prediction of treatment response to interferon in the HBeAg-positive cohort.
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None of the 40 configurations with respect to the feature subset and the genomic region
exceeded the prediction accuracy of the baseline method (correlation of the pretreatment
ALT level with the response (AUC = 0.76)).
HBeAg-negative cohort. The ability to predict the response to interferon in the
HBeAg-negative cohort strongly depended on both the genomic region and the features in
use. Best performance was achieved using GG-to-AG HMRs based on sequence data from
amplicon 2 (nucleotide positions 524 to 1197). The AUC of this model was 0.89±0.03.
Compared to the baseline model (correlation of the pretreatment HBV DNA level with
the response (AUC = 0.73)), only one other configuration showed minor improvements in
prediction accuracy, namely, GG-to-AG HMRs based on the full genome with an AUC of
0.79±0.06. The mean prediction performance of the other configurations did not exceed
the AUC of the baseline method. The hypermutation rates based on G-to-A, GA-to-
AA, GC-to-AC, and GT-to-AT preferences do not significantly contribute to prediction
accuracy.
Informative predictors for the HBeAg-negative cohort. We analyzed in more
detail the cutoff values that were inferred by the model using amplicon 2 sequences (NT
524 to 1197) and GG-to-AG hypermutation rates. For this purpose, we examined the
coefficients of the respective SVM model. The most relevant feature was the GG-to-AG
HMR defined on the basis of at least four G-to-A mutations and a preference cutoff of
50% on a window size of 300 followed by the pretreatment HBV DNA levels. Figure 6.2A
illustrates the support vector machine model using these two features. Linear separation of
responders and nonresponders with only one misclassification can be achieved using HBV
DNA levels and the GG-to-AG HMR.
We computed the distribution of GG-to-AG hypermutation rates for the genomic regions
obtained from different amplicons separately for both responders and nonresponders. For
amplicons 1, 4, 5, 6, and 7 the median GG-to-AG hypermutation rates were zero. This is
in accordance with the very low general G-to-A hypermutation rates of these regions. For
amplicon 2, responders and nonresponders showed different GG-to-AG hypermutation rates
with median rates of 0.19% and 0% (P = 0.0002, Wilcoxon rank-sum test), respectively. For
amplicon 3 the GG-to-AG hypermutation rates of the responders ranged from 0% to 0.36%
(median 0.12%) and the GG-to-AG hypermutation rates of the nonresponders ranged from
0.00% to 0.40% (median 0.07%). Thus, the hypermutation rates in the genomic region
covered by amplicon 3 did not allow for separation of the two patient groups (P = 0.59,
Wilcoxon rank-sum test). We conclude that only GG-to-AG HMRs found in the genomic
area of NT positions 524 to 1197 were informative of sustained response.
Prediction model for the HBeAg-negative cohort. We found that the performance
of the prediction model could be slightly improved by removing the pretreatment ALT from
the set of features. The AUC of the model trained on amplicon 2 and GG-to-AG HMRs
using only the pretreatment HBV DNA as secondary criterion was 0.90±0.03. Therefore,
our final prediction model only included the pretreatment HBV DNA levels and the four
top-ranked GG-to-AG hypermutation features. To predict sustained response on new data
the weighted sum of the four HMRs and the pretreatment HBV DNA using the definitions
and weights in Table 6.1 need to be computed. Positive response predictions must have a
weighted sum that exceeds a cutoff value of -0.14053. On the HBeAg-negative cohort this
model’s accuracy amounted to 73±3%.
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Figure 6.2: Separation of responders and nonresponders based on the GG-to-AG hyper-
mutation rates and the HBV DNA levels in the original study (A) and the
validation study (B). (A) In the original study very good separation with only
one misclassification can be observed. (B) The GG-to-AG hypermutation rates
and the HBV DNA levels did not allow for separation of responders and non-
responders in the validation cohort.
Predictor Predictor definition Predictor weight
GG-to-AG HMR1 Primer pair 2; window size 300; G-
to-A mutations at least 4; GG-to-
AG preference at least 50%
2.76028
GG-to-AG HMR2 Primer pair 2; window size 100; G-
to-A mutations at least 4; GG-to-
AG preference at least 70%
2.74560
GG-to-AG HMR3 Primer pair 2; window size 75; G-to-
A mutations at least 4; GG-to-AG
preference at least 70%
3.34946
GG-to-AG HMR4 Primer pair 2; window size 50; G-to-
A mutations at least 4; GG-to-AG
preference at least 50%
3.60747
HBV DNA Log10 copies per milliliter -0.02012
Table 6.1: Prediction model specification derived from the original study. Positive response
predictions had a weighted sum that exceeded the cutoff value of -0.14053.
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6.3 Validation Study
To test the prediction model derived on a rather small sample size of 33 patients with
only eight responders and 25 nonresponders a validation study was performed. Therefore,
second-generation sequencing data covering NT positions 524 to 1197 were generated for a
validation cohort. In total 45 HBeAg-negative patients treated with pegylated interferon
α-2a were enrolled in the validation study, 23 of which were responders according to the
definition of sustained response.
Sequencing data were processed according to the original study. Due to the low preva-
lence of the GG-to-AG hypermutated genomes it was essential to provide sufficient coverage
for the genomic region of interest. The median coverage (number of reads per patient sam-
ple and nucleotide position) in the validation cohort had a mean of 60037 ± 17869. Thus,
the coverage was approximately 41 times higher compared to the original study.
The accuracy of the prediction model as specified in Table 6.1 on the validation data
set amounted to 46.7%. The correlation of the distance to the SVM hyperplane with
the actual response in terms of AUC was 0.56. Thus, the model performs no better
than random guessing on the validation data set and does not facilitate the prediction of
treatment response.
6.4 Discussion
By analyzing pretreatment second-generation sequencing data of the complete HBV genome
of 47 HBeAg-positive and 33 HBeAg-negative patients, we investigated whether G-to-A
hypermutation patterns might serve as a novel predictor for sustained response to pegy-
lated interferon α-2a. Sustained response was defined as HBV DNA level below 20,000
copies per milliliter combined with normalization of ALT (below 30 international units per
milliliter) after 24 weeks of follow-up. For HBeAg-positive patients HBeAg seroconver-
sion was also required for sustained response. Initial promising results for HBeAg-negative
patients using GG-to-AG hypermutated sequences could not be successfully verified on a
validation cohort.
Various definitions based on the combination of hypermutation criteria were employed to
derive a feature set for predicting treatment response to interferon. Prediction performance
was evaluated using 20 times ten-fold cross validation and expressed in terms of the AUC.
Elevated pretreatment ALT levels and low HBV DNA levels are established indicators of
sustained response for HBeAg-positive and HBeAg-negative patients, respectively.
HBeAg-positive cohort. Using hypermutation rates based on second-generation se-
quencing data did not improve treatment response prediction performance compared to
the AUC of the baseline method (pretreatment ALT levels) for HBeAg-positive patients.
This negative result might be the consequence of three major limitations of our study de-
sign. First, the low sample size of only 47 HBeAg-positive patients might undermine the
identification of relevant features. Second, positive responders were underrepresented in
our patient cohort as only six of 47 achieved sustained response. Unbalanced distributions
of labels have been shown shown to hamper optimal classifier performance (Japkowicz and
Stephen, 2002). We accounted for these two limitations by the use of SVMs, which have
been shown shown to perform well with low sample sizes and unbalanced class distribu-
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tions, by using class weights to assign higher weights to the underrepresented class, and
with a rigorous univariate feature selection based on resampling. Third, hypermutation
rates for HBeAg-positive patients are very low in relation to the coverage. As presented
in Chapter 5, median hypermutation rates for segments of 100 base-pair along the genome
did not exceed 0.047% while the median coverage was 1,480. Thus, for half of the samples
only 1, 480 · 0.047/100 ≈ 0.7 can be expected within each segment.
HBeAg-negative cohort. Using the original data set of 33 HBeAg-negative patients
we found that GG-to-AG hypermutations, which occur at frequencies of approximately
10−3, in combination with HBV DNA levels allowed accurate prediction of treatment
response to interferon with an AUC of 0.9 ± 0.03. In cell culture, a high number of
GG-to-AG mutations is characteristic for the antiviral activity of A3G on HBV. Other A3
deaminases have a weaker or different dinucleotide context associated with editing and, e.g.
A3B, A3C, and A3F induce G-to-A hypermutations also in other dinucleotide contexts.
This might explain the high prevalence and low association with treatment response of
hypermutated reads that do not exhibit a strong GG-to-AG preference. However, the
prevalence of GG-to-AG hypermutated genomes suggests expression and antiviral activity
of A3G on HBV prior to treatment with interferon. The detected difference in the GG-
to-AG HMR between responders and nonresponders might be a marker for inter-patients
variability of expression of A3G or, more generally, of interferon stimulated genes that
inhibit HBV.
GG-to-AG HMRs were observed at very low frequencies (≈ 10−3). The number of GG-
to-AG hypermutated reads ranged between one and eleven (median of 2.5) for responders
and between zero and four (median of zero) for nonresponders. Hence, providing sufficient
sequencing depth was critical for the validation study. Therefore, Illumina/MiSeq sequenc-
ing was applied which provides an approximately 60-fold lower price per megabase (Loman
et al., 2012).
Validation study. The prediction model based on pretreatment GG-to-AG hypermu-
tation rates and HBV DNA levels was not successfully verified on the validation cohort of
45 patients. Prediction accuracy amounted to 46.7% and the AUC was only 0.56. Thus,
model performance was no better than random.
The change of the sequencing technology, which subsequently also implied a different set
of primers, might have introduced several kinds of biases that might have altered the result
of the analysis. Even though this cannot be excluded, it seems unlikely as both sequencing
technologies (Roche/454 pyrosequencing and Illumina/MiSeq) have been proven to provide
state-of-the-art sequencing results. Read length is critical to identifying hypermutated
reads as the criteria of hypermutation are applied at (sub) read level. Read length of 400
bases as provided by Roche/454 pyrosequencing is not required. Our prediction model
gave high weights to GG-to-AG HMRs evaluated on window sizes of 50, 75, and 100 bases
(Table 6.1). The Illumina/MiSeq sequencing platform produces reads of 250 bases length,
which is sufficient to compute GG-to-AG hypermutation rates. Consequently, the relative
frequency of GG-to-AG hypermutation rates did not differ notably between the original
and validation data sets (see Figure 6.2). Nevertheless, GG-to-AG hypermutation rates
did not allow separation of responders and nonresponders in the validation cohort.
Thus, we think in the original study the GG-to-AG HMRs correlated with treatment
response just by chance due to the low sample size of only 33 patients with only eight
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responders. Studies performed on small sample sizes always bear the risk of producing false
positive results (Hackshaw, 2008). We maintained a consistent separation of training and
test data when selecting the features and evaluating the performance on the original data
set. The validation of our prediction method showed that the GG-to-AG hypermutation
features did not generalize to the patient samples of the validation study. To further
investigate this, the prediction procedure (including feature selection and SVM prediction
in a ten-fold cross-validation setting) was repeated 500 times with randomized response
labels on the original data set. In three (0.6%) repetitions a performance in terms of AUC
that exceeded 0.89 was observed.
Conclusions. Our hypothesis that G-to-A hypermutation patterns might serve as
a novel indicator to predict sustained response to interferon could not be successfully
validated on our patient cohorts of 47 HBeAg-positive and 33 HBeAg-negative patients.
The study suffered from several major limitations, low sample size and underrepresentation
of positive responders. Additionally, the low prevalence of G-to-A hypermutated genomes
among HBeAg-positive carriers in relation to the coverage also impaired the evaluation
of our hypothesis. Despite these limitations, our analysis provides evidence that G-to-A
HMRs do not facilitate the prediction of interferon treatment response.
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7 Conclusions
Real Biology has at least 50 more interesting years.
(James Watson, 1988)
We have presented methods for determining and utilizing the quasispecies of the hepatitis
B virus in the context of clinical applications. Determining the viral quasispecies relies
on data obtained from DNA sequencing technologies of the first or second generation,
which were analyzed using methods from the field of statistical learning and probabilistic
reasoning. This Chapter provides summarizing remarks and offers possible directions to
extend the presented work.
7.1 Summarizing Remarks
The main objective of our work was to develop statistical methods to analyze the quasis-
pecies of the hepatitis B virus to improve the clinical care of infected patients.
In particular, we developed the first in silico genotyping method that can identify and
genotype HBV intra- and intergenotype dual infections. The method showed high accuracy
on synthetic test data. Intergenotype dual infections were correctly genotyped in 98.5% to
100% of the test cases depending on the genomic region, and intragenotype dual infections
were identified correctly in 44.2% to 48.6% of the test samples. Other state-of-the-art
genotyping methods do not account for dual infections and might underestimate the risk
of interferon therapy failure if one of multiple genotypes is not recognized. The method
was used to assess the frequency of dual infections in routine diagnostics. Eight (3.3%)
intergenotype and four (1.7%) intragenotype dual infections were identified in our patient
cohort (n = 241). Clonal sequence analysis performed on three patient samples confirmed
our predictions and revealed very complex compositions of the quasispecies, which involved
multiple distinct recombinant forms in each patient. The dual infection model was inte-
grated into the web-service geno2pheno[HBV] and is freely available to be used with HBV
sequences generated within the clinical routine.
We presented the first approach that utilized peak height profiles from Sanger sequenc-
ing chromatograms to infer linkage information about nearby ambiguous positions. A
generative model was employed to compute the expected peak heights of a mixture by
combining the chromatograms of the underlying haplotypes. The model was shown to
infer the haplotypes present in mixtures with high accuracies of 97.4% and 84.5% on two
in vitro test-sets. The effectiveness of our method shows that short-range linkage informa-
tion can be inferred from sequencing chromatograms with no further assumptions on the
mixture composition. Our model provides new insights into the established and widely
used Sanger sequencing technology and facilitates the estimation of the relative frequen-
cies of nearby ambiguous sequence positions, thus it overcomes the limitations of previous
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methods. Nevertheless, the model relies on the availability of the chromatograms of all
possible haplotypes in the mixture, which limits its widespread applicability. Additionally,
we showed that the approach has several significant limitations. First, it is not possible
to reliably detect minor variants with a relative frequency of no more than 10%. Second,
the model cannot distinguish between mixtures of two or four clonal variants if one of two
sets of linear constraints is fulfilled. Third, linkage can only be inferred over a relatively
short range of maybe up to five bases. This is due to the locality of the effect of sequence
context-dependent incorporation of dideoxynucleotides. Prediction accuracy was already
impaired on a test set, in which the positions under analysis were separated by three bases.
The advent of second-generation sequencing technologies offers new perspectives on the
viral quasispecies of HBV. We conducted the first full-genome analysis of the G-to-A hyper-
mutation patterns of the HBV genome. We studied hypermutation, mediated by APOBEC
deaminases, with respect to clinical patient characteristics, which has not been done before
using second-generation sequencing data. We revealed associations of hypermutation with
the replication cycle of HBV and with the natural progression of chronic hepatitis B in
terms of HBeAg seroconversion and disease progression towards cirrhosis. We showed that
hypermutation significantly depends on the genomic region as well as the patients’ HBeAg
and fibrosis status. To detail this, we provided actual numbers of the relative prevalences
of hypermutated genomes with respect to these factors, which might serve as reference for
further studies.
One of our key observations was that hypermutation rates for HBeAg-negative patients
are about ten-fold higher than for HBeAg-positive patients. Additionally, we could demon-
strate that in HBeAg-positive patients the relative prevalence of the core promoter muta-
tion G1764A, which is an early indicator of HBeAg seroconversion correlates with hyper-
mutation rates.
Last, we investigated the potential of G-to-A hypermutation patterns to serve as informa-
tive pretreatment indicators to predict treatment response to interferon. Various features
based on the dinucleotide context of editing and the number of G-to-A mutations were
derived. A supervised learning algorithm was applied to compute prediction models for
different genomic regions and different subsets of the feature set for HBeAg-positive (n =
47) and HBeAg-negative (n = 33) patients. The prediction model for the HBeAg-positive
cohort did not facilitate the prediction of treatment response, but for HBeAg-negative
patients we found that prevalence of GG-to-AG hypermutations in a specific genomic re-
gion correlated highly with treatment response on our original data set with an AUC
of 0.90 ± 0.03. However, our finding was not successfully validated on a second patient
cohort of 45 HBeAg-negative patients. The accuracy of the prediction model based on
pretreatment GG-to-AG hypermutation rates amounted to only 46.7% with an AUC of
0.56. We kept a consistent separation of training and test data when selecting the features
and evaluating the performance on the original data set. Nevertheless, the validation of
our prediction method on the validation cohort showed that the GG-to-AG hypermutation
rates did not facilitate the prediction of treatment response to interferon.
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7.2 Outlook
One natural direction of further research would be to apply the developed methods to other
viruses. The dual infection model was successfully evaluated using synthetic test data to
genotype HCV dual infections and HIV dual infections in a Bachelor’s thesis (Savenko,
2013). These models have to be validated on sequence data derived from patient sera and
could be integrated into freely available web-services.
The dual infection model was developed to genotype dual infections based on first-
generation sequencing data. Second-generation sequencing data can represent viral popu-
lations with high sequencing depth and provides linkage information over distances up to
the read length. At first glance, this facilitates a more direct and more sensitive way of
identifying and genotyping dual infections simply by analyzing each read individually. At
second glance, several difficulties with this approach become evident involving short reads
and conserved regions that might not facilitate reliable genotyping, multiple recombination
events that hamper genotyping on single-read level, heterogeneous coverage, and contam-
inations of various kinds that need to be identified as such to prevent false positive dual
infection predictions. Thus, genotyping each read individually seems to shift the burden of
deciding whether or not a dual infection is present back to humans to interpret thousands
of single-read genotyping results. Another alternative to identifying and genotyping dual
infections based on second-generation sequencing data is to make use of quasispecies re-
construction models (reviewed in Beerenwinkel et al. (2012)) to infer the set of underlying
haplotypes and perform genotyping on these. This alternative has its own set of difficul-
ties, namely high computational costs implying long run times and error-proneness in case
of low prevalences of minority strains or heterogeneous coverage. The basic idea of the
dual infections model to use genotype-specific profiles (derived from genotype annotated
sequence data) might be of assistance in overcoming these difficulties.
Our method for quantifying the relative frequencies of ambiguous sequence positions
and for inferring short-range linkage from Sanger sequencing chromatograms is also not
limited to HBV. It can be applied to other viruses or other genomic mixtures for which
short-range linkage is of interest. Second-generation sequencing technologies, which are
far more sensitive and accurate in determining the composition of mixtures than first-
generation methods, superseded our approach in many possible applications. Nevertheless,
our methodology is a core building block for resolving the viral quasispecies based on first-
generation sequencing data. Our method might be used in conjunction with other sources
of information, e.g. patterns of co-occurring mutations derived from sequence databases.
To approach this, several difficulties have to be addressed. First, the statistical model
and the respective inference procedure need to be extended to include more than two
ambiguous positions. Second, the model needs to be applicable in situations in which not
all peak height profiles of all possible underlying haplotypes are known, as the number
of all possible haplotypes grows exponentially with the number of ambiguous positions
under consideration. Third, multiple sources of information and their associated levels of
uncertainty have to be incorporated into a joint probabilistic model. Last, the resulting
model needs to be computationally tractable.
Finally, we discovered interesting associations between G-to-A hypermutation patterns
and the natural progression of hepatitis B. We observed that patients in the HBeAg-
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negative chronic phase show about ten-fold higher hypermutation rates than patients in
the immune-active phase and that hypermutation might serve as an early indicator of
HBeAg seroconversion. Nevertheless, our data could not elucidate during which phases
of the chronic infections hypermutations are accumulated and how hypermutation might
shape the development of the disease. The analysis of longitudinal second-generation
sequencing data of chronically infected HBV carriers could provide additional insights into
the development of the quasispecies during the natural progression of hepatitis B.
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Acronyms
2ndGS second generation sequencing
3TC Lamivudine
A3 APOBEC3
A3A APOBEC3A
A3B APOBEC3B
A3C APOBEC3C
A3DE APOBEC3DE
A3F APOBEC3F
A3G APOBEC3G
A3H APOBEC3H
AASLD American Association for the Study of Liver Disease
ADV Adefovir
ALT alanine aminotransferase
anti-HBc antibody to the Hepatitis B core antigen
anti-HBe antibody to the Hepatitis e antigen
anti-HBs antibody to the Hepatitis B surface antigen
APASL Asian Pacific Association for the Study of Liver
APOBEC apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like
ASHV artic squirrels hepatitis B virus
ATP adenosine triphosphate
AUC area under the receiver operating characteristic curve
cccDNA covalently closed circular DNA
CHBV crane hepatitis B virus
ddNTP dideoxynucleotide triphosphates
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DHBV duck hepatitis B virus
dNTP deoxynucleotide triphosphates
DR direct repeat element
EASL European Association for the Study of Liver
ELISA enzyme-linked immunosorbent assay
ER endoplasmic reticulum
ETV Entecavir
GSHV ground squirrels hepatitis virus
HBcAg hepatitis B core antigen
HBeAg hepatitis B e antigen
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HBxAg hepatitis B virus X antigen
HCC hepatocellular carcinoma
HCV hepatitis C virus
HHBV heron hepatitis B virus
HHBV heron hepatitis B virus
HIV human immunodeficiency virus
HMM hidden Markov model
HMR hypermutation rate
HPV human papillomavirus
HSV-1 herpes simplex virus type 1
IFN interferon
IU international units
IUPAC International Union of Pure and Applied Chemistry
LdT Telbivudine
LHBsAg large hepatitis B surface antigen
LOESS local polynomial regression lines
MAP maximum a posteriori probability
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MHBsAg middle hepatitis B surface antigen
NA nucleos(t)ide analogue
NCBI National Center for Biotechnology Information
NT nucleotide
PAG polyacrylamide gel
PCR polymerase chain reaction
pgRNA pregenomic RNA
PGSND position- and genotype-specific nucleotide distribution
PHBV parrot hepatitis virus
rcDNA relaxed circular DNA
RGHV rose goose hepatitis B virus
RN RNaseH
RT reverse transcriptase
SHBsAg short hepatitis B surface antigen
SIV simian immunodeficiency virus
SNP single nucleotide polymorphism
SP spacer
STHBV stork hepatitis B virus
SVM support vector machine
TDF Tenofovir
TM transmembrane region
TP terminal protein
WHV woodchuck hepatitis B virus
WMHBV woolly monkey hepatitis virus
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